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Influenza is an infectious disease caused by influenza A viruses. Influenza occurs as 
seasonal epidemic and pandemic. Almost every human is susceptible to contract this 
virus. In seasonal outbreaks, the influenza virus causes illness ranging from mild fever 
to death. In future pandemics, there is a serious risk for high mortality rates because 
humans are naïve to new influenza virus strains especially the bird flu strains H5N1 
and H7N9 [1]. Therefore, it is very important to control the spread of influenza 
virus during both epidemic and pandemic outbreaks.
The spread of influenza during outbreaks can be controlled either by the administration 
of antivirals (neuraminidase inhibitors) or by vaccination [2,3]. The neuraminidase 
inhibitors like oseltamivir and zanamivir are used to control the disease in seasonal 
and pandemic outbreaks.  During the 2009 swine flu pandemic, oseltamivir was the 
drug of choice for the treatment and prophylaxis of swine flu (H1N1) [4]. However, 
it does not prevent one’s ability to acquire the virus from an infected person. In 
principle, influenza vaccines are capable of inducing an immune response that can 
immediately neutralize the virus. Therefore, vaccination is considered to be more 
effective than the administration of antivirals. Influenza vaccines are available as 
inactivated vaccines i.e. subunit, split, virosome and whole inactivated virus (WIV) 
and live attenuated virus (e.g. Flumist®). WIV, subunit and split vaccines are widely 
used because virosomal and live attenuated virus vaccines are only approved in a few 
countries [5–7].
Although influenza vaccines are advantageous over antivirals there are several 
shortcomings related to the route of administration and the production and properties 
of the vaccine formulation. Except for the live attenuated virus vaccine, which is 
administered intranasally, all the other types of influenza vaccines are administered 
either through the intra muscular or subcutaneous route. These routes of vaccination 
require resources like syringes, sterile needles and the help of trained healthcare 
workers. These prerequisites further add up to the costs of vaccination. Moreover, 
due to needle phobia compliance can be compromised. Furthermore, the possibilities 
of needle stick injuries also add up to limitations of conventional vaccination routes. 
In terms of vaccine production capacities, both egg and cell culture based influenza 
vaccine production is limited. As a result during a pandemic, mass vaccination 
involving high and multiple vaccine doses may not be feasible at the present 
situation. Current influenza vaccines also have several shortcomings with respect to 
the immune response they elicit. Despite vaccination, people still can get sick and 
this could be overcome by inducing stronger immune response in the respiratory 
tract, i.e. the port of entry of virus. Finally, current influenza vaccines including the 
live attenuated virus vaccine are unstable and therefore require refrigerated storage 
and transport, the so-called cold chain. In particular for stockpiling pandemic 
and seasonal influenza vaccines, storage at ambient temperature would be highly 
advantageous, as it would significantly reduce the costs. Summarized, there is a need 
for an influenza vaccine that can  be self-administered via a non-parenteral route, 
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2induces a potent immune response at relatively low dose, and is stable. In this thesis, 
we explored two different strategies to develop a vaccine/vaccination routine that 
could possibly fulfill these requirements.
In the first strategy, we envisage to develop a dry and stable powder vaccine that 
can be administered through the pulmonary route. The main advantage of this 
route of administration is its ease of administration. Therefore, it requires a minimal 
involvement of trained health care workers [8]. A dry powder formulation is 
preferred over a liquid formulation because it has been shown before that when dried 
in the presence of stabilizing excipients, the antigenicity of the vaccine is not affected 
during drying and storage for extended period of times at ambient conditions. [9]. 
Moreover, with the application of proper drying techniques, powder particles can 
be produced that are suitable for inhalation [10–12]. Obviously, it is of utmost 
importance that during storage not only the antigenicity of the vaccine is maintained 
but also the physical powder properties. Changes in physical powder properties e.g. 
irreversible agglomeration, would severely compromise the suitability of the powder 
for pulmonary administration. As the physical characteristics of vaccine powders 
during storage have not been studied before, this issue will be addressed in this thesis. 
The feasibility of pulmonary administration of influenza vaccine has been studied 
before. In several studies it has been shown that pulmonary vaccination can induce 
not only potent systemic immune responses but can also elicit immune responses in 
the respiratory tract, the port of entry of  virus [9,12]. However, it fails to induce 
a balanced Th1/Th2 immune response [9]. In addition, pulmonary vaccination 
induces poor IgA antibody responses in the nose. We hypothesize that the quality of 
immune response can be improved by the co-administration of adjuvants. Moreover, 
application of adjuvants may facilitate dose sparing. Therefore, in this thesis various 
adjuvants were incorporated in the dry powder formulations and evaluated in a 
mouse model.
In the second strategy, which might be in particular suitable during a pandemic 
outbreak, we envisage to develop a sublingual tablet containing a stabilized vaccine 
of a previous strain, which can be used as primer for a booster vaccine prepared from 
the current drifted strain. As described above, the influenza pandemic outbreaks 
create a big risk of vaccine shortage. It has been described that the immune response 
against newly drifted influenza strains can be primed with old vaccine strains [13]. 
The major advantage of this strategy is that the old vaccine can be produced in 
large quantities because time constraints lack. However, the priming doses used in 
that study were unstable liquid formulations, which will hamper stockpiling of these 
vaccines. Moreover, the liquid formulations were administered by injection, which 
has the shortcomings as described above. To overcome both the disadvantage of the 
antigen instability and the parenteral administration, we propose to develop a stable 
tablet formulation that can be administered sublingually. As described above, using 
stabilizing excipients and proper drying techniques, the vaccine can be brought in a 
dry and stable state. In this thesis, it is investigated whether or not this powder can 
be formulated into a tablet suitable for sublingual applications while the antigenicity 
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3of the vaccine is maintained. We propose to apply a sublingual tablet because it is in 
particular suitable for mass vaccination campaigns during a pandemic. Furthermore, 
we have chosen for this route of administration because it has been shown in previous 
studies that the sublingual administration of influenza vaccines can successfully 
induce immune responses [14–16]. However, these studied were performed with 
unstable liquid influenza vaccines. Moreover, to our knowledge the sublingual prime 
and heterologous booster strategy has never been explored before.
Highlights of this thesis
The highlights of this thesis are,
• The storage stability for stockpiling influenza vaccines
• Improve the immune response by co-administering adjuvants with stabilized 
pulmonary influenza vaccines
• The prime-boost strategy for vaccination during pandemics with sublingual 
tablet and heterologous i.m. booster vaccine. 
Outline of the thesis
In chapter 2, we reviewed the importance of particulate influenza vaccines. The 
current status of liposomes, virosomes, nanoparticles and virus like particles 
in influenza vaccination was discussed in a broader context. The advantages and 
limitations of these vaccine systems were described. This review also includes a 
discussion on regulatory challenges, compliance issues and perspectives of particulate 
influenza vaccines. 
In chapter 3, the physical powder properties and the immunogenic stability of 
pulmonary influenza vaccine powders during storage was evaluated. The influenza 
vaccine was spray freeze dried in the presence of inulin, dextran and a mixture 
of dextran and trehalose. The dry powder formulations were stored at different 
temperatures for 3 months. The physical powder properties such as particle size 
and specific surface area before and after storage were evaluated. The immunogenic 
stability of the stored influenza vaccines was evaluated in mice. 
In chapter 4, δ-inulin, a carbohydrate based adjuvant was evaluated for its adjuvant 
effect when co-administered with pulmonary influenza vaccines. The immune 
responses induced by adjuvanted and pulmonary influenza vaccines alone in mice 
were compared. 
In chapter 5, monophosphoryl lipid A, a lipid based vaccine adjuvant was tested 
with pulmonary influenza vaccine powder in mice. The receptor binding capacity 
and immunostimulatory properties of the adjuvanted influenza vaccine was 
evaluated. The antibody levels and memory B cell levels induced by adjuvanted 
vaccine were compared to that of pulmonary vaccine alone. The advantages of 
Introduction
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4adding monophosphoryl lipid A to influenza vaccine are discussed in comparison 
to vaccine alone. 
In chapter 6, a wide range of vaccine adjuvants were evaluated with pulmonary 
influenza vaccine powders in mice. The adjuvants tested were Pam3CSK4, 
monophosphoryl lipid A, CpG-ODN-1826 and GPI-0100. The immune responses 
induced by these adjuvanted influenza vaccines were compared. The choice of 
optimal adjuvant for pulmonary influenza vaccine is also discussed in this chapter.
In chapter 7, a prime-boost strategy of influenza vaccination was evaluated in an in-
vivo study using mice. In this study, the immune responses were primed with a single 
dose of sublingual influenza vaccine. Later, the immune response was boosted with a 
heterologous i.m. influenza vaccine. Furthermore, the possibilities to formulate the 
influenza vaccine into stable sublingual tablet were explored. 
In chapter 8, the results of the research described in this thesis are summarized and 
the perspectives are discussed.
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Influenza is an airway infection caused by influenza viruses. Influenza viruses are 
classified into three types, Influenza A, B and C. Influenza A infections are more 
common compared to the other types. Influenza A virus mutates rapidly, hence 
humans are susceptible to frequent influenza virus attacks. In an influenza epidemic, 
the symptoms of infection range from cough, sore throat and fever, to a general 
feeling of illness. Antigenic shift in influenza may result in a pandemic strain that 
can be fatal. The burden of influenza epidemics is huge and both direct (health care) 
and indirect (a.o. economic losses due to reduced productivity) costs add to this 
burden. Direct health care costs alone are already estimated to be over 50 million 
Euro per million of inhabitants in Europe [1]. Both vaccines and antiviral drugs 
(neuraminidase inhibitors) can contain the spread of influenza virus. However, in 
terms of protection, vaccines provide protection for longer period compared to the 
current antiviral drugs. 
Vaccination against the influenza virus is an effective strategy to control the spread of 
virus in pandemics. Currently, influenza vaccines are available as subunit, split, and 
live attenuated virus (LAV) and whole inactivated virus (WIV) vaccine. A subunit 
influenza vaccine comprise of surface antigen hemagglutinin and/or neuraminidase. 
Subunit vaccines are safe for vaccinating more fragile patient populations. Split 
influenza vaccines are prepared by splitting the viral membrane with diethyl 
ether and a detergent or a detergent alone to impair the replicating ability of the 
virus. Split vaccines usually include the essential viral proteins like hemagglutinin, 
neuraminidase along with other membrane proteins. Both the subunit and split 
influenza vaccines are considered to be safe. Nevertheless, they have their own 
limitations regarding stability and antigenicity. The WIV and LAV vaccines are 
more immunogenic compared to subunit and split vaccines. Previous studies have 
reported that high immunogenicity of WIV and LAV is due to the presence of 
genetic material. The RNAs are potent  TLR 7 (toll-like receptor 7) agonists [2]. Due 
to their high immunogenicity WIV and LAV are not suitable for vaccination against 
influenza in high-risk patient populations. Usually, the high-risk group includes the 
elderly population (age above 65 years), children (age above 6 months), pregnant 
and lactating women and people with an impaired immune system.
High-risk patient populations are the main target for influenza vaccination 
programs during pandemic outbreaks. Since the WIV and LAV are not suitable for 
vaccination in this group, they are vaccinated either with subunit or split influenza 
vaccines. However, both subunit and split influenza vaccines are moderately 
immunogenic. Hence, it is very important to improve their immunogenicity. To 
improve the immunogenicity of these vaccines several options exist, they include (i) 
the administration of multiple vaccine doses, (ii) the use of an adjuvant or (iii) or 
formulation of the antigens in special delivery systems.
Review on particulate influenza vaccines
2
10
Influenza vaccines are supplemented with adjuvants either to improve their 
immunogenicity or to save doses during pandemics. The immunogenicity of vaccine 
can be improved with a variety of adjuvants (Table 1). The licensed and widely 
used adjuvants for influenza vaccines include: alum, MF59, ASO3, and ASO4 [3]. 
Many other adjuvants have been described but they are mostly in the preclinical and 
clinical trial stages [4–6], and for most is still unclear whether they will ever meet the 
strict requirements necessary to gain regulatory approval.
Particulate vaccines are vaccines in which the key antigen is formulated together with 
one or more adjuvants in a special delivery system to form a particular structure. 
Most of the particulate-based vaccine (PBV) systems and the adjuvants used are still 
in the developmental stage, only a few products have made their way to market. 
Inflexal®, a virosomal influenza vaccine, is an example of this last category. A special 
feature of this product is that it is considered safe even in children [7].
Particulate vaccines facilitate effective antigen presentation, but in a different manner 
compared to other adjuvants like alum, saponin or TLR ligands. The latter adjuvants 
will, in general, stimulate the immune response through mechanisms such as slow 
release of antigens (Alum), induction of proinflammatory cytokines (saponin), 
activation of TLR receptors induction of immunomodulatory cytokines, whereas, 
PBVs improve the immune response through antigen presentation. 
Category Adjuvants Refs
Alum [8]
Nano-emulsion ASO3, MF59 [9,10]
CpG oligonucleotide CpG-A, CpG-B [4] 
Cytokines IL-1, γ - IFN, IL-2, IL-4, IL-12 [11,12]
Fusion Proteins Flagellin [13]
Inulin γ Inulin, δ Inulin [14]
GEM [15,16]
Lipids Ceramide Carbomyl- Spermine, α-Galactosylceramide [17,18]
Bacterial Toxin CT, LT, mCTA-LTB [19]
Saponin GPI-0100 [20]
Other adjuvant MPLA (TLR 4) [21]












Virosomes Heat labile toxin from E.coli
LpxL1
s.l., i.n. [29,30]
Virus-like particles Flagellin from salmonella i.m, i.n [31]








s.c., i.n., oral [6,33]
[34–36]
Microparticles Surf clam 
Eudragit S and trehalose
ISCOMS Quil A glycoprotein, 
cholesterol, phospholipid
i.m., i.n. [37,38]
Bliosomes Bile salts oral [39]
The components used in PBV-based vaccine delivery systems target the antigen 
effectively to antigen presenting cells (APC). Additionally, PBVs are particulate in 
nature which may make their appearance similar to that of influenza virus particles 
[22–24]. At present the research on PBVs mainly focuses on systems like liposomes, 
nanoparticles and microparticles. Other PBV delivery systems include proteosomes 
and bilosomes, whereas nanoemulsion based systems like MF59 and ASO3 have 
been approved for human use. In figure 1 a schematic overview of the structure and 
appearance of different PBVs is presented.
Particulate vaccine delivery forms have their own specific advantages and limitations 
when used with influenza vaccines. An update on these vaccine delivery systems will 
Table 2. Particulate influenza vaccine adjuvants and their route of delivery
Review on particulate influenza vaccines
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Figure 1. Schematic overview of the structure and appearance of different PBVs.
Chapter 2
13
be presented in this review (Table 2). In addition, the compliance and regulatory 
issues pertaining to different PBVs will be discussed briefly. Finally, the future 
perspectives of PBV also in relation to their intrinsic stability will be discussed.
1. Liposomes
Liposomes were first described in the early 1960’s. Since their discovery, significant 
research efforts have been devoted to tap the potentials of liposomes. Liposomes can 
contain both hydrophilic and lipophilic drugs. The presence of hydrophilic inner 
core and lipophilic compartment in the bilayer made the liposome an attractive 
carrier for vaccine delivery. Nevertheless, the antigen entrapment in liposome is a 
challenging task. Only twenty year after their discovery, the liposomes were first 
investigated for possible adjuvant activity. The first study focused on the adjuvant 
activity of liposomes on tetanus toxoid vaccine [40]. Later, researchers investigated a 
wide range of antigens originating from bacteria, protozoa, and viruses. The immune 
responses induced by the liposomal antigen products were reported to be better than 
the responses induced by native antigens [41,42]. The main reason for effective 
antigen presentation of liposome is considered to be the lipid bilayer, which adsorbs 
the antigens with electrostatic charge. Moreover, the liposomal bilayers serve as a 
depot to supply antigens to APC at a slower rate [43]. 
Although the basic liposomal vaccine formulations were already shown to boost the 
immune response, research was progressed by investigating the effects of modified 
liposomes. The modifications included altering the size, entrapment efficacy and 
charge, as well as the incorporation of secondary adjuvants like cytokines, ceramide 
carbamoyl-spermine, lipid-DNA complex and peptides [44–47]. The size and the 
entrapment efficacy of liposomal influenza vaccines was shown to have some relation 
to the adjuvant activity [44]. It was reported that split influenza vaccine has the 
tendency to bind strongly to cationic liposomes formulated with cholesterol [48] 
this could potentially improve the antigen entrapment in the liposome which is 
still one of the major challenges in this type of products. The adjuvant effect in 
cationic liposomes mainly depends on the activation of extracellular signal regulated 
kinase and induction of CC chemokine by the cationic phospholipids [46]. It was 
shown that electrostatic forces of liposomal bilayer resulted in improved adsorption 
of antigens to bilayer and that improved adsorption resulted in good entrapment 
efficacy of antigen in liposome [49]. Liposomal flu vaccines supplemented with 
IL-2 proved to be safe in clinical trials and the incorporation of the cytokine in the 
liposomal formulation enhanced the immune response [47]. 
The parenteral administration of liposomal flu vaccines induced both humoral 
and cell mediated immune response. The liposomes form a vaccine-depot at the 
injection site which prolongs the antigen presentation and mediates a strong Th1 
immune responses [50]. However, a liposomal formulation containing matrix 2 
(Me2) proteins as antigen induce a Th2 immune response [123]. Hence, the type 
of immune response induced by liposomal vaccines depends on the type of antigen 
Review on particulate influenza vaccines
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in liposome vaccine formulation administered.  Intra nasal (i.n.) administration 
of liposomal flu vaccines induced a mucosal immune response [51]. Influenza 
vaccines capable of inducing mucosal immune responses are considered superior to 
conventional influenza vaccines, as they induce the immune response at the port of 
entry of the virus (nose and airways). This boosts the research on mucosal liposomal 
influenza vaccines [52–54]. Muco-adhesive formulations of these liposomal flu 
vaccines improved the residence time of antigen for the uptake by APC in the 
mucosal sites [27].
In recent years, the inclusion of secondary adjuvants to liposomes has improved the 
transport and uptake of antigen from the mucosal surfaces. A synthetic cord factor 
from M. tuberculosis in liposomes was reported to improve the transport of antigens 
through the mucus membrane [53]. Transport of antigen in the mucosal layer can 
be adopted for vaccination against respiratory viruses like influenza. Liposomes with 
poly-cationic lipids like CCS can further boost the immune response of influenza 
antigens via the i.n. route and, has been demonstrated in mice and ferrets [55]. 
Furthermore, complexation of DNA with cationic liposomes improved the antibody 
responses by providing cross protection against drifted influenza strains [26,56]. 
2. Virosomes
The main difference between virosomes and liposomes is the presence of the surface 
antigens like HA or NA on the outside of the latter. Virosomes more or less resemble 
a virus particle without the genetic material of native influenza. The term virosome 
was proposed in 1975 to the modified liposomes with influenza surface proteins over 
the lipid bilayer [57].  In the virosomes the influenza surface protein HA is bound 
to the surface of the lipid bilayer, arranged in a mode similar to that of the HA in 
the influenza virus.  This specific arrangement increases the fusion capacity of the 
virosomes with cell walls significantly [58,59].
In the early years of virosome research, they were developed as a carrier for 
biopharmaceuticals [60]. Virosomal vectors containing viral envelopes of stomatitis 
and sendai virus have been developed [61,62]. However, the virosome with influenza 
viral proteins is the most commonly used due to its preserved fusion activity [63]. 
Next to being an influenza vaccine type, influenza virosomes can also be used as a 
carrier or adjuvant for other antigens like hepatitis A. They can actively present the 
antigen to APC by binding to the sialic acid end receptor as they still maintain the 
binding capacity and fusion properties of the HA [64].  
Vaccination studies in humans have reported that influenza virosomes are more 
immunogenic compared to influenza subunit vaccine, and they have been approved 
for human use, administered via i.m. injection [65,66]. The positive response after 
parenteral administration paved the way to investigate other routes of administration 
for virosomal vaccine formulations. Virosomal vaccines given intranasally to ferrets 
showed that virosomes elicited an immune response after mucosal vaccination 
[67]. Moreover, the virosomes induced a local immune response in addition to 
Chapter 2
15
the systemic immune response. Safety studies revealed that the phospholipids used 
in virosomes are safe and immuno-tolerable making them suitable for frequent 
influenza vaccination [68]. 
The addition of secondary adjuvants to virosomes can further improve the immune 
response (after mucosal administration). Preclinical studies of virosome with trivalent 
influenza vaccine and heat labile toxin from E. coli in different animals proved to 
be safe and efficient in inducing antibodies against the viruses [29]. The addition 
of lipopolysaccharide LpxL1 to influenza virosome shifted the immune response 
towards Th1 [30]. Sublingual administration of virosomal flu vaccines was shown 
to induce secretory IgA antibodies in the upper respiratory tract. Hence, virosomal 
influenza vaccines are considered  effective formulations for controlling the virus in 
pandemics [69].
3. Virus-like particles
 Virus-like particles (VLP) are developed to improve the immunogenicity of 
recombinant protein antigens that suffer from poor presentation to APC [70]. VLPs 
can actively present the antigen to the APC, which in turn increases the immune 
response against the native virus [71]. They resemble native virus particles, however 
they carry no genetic material in them. Hence, they cannot replicate, but they are 
immunogenic to the same extent as the native virus when loaded with antigens. 
VLPs can be produced by cloning the genome responsible for the expression of the 
antigenic material in the virus to the target vector plasmid [72]. Usually they are 
expressed in insect cell lines and in some cases even in plants [72–74]. The vaccine 
against the human papilloma virus and hepatitis B has been tested clinically and 
showed positive response in boosting the immune response [75].
Influenza VLPs comprising HA, NA and M1 proteins induced protective immune 
response against the virus in preclinical studies [76,77]. The i.n. immunization with 
influenza VLPs induced a broad spectrum of antibodies against heterologous influenza 
viruses [78]. In addition, cross-protection over different clades has been reported 
when animals were immunized with H5N1 VLPs [79]. Mucosal vaccination of VLPs 
can induce both systemic and mucosal immune responses [80,81]. One i.n. dose of 
influenza VLPs in mice was shown to induce an immune response comparable to 
that induced by two i.m. doses of VLP or adjuvanted VLPs, a response sufficient to 
protect against the virus [82]. This observation demonstrates once more that also 
the route of immunization affects the immune response. This was further confirmed 
by a study showing that the intradermal immunization of VLPs with micro-needles 
prompted an immune response superior to i.m. VLP immunization [83]. 
Influenza VLPs mixed with secondary adjuvants like Novosome and flagellin from 
salmonella further boosted the immune response [31,84]. The influenza VLPs with 
Me2 protein induced superior immune response with cross-protection against a 
variety of influenza virus strains [72]. Hence, this approach could open the avenues 
for research towards universal influenza vaccines. The Me2 protein (considered to 
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be the conserved epitope in influenza virus) with the VLP may improve the antigen 
presentation. 
4. Proteosomes
Proteosomes are hydrophobic particles that include bacterial outer membrane 
proteins and trace amounts of purified lipopolysaccharide. The outer membrane 
proteins are isolated from Neisseria meningitides [85]. Two strategies have been 
adopted in the development of proteosome-based vaccines. In the first approach, 
the vaccine antigen is combined non-covalently with proteosomes by complexation. 
This approach may incur some antigen loss [86]. In the second approach, the vaccine 
antigen is simply mixed with proteosomes prior to vaccination [87]. The proteosome 
particles activate the APCs by both TLR2 and TLR4 activation [88]. Proteosome-
based vaccines produced by both methods induce both mucosal and systemic 
immune response when administered via the mucosal route [86,87]. Furthermore, 
i.n. vaccination studies with influenza subunit vaccine with proteosomes showed 
induction of a mucosal immune response that protected  mice from virus challenge 
[89,90]. The i.n. proteosome-based influenza vaccines induce a strong Th1 immune 
response [91]. After successful preclinical studies in animals the clinical studies were 
performed with healthy volunteers for the evaluation of safety and efficacy in man 
and the outcome this study showed that influenza proteosome vaccines are safe and 
effective in inducing immune responses [32,92].  In the last decade, research on 
proteosome-based influenza vaccines has been performed with the conserved epitope 
of the influenza virus. The i.n. vaccination of this proteosome–based vaccine with 
conserved epitopes resulted in a positive immune response [93]. Hence, influenza 
vaccines based on proteosomes can be used as a carrier/adjuvant to elicit a protective 
immune response against the influenza virus. Noticeably, the proteosome-based 
vaccines are effective when administered via i.n. route, making proteosomes 
interesting adjuvants for non-invasive influenza vaccination.
5. Nanoparticles and micro-particles 
Nanoparticles are used as a carrier of a variety of biopharmaceuticals including 
vaccines, toxins and other antigens. A wide range of materials is used to formulate 
these nanoparticles. The most commonly used materials are chitosan, chitin and 
combination of these materials with γ-glutamate or poly-(ε-caprolactone). Preclinical 
studies have been performed to ascertain the safety and efficacy of the vaccine 
nanoparticles [94]. The encouraging results of these nanoparticle based vaccine studies 
opened new avenues in vaccine research. Later, research on nanoparticle influenza 
vaccines administered through i.n. route showed that i.n. vaccination is effective. 
The immune response induced by these influenza nanoparticles are comparable to 
those induce by conventional vaccine [94]. Additionally, influenza nanoparticle 
vaccination via i.n. route induced mucosal immune response. Although effective 
immune responses after i.n. administration to humans of chitosan formulations 
have been reported, little progress was seen in this field over the past decade. The 
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inclusion of Poly (γ-glutamic acid) in chitosan nanoparticles with influenza subunit 
vaccine further improved the immune response, by providing protection against the 
influenza virus challenge [6,95]. It was also reported that the adjuvant activity of the 
chitosan / poly(γ-glutamic acid) nanoparticles is mediated through both humoral 
and cellular immune response [96]. Simple physical mixing of trimethyl chitosan 
nanoparticles with WIV also boosted immune response in mice with protection 
against the virus [97]). The chitosan nanoparticles with poly-(ε-caprolactone) also 
induced superior immune response with protection against influenza [33]. 
Similar to nanoparticles, microparticles can be formulated with chitosan and chitin. 
Chitin microparticles vaccination through the i.n. route induces immune responses 
that protect against a viral challenge [34,98]. The micronized particles of surf clam 
shell showed adjuvant activity with i.n. influenza vaccines [99]. The i.n. administration 
of influenza vaccines adjuvanted with surf clam microparticles reduced the lung virus 
titers after challenge [100]. Oral administration of microparticles formulated with 
Eudragit S and trehalose induce cross protective immune response against different 
influenza virus [36]. Since these microparticles induce good level of immune response 
compared to conventional influenza vaccines, chitosan based delivery systems may 
act as potential influenza vaccines in the future. Recent study on safety of the chitosan 
revealed that it is safe for use in humans for i.n. administration [101]. The preclinical 
studies on chitosan based nanoparticles have showed promising results. However, 
the safety and immunogenicity of nanoparticles based influenza vaccines have to be 
reaffirmed with successful clinical studies. 
6. Bilosomes
Bilosomes are lipid vesicles formulated with bile salts. The bile salt vesicles protect the 
conformation of proteins/antigens even at low pH values like that in the stomach. 
Moreover, this kind of vaccine formulations were reported to effectively transport 
the antigen through the GI mucosa to gut-associated lymphoid tissue [102]. Studies 
on influenza subunit vaccine in bilosome revealed that it induces Th2 with no Th1 
type of immune response. Additionally, it induces mucosal immune response [103]. 
Tailoring of immune response with influenza bilosome is achieved by altering the 
size of the bilosome [39].
7. ISCOMs
ISCOMs are composed of Quil A glycoprotein matrix, cholesterol and phospholipid. 
The hydrophobic nature of matrix facilitates the antigen attachment [104]. 
Administration of ISCOM adjuvanted vaccines via the i.m., i.n. and intraperitoneal 
route was studied for effectiveness [105–107]. The ISCOMs formulated with 
influenza glycoprotein showed superior immune responses compared to native 
influenza glycoproteins. Moreover, it also protected the animals against the lethal 
virus challenge [108]. However, the vaccine failed to protect the animals against the 
virus challenge with distant drifted influenza virus [109]. Indicating that, ISCOM 
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influenza vaccine may provide better protection against the closely related influenza 
strains but not against distant drifted variants.
Regulatory challenges
Currently adjuvants are not licensed separately; they are licensed only in combination 
with a specific vaccine. This is a logical approach since efficacy can never be proven 
in formulations without any antigen and because the adjuvant activity may vary 
between different vaccines. The regulatory challenges involved in licensing of these 
adjuvanted vaccines normally includes mode of action, non-clinical toxicity studies, 
clinical safety and post marketing surveillance [110]. Hence, it can take a while 
before a vaccine for human use will be approved. The EMEA and WHO guidelines 
stress that adjuvanted vaccines should be non-toxic, safe and effective. Moreover, the 
WHO also suggests that the new adjuvanted vaccines should prove their effectiveness 
over the standard adjuvant i.e. the alum adjuvanted vaccine [111,112] or over the 
non-adjuvanted formulations (when the current standard is non-adjuvanted).
Compliance issues
The particulate influenza vaccines have to be safe when compared to the conventional 
vaccines. The preclinical studies showed that several PBVs are safe and immunogenic. 
However, safety and immunogenicity studies in humans are required and their success 
will determine the future of PBVs. In addition to administration via conventional 
(parenteral) routes, PBVs are also developed to enhance the immune response after 
administration via non- invasive routes like sublingual, pulmonary, intranasal or oral 
administration.
Almost all the PBVs were shown to boost the immune response after i.n. 
administration in animal studies, however, none has be approved for human use so 
far. An important aspect of i.n. vaccination is neurotoxicity, because in recent past 
a virosomal influenza vaccine with CTL adjuvant induced Bell’s palsy in humans. 
Hence, it is very important to study the toxicity of adjuvants used in influenza 
vaccine formulations before proceeding to the clinical studies. 
Influenza vaccination via the sublingual mucosa has gained interest in recent years, 
because s.l. vaccination with adjuvanted influenza vaccine was shown to induce local 
immune responses along with serum level protection in preclinical studies. This route, 
however, requires high doses of antigen to elicit an adequate immune response as the 
tolerance level is high for microbial antigens in the oral mucosa. Hence, a potent 
adjuvant is required for s.l. vaccines. Lipid-based delivery systems like liposomes and 
virosomes are likely to provide the best chances for transporting the vaccines across 
the mucosal membrane [69], although the success of this approach in humans has 
not been proven so far. 
The oral route of vaccination was considered ineffective in flu vaccination. However, 
research on oral vaccination has demonstrated that administration via this route can 
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also elicit immune responses once the antigen is protected against the low gastric pH 
and enzymatic degradation [113,114]. Although it is to be mentioned that so far 
this concept was proven effective in animals only. Novel oral delivery approaches like 
bilosomes can protect the antigen from denaturation or inactivation. Furthermore, 
they can transport the antigen effectively across the g.i. mucosa to elicit an immune 
response thereby improving the compliance level of vaccination. 
Perspectives of particulate influenza vaccines
At present, only a few PBVs are commercially available and they are all liquid 
formulations. Liquid formulations have a major drawback regarding stability. The 
particulate structure mixed with or containing the antigen has to be stabilized since its 
efficacy is thought to depend on its structure. A complicating factor is that in several of 
the new formulation types the antigen degrades faster than in the native WIV or LAV 
type formulations, since the intrinsic stabilizing effects of the virus wall components 
are missing in the new formulations. One of the options described to prevent the 
degradation of antigens in the particulate vaccine formulations is to convert them 
into solids [115–117]. Thereby, the movement of the antigens is restricted at the 
molecular level [118]. This can be achieved by lyophilizing the antigen with suitable 
lyoprotectants. Lyoprotectants that have been described include trehalose, mannitol, 
inulin and dextran. Choosing the corrected stabilizer is an important parameter as 
different materials provide different degrees of stabilization. For novel vaccination 
formulations with an improved compliance level, the particulate vaccines should be 
formulated in a form that is suitable for their intended route of administration. 
The liquid vaccines seem best suited for the i.n. vaccination as suitable delivery 
devices exist. However, devices for nasal powder administration have also been 
described [119,120]. Administration via the s.l. or oral route requires a suitable unit 
dosage form too. Formulating the stabilized vaccine into a tablet will further improve 
the compliance and reach of vaccination among the population during pandemics. 
Alternatively, the novel particulate vaccines can be formulated as powder vaccines 
for pulmonary delivery. Pulmonary vaccination of particulate influenza vaccines may 
improve immune response through active presentation of antigen to the APC in lung 
[121,122]. Mucosal vaccination with PBV formulations may increase the immune 
response. Especially, the induction of local IgA responses may be of interest since this 
may actively neutralize the virus at the port of entry. 
Conclusion
The formulation of influenza antigens in novel particulate-based formulations may 
boost the immune response after vaccination and open new (non-invasive) routes 
of administration. Moreover, the immune response could be boosted by combining 
these new PBVs with other potent adjuvants. PBVs mainly boost the immune 
response through an improved (often active) presentation of the antigen to APCs. 
However, several particulate vaccine formulations may need stabilizing formulations 
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Abstract
One of the advantages of dry influenza vaccines over conventional liquid influenza 
vaccines is that they can be used for alternative routes of administration. Previous 
studies showed that spray freeze drying is an excellent technique to prepare vaccine 
containing powders for pulmonary delivery (Amorij,J-P.; et al, 2007; Audouy,S.A.; 
et al, 2011). The aim of this study was to investigate the physical and immunogenic 
stability of spray freeze-dried whole inactivated virus influenza vaccine prepared 
by using inulin, dextran and a mixture of dextran and trehalose as protectants. 
Physical and biochemical characteristics of the vaccine powder were maintained at 
temperatures up to 30 °C for three months. In addition, in vivo data indicate that 
also the immunogenic properties of the vaccine were maintained under these storage 
conditions. On the other hand, in vivo results also revealed that subtle changes 
in powder characteristics were induced during storage at 30 °C. However, laser 
diffraction measurements showed that problems associated with these subtle changes 





Influenza vaccination is the main strategy for the containment of the virus during 
influenza outbreaks. Unfortunately, every year many doses of influenza vaccines are 
discarded as the potency of the vaccine is lost due to the limited stability of the 
aqueous dispersion[1,2]. A major disadvantage of current influenza vaccines is that 
they remain stable within the narrow temperature range of 4 to 8 °C only, which 
limits their widespread use especially during pandemic outbreaks. In addition, liquid 
vaccines are mainly administered via conventional routes like intramuscular (i.m.) 
and subcutaneous (s.c.) injection. Drawbacks like pain and needle fear reducing 
compliance, the chance for needle stick injuries and the need for trained health 
care workers to administer the injection, make injection a far from ideal method for 
vaccination [3]. Finally, influenza vaccines administered by injection predominantly 
induce a systemic immune response, which only provides protection at the systemic 
level and is not considered to be very effective in protecting the most vulnerable 
population, e.g. young children and elderly adults [4-6]. Although intranasally 
administered (i.n.) live attenuated influenza vaccine provides both local and systemic 
immune responses [7,8], it shares other drawbacks with conventional vaccines such 
as the requirement of a cold chain. Furthermore, this vaccine is not suitable for 
immune-compromised persons and children.
An attractive alternative to the current dosage forms could be a dry powder for 
pulmonary administration. Already more than 40 years ago several studies were 
performed to demonstrate the potential of pulmonary immunization using liquid 
influenza vaccine formulations [9,10]. The outcomes of these studies indicate that 
pulmonary immunization can induce same level of systemic immune responses 
compared to immune responses induced by vaccine administered via injection in 
humans. In addition, more recent studies show that pulmonary immunization 
also induce a local immune response, which bestows additional protection against 
influenza virus infection at the site of virus entry and might even provide cross-
protection against infection by heterologous viruses [11]. A further advantage of 
pulmonary immunization is the improved patient compliance. In addition, these 
vaccines do not require the involvement of trained health care personnel as they can 
be self-administered. This procedural simplicity would be an advantage in particular 
during a pandemic.
In the early studies in man liquid vaccine formulations were used and they 
were administered via nebulizers which are currently known for their poor and 
irreproducible dosing in the lung [12]. These problems may have been the reason for 
discontinuation of this research in the seventies of the previous century. However, 
modern technologies can overcome these problems. Moreover, scientific progress in 
drying technologies and dry powder inhalation systems has opened new possibilities 
for the development of stable dry powder inhalation systems for vaccines.
Pulmonary administration of influenza vaccines recently has regained interest 
because it became apparent that biopharmaceuticals such as vaccines can be brought 
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in a dry and stable state by incorporating them in a matrix of a sugar glass by freeze 
drying, spray drying or spray freeze drying (SFD) [13-16]. In previous studies we 
have shown that various types of influenza vaccines can be stabilized by freeze drying 
using the oligosaccharide inulin as stabilizer [17-19]. For pulmonary delivery we 
envisage that whole inactivated virus (WIV) influenza vaccine would be the best 
option since it is more immunogenic than other types of influenza vaccines [20-23]. 
For an effective deposition in the lungs, WIV has to be formulated into powder 
particles with an aerodynamic particle size ranging from 1-5 µm [12,24,25], which 
can be achieved by SFD [26]. Recently, Audouy et al [27] showed that WIV can 
be SFD in the presence of inulin without loss of its immunogenicity and that the 
powder is suitable for pulmonary administration. However, neither the physical nor 
the immunogenic storage stability of the SFD WIV powder was investigated.
The aim of the present study was to investigate these aspects of storage stability for 
a period of three months at various temperatures. The following parameters were 
evaluated: (i) physical powder characteristics, (ii) biochemical integrity of WIV, 
and (iii) in vivo antigenicity after pulmonary administration to mice. Additionally, 
we studied the possibilities to replace inulin by dextran or a mixture of dextran 
and trehalose (dex/trh) as a stabilizer. Dextran has excellent amorphous bulking 
properties when lyophilized [28] and low molecular weight dextran can also act as a 
lyoprotectant [29]. Also trehalose, a disaccharide, can preserve biopharmaceuticals 
during lyophilization [30-32]. However, due to its large specific surface area, SFD 
trehalose rapidly absorbs moisture when exposed to air and due to its relatively 
low glass transition temperature (Tg) of 121 °C, the powder easily becomes sticky 
(personal observations). These properties of SFD trehalose will impose problems 
while handling and dispersing a powder to an aerosol for inhalation. Therefore, to 
circumvent problems with stickiness of SFD trehalose we investigated a mixture of 
trehalose with dextran as the latter possesses a much higher Tg (220 °C). Hence, 
dextran and dex/trh [30] were investigated next to inulin in this study.
2. Material and Methods
2.1 Virus
Live influenza virus A/Hiroshima/52/2005 (A/Hir/H3N2) was kindly provided by 
Solvay Biologicals (Weesp, The Netherlands).
2.2 Vaccine preparation
WIV was produced by inactivating live A/Hir/H3N2 virus by overnight incubation 
with 0.1 % β-propiolactone (Acros Organics, Geel, Belgium) at room temperature 
in citrate buffer (125 mM Na3C6H5O7, 150 mM NaCl, pH 8.2) under continuous 
rotation. The inactivated virus was then dialyzed overnight at 4 °C against hepes 
buffered saline (HBS, 2 mM hepes, 125 mM NaCl, 0.9 mM CaCl2.2H2O and 
0.5 mM MgCl2; pH 7.4).  WIV protein content was determined by micro-Lowry 
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assay and its purity was analyzed by SDS-PAGE under reducing and non-reducing 
conditions followed by silver staining.
2.3 Spray freeze-drying
WIV was SFD together with inulin (4 kD; Sensus, Roosendal, The Netherlands) or 
dextran (6 kD; Sigma-Aldrich, Zwijndrecht, The Netherlands) or dex/trh (Cargill, 
Kerfeld, Germany) at a weight ratio of 1:1. A dispersion of WIV in HBS buffer 
containing 5 % w/v stabilizer was prepared at an HA:sugar weight ratio of 1:200. 
For placebo powder, a solution containing 5 % w/v stabilizer in HBS buffer without 
WIV was used. The dispersion/solution was pumped at a flow rate of 5 ml/min 
through a two-fluid nozzle (diameter 0.5 mm) of a Büchi 190 Mini Spray Dryer 
(Büchi, Flawil, Switzerland) and sprayed using an atomizing air flow of 600 ln/
hour in liquid nitrogen. The liquid nitrogen was allowed to evaporate after which 
the frozen droplets were placed on the shelf (pre-cooled to a temperature of -55 °C) 
of a Christ Epsilon 2-4 freeze dryer. Drying was performed at a pressure of 0.220 
mBar with a condenser temperature of -85 °C. The shelf temperature was gradually 
increased from -55 °C to 4 °C over 32 hours. Thereafter, the pressure was decreased 
to 0.055 mBar and the shelf temperature was gradually increased to 20 °C over 11 
hours. The powder vaccine was then collected in a hood at a relative humidity of 
10% or less and was stored at -20, 4, 30, and 40 °C in hermetically sealed injection 
vials for various periods of time.
2.4 Transmission electron microscopy
SFD vaccines were reconstituted with sterile water. Liquid and SFD formulations 
were dialyzed against ammonium acetate buffer (75 mM ammonium acetate, 
2.5 mM Hepes, pH 7.4) overnight at 4 °C. Dialyzed samples were placed on a 
glow discharged 200 mesh copper grid covered with Formvar film. Samples were 
stained with 3 % ammonium molybdate, pH 7.2 and analyzed on Philips CM 12 
transmission electron microscope (TEM).
2.5 Hemagglutination assay
WIV containing 0.1 µg/µl of hemagglutinin (HA) was diluted 1:10 (w/v), in PBS 
(154 mM NaCl, 12 mM Na2HPO4 0.9 mM KH2PO4, pH 7.4) and 50 µl was added 
in 96-well V-bottom plates containing 50 µl of PBS and serially diluted twofold 
in PBS. Subsequently, 50 µl of 0.1 % guinea pig red blood cells (RBC; Harlan, 
Zeist, The Netherlands) in PBS was added. Hemagglutination was determined two 
hours after incubation at room temperature. Hemagglutination titers were expressed 
as log2 of the highest dilution showing agglutination of RBC and recorded as one 
hemagglutination unit (HAU).
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2.6 Physical characterization of the powders
Scanning electron microscopy (SEM) was performed with a JEOL JSM 6301-
F microscope (JEOL Ltd., Tokyo, Japan). Samples were prepared by placing the 
powders on double-sided sticky carbon tape on a metal disk. Then the particles were 
coated with a layer of approximately 10 nm of gold using a Balzers 120B sputtering 
device (Balzer UNION, Liechtenstein). Images were captured at a magnification of 
1000x.
The geometric particle size distribution of the SFD powders was measured using 
a HELOS compact model KA laser diffraction apparatus (Sympatec GmbH, 
Clausthal-Zellerfeld, Germany). The powders were dispersed using a RODOS 
dispersing system at a pressure of 1 bar or using the dry powder insufflator (Penn-
Century Inc., Wyndmoor, USA).
The specific surface area of the SFD powders was determined using a Tristar surface 
analyzer (Micrometrics Instrument Corp., USA). The samples were loaded on the 
surface area analyzer, and the surface area was determined using the multipoint BET 
method from the nitrogen adsorption isotherm at 77 K.
2.7 Immunization of mice
Animal experiment handling and work protocols were approved by the local animal 
welfare and use committee of the University of Groningen, The Netherlands. An in 
vivo study was carried out in 6-8 weeks old female BALB/c mice (Harlan, Zeist, The 
Netherlands).
Mice were immunized twice at an interval of three weeks with the different WIV 
formulations containing 5 µg HA. For pulmonary vaccination, mice were anesthetized 
by inhalation of isoflurane/O2. Then the mice were intubated in vertical position 
with a modified Autograde catheter (Becton Dickinson, Breda, The Netherlands). 
SFD vaccine powder was delivered using a dry powder insufflator (Penn-Century 
Inc., Wyndmoor, USA). Approximately 1 mg of SFD vaccine powder was delivered 
to the lungs by giving three puffs with the insufflator. 50 µl of liquid aerosol vaccine 
was administered using an IA-1C Micro-sprayer aerosolizer for mice attached to the 
FMJ-250 high-pressure syringe (Penn-Century Inc., Wyndmoor, USA), and 50 µl of 
liquid aerosol of HBS was administered to the control group. Mice were placed in a 
recovery incubator at a temperature of 25 °C for two hours, and then placed back in 
the housing facility.
One week after the second dose, mice were sacrificed for evaluation of the immune 
response. After sacrifice, blood was withdrawn by heart puncture. Serum was stored 
at -20 °C until used. Nose washes and broncho-alveolar lavages (BAL) were obtained 
using 1 ml PBS, pH 7.4, containing complete protease inhibitor cocktail tablets 




Influenza specific IgG, IgG1, and IgG2a antibody amounts in serum and IgA 
antibody levels in nose wash, BAL and serum were measured using ELISA. The 
ELISA plates (Greiner bio-one, Alphen a/d Rijn, The Netherlands) were coated 
overnight at 37 °C with 500 ng/well of A/Hir/H3N2 WIV. Coated plates were 
washed once with coating buffer (17.8 mM Na2CO3, 22.5 mM NaHCO3, pH 9.6) 
and blocked with 2.5 % milk powder in coating buffer. After washing once with 
coating buffer and twice with PBS containing 0.05 % Tween 20 (PBST, pH 7.2), 
serial dilutions of the serum samples were applied to plates. Plates were then incubated 
at 37 °C for 90 minutes and were subsequently washed with PBST. Then, 100 µl of 
horseradish peroxidase (HRP) conjugated antimouse IgG, anti-mouse IgG1, anti-
mouse IgG2a or anti-mouse IgA (Southern Biotech, Birmingham, USA) diluted 
1:5000 in PBST was added followed by incubation at 37 °C for 60 minutes for the 
detection of IgG, IgG1, IgG2a and IgA, respectively. After extensive washing, 100 
µl phosphate-citrate buffer (0.2 M NaH2PO4, 0.1 M citric acid, pH 5, containing 
0.04% o-phenylenediamine and 0.012 % H2O2) was added. The enzymatic reaction 
was allowed to proceed at room temperature for 30 minutes and stopped by adding 
50 µl of 2 M H2SO4. The absorbance was measured at 492 nm using a Synergy 
HT reader (BioTek, Winooski, USA). Average IgG titers were determined as log10 
of the reciprocal of the sample dilution corresponding to an absorbance of 0.2 at a 
wavelength of 492 nm. IgA titers are presented as average of maximum absorbance of 
1:1 diluted nose and lung washes. IgG1 and IgG2a concentrations were determined 
using a calibration curve made by overnight coating 0.1 µg anti mouse IgG at 37 °C. 
Following extensive washing, increasing concentrations of 100 µl of IgG1 or IgG2a 
(Southern Biotech, Birmingham, USA) was added to the plates. Average influenza 
HA-specific IgG1 or IgG2a responses are presented as concentrations µg/ml.
2.9 Hemagglutination inhibition (HI) assay
HI titers were determined by HI assay as described before [33]. In brief, 75 µl of 
serum (pooled per experimental group) was inactivated by incubation at 57 °C for 
30 minutes. In order to prevent the non-specific hemagglutination, 225 µl of 25 % 
kaolin was added and incubated for 20 minutes. The suspension was then centrifuged 
for 2 min at 1400 x g. 50 µl of the resulting supernatant was added in duplicate to 
96-well V-bottom plates containing 50 µl of PBS and, diluted serially till the last 
well of the plate. Subsequently, 50 µl of PBS containing 4 HAU was added to each 
well and  mixed with a multichannel pipette. The plates were then incubated at room 
temperature for 40 minutes. Finally, 50 µl of 1 % guinea pig RBC was added and 
hemagglutination was allowed to proceed at room temperature for 2 h. The highest 
serum dilution capable of preventing hemagglutination was recorded as the HI titer.




The antibody titers are mentioned as geometric mean ± standard error mean. The 
difference in antibody titers was analyzed by one tailed Mann Whitney U-test at a 
confidence interval of 95 % (P≤0. 05). The significance was denoted by an increase 
in the number of symbols: one symbol (P≤0.05); two symbols (P≤0.01).
3. Results
3.1 Physical characterization of powders
Several physical characteristics of the SFD vaccine and placebo powders were 
evaluated in this study i.e. particle size, powder morphology, and specific surface 
area.
SEM of SFD powders
Analysis of the morphology of freshly prepared SFD inulin, dextran and dex/trh 
by SEM revealed that all three sugars formed highly porous spherical particles with 
interconnected pores and a particle size ranging from 1 to 10 µm (Figure1). No 
difference in powder morphology was observed for the different sugars. The high 
porosity and interconnectivity of the pores can be contributed to the removal of 
the ice crystals by sublimation, which were formed during freezing. Hence, mirror 
images of ice crystals are seen in the SEM images. 
a b
c
Figure1. Analysis of powder morphology 
by SEM (a) SFD inulin (b) SFD dextran 
and (c) SFD dex/trh.
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Particle size of vaccine and placebo powders
To be deposited in the lungs after inhalation, a particle should have an aerodynamic 
particle size between 1 and 5 µm. Larger particles are likely to be deposited in the 
throat while smaller particles will be exhaled after inhalation [34]. Laser diffraction 
measurements revealed that SFD yielded powder particles with cumulative 
geometric size distribution of X10, X50 and X90 of 3.5, 8 and 15 µm, respectively, 
(Table1) which may seem too large. However, laser diffraction measurements yield 
the geometric particle size and not the aerodynamic particle size. The aerodynamic 
particle size can be calculated from the geometric particle size by the following 
equation [35]:
 Where, dae is the aerodynamic diameter, de the geometric particle size, ρp the density 
of the particles (g/cm3), ρ0 the unit density (1 g/cm3) and, χ the dynamic shape 
factor. The atomized liquid droplet leaving the nozzle was measured by the laser 
diffraction and had an average geometric particle size of approximately 8 µm that 
was similar to the particle diameter of SFD powders. Apparently, the particle size 
of liquid droplet did not shrink during freeze-drying. Therefore, the solid content 
of the solution before SFD can be used to calculate the density of the final SFD 
powder particles. Since the total solid concentration of the solution before SFD 
was 50 mg/ml, the density of the SFD powder particles will be:  = 0.05 g/cm3. The 
dynamic shape factor of spherical particles is 1 and the SEM (Figure 1) confirmed 
the spherical shape of particles. Hence, it can be calculated that the aerodynamic 
diameter of X10, X50 and X90 of the SFD vaccine powder were around 0.8, 1.8 and 
3.3 µm, respectively, indicating that except for a small fraction these powders were 
suitable for inhalation.
Table 1. Comparison of geometric diameter of spray freeze-dried vaccine and placebo 
powder as determined by laser diffraction using the RODOS disperser. 
Sample
Vaccine powder (µm±SD) Placebo powder (µm±SD)
X10 X50 X90 X10 X50 X90
Inulin 3.56 ± 0.01 8.01 ± 0.03 14.84 ± 0.02 2.94 ± 0.12 7.48 ± 0.39 20.93 ± 0.11
Dextran 3.67 ± 0.02 8.30 ± 0.04 15.42 ± 0.01 2.29 ± 0.12 7.64 ± 0.05 17.95 ± 0.17
Dex/trh 3.25 ± 0.01 7.65 ± 0.31 14.78 ± 0.23 2.78 ± 0.83 6.96 ± 0.12 14.85 ± 0.33
Laser diffraction measurements revealed that immediately after production the 
geometric particle size distributions of the SFD inulin, dextran and dex/trh powders 
containing WIV and the corresponding placebo powders were similar (Table 1). 
Since for physical characterization huge amounts of powder are required and because 
the sugars were in large excess in the powders (weight ratio HA/sugar = 1/200), 
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placebo powders were used to evaluate the effects of storage on the shape and size 
characteristics.
To evaluate whether the particle size of the SFD powders changed during storage, the 
powders were analyzed by laser diffraction at various time intervals. The measurements 
(Figure 2) revealed that the particle size of SFD inulin, dextran and dex/trh stored 
at -20, 4 or 30 °C did not change. However, the particle size of SFD inulin stored 
at 40 °C was reduced 15 day after storage. The particle size of the SFD dextran was 
found to remain the same for 3 months at 40 °C. In case of the SFD dex/trh stored 
at 40 °C, particle size slightly reduced after 15 days of storage, and substantially after 
3 months of storage.
Evaluation of dry powder insufflator performance
The powder dispersing capacity of the dry powder insufflator was evaluated with 
the SFD inulin, dextran and dex/trh powders using laser diffraction. It was found 
that the particle size distribution of powder leaving the dry powder insufflator was 
highly irreproducible between the puffs. Moreover, it was found that the dry powder 
insufflator was dispersing particles with a bimodal distribution, i.e. particles with 
a size of about 10 µm and some with a size of about 100 µm. The X10, X50 and 
X90 values of a typical measurement with SFD powders dispersed by the insufflator 
are shown in Table 2. Laser diffraction measurements using the RODOS disperser 
showed no bimodal particle size distribution but small particles only (average of 
























































Figure 2. Particle size analysis of SFD 
(a) inulin, (b) dextran, and (c) dex/trh 
for a period of 3 month at  
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 40 °C. Values are 
represented as X50. The particle size was 
measured in triplicate. Since the standard 




Table 2. Results of a typical example of a laser diffraction measurement of SFD inulin, 
dextran and mixture of dextran and trehalose using the dry powder insufflator.
Sample
Freshly  prepared powder (µm)
X10 X50 X90
Inulin 21.99 100.55 153.13
Dextran 19.81 92.04 149.55
Dex/trh 4.06 13.96 119.84
around 8 µm; see Table 1). Dry powder insufflator has been reported efficient in 
dispersing spray dried powders [36]. However, our results show that the dry powder 
insufflator was not able to deagglomerate the highly fluffy SFD powders efficiently.
Specific surface area of placebo SFD powders
The specific surface area of placebo SFD powders before and after storage at different 
temperatures up to three months was evaluated by BET analysis (Figure 3). This 
analysis indicated that, immediately after preparation, the produced powders, 
irrespective of the sugar used, had a high surface area, thus confirming the presence 
of highly porous particles as observed by SEM. Yet, SFD inulin and SFD dextran 
both had a higher specific surface area (100-120 m2/g) than dex/trh (around 75 
m2/g). As mentioned in section 1.2., the density of the SFD particles were the same 
for all three sugars, which implies that the porosity was same in all cases. Since the 
specific surface area of SFD inulin and dextran was smaller than that of SFD dex/
trh, it can be concluded that the pore sizes in the SFD inulin and dextran particles 
were smaller than those in the SFD dex/treh particles. This indicates that during the 














































Figure 3. Specific surface area analysis of 
SFD (a) inulin, (b) dextran and, (c) dex/
trh stored for a period of 3 month at   
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 40 °C. 
The specific surface area was measured in 
triplicate. Since the standard deviations 
were small the error bars are not visible. 
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freezing step of the SFD process, nucleation of ice crystals was slower in the inulin 
and dextran solution than in the dex/trh solution which might be related to the 
lower viscosity of the latter. 
The specific surface area of all SFD powders remained unchanged during storage for 
3 months at -20, 4 or 30 °C.  However, at 40 °C the specific surface area of the SFD 
inulin was significantly reduced after 15 days of storage. Also the specific surface 
area of the SFD dex/trh was not stable during storage at 40 °C as it was reduced 
to 40 m2/g after 2 months and to 5 m2/g after 3 months. In contrast, the specific 
surface area of the SFD dextran sample was maintained during storage at 40 °C for 
3 months.
In conclusion, all three SFD powders could be stored at temperatures up to 30 °C for 
at least 3 months without substantial change of their physical powder characteristics. 
However, higher storage temperatures led to changes in the physical properties of 
SFD inulin and dex/trh but the powder properties were retained in SFD dextran.
3.2 Characterization
Morphology of WIV
The immunogenicity of WIV relies on the presence of intact virus particles, which 
retain the structure of the live virus and harbor all virus components including the 
single stranded viral RNA which is an important trigger of innate immune reactions 
[37]. To evaluate whether the particulate nature of WIV was preserved during the 




Figure 4. TEM images of (a) unprocessed WIV and WIV SFD in the presence of (b) 
inulin, (c) dextran and (d) dex/trhand then reconstituted.
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Figure 5. Hemagglutination titers of WIV in (a) unprocessed liquid, (b) SFD inulin, (c) 
SFD dextran and (d) SFD dex/trh  stored  for 3 months at   
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30, and  















 40 °C. The HA titers of SFD dex/trh stored at 30 °C are superimposed 
with HA titers of samples stored at 40 °C from 2 months. The HI titers were measured 
in triplicate. Since no differences in HA titers were found no error bars are shown. (e) 
SDS PAGE analysis of freshly prepared and SFD and reconstituted WIV stored for three 
months at 30 °C.
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TEM images of liquid WIV and WIV SFD in the presence of inulin, dextran or 
dex/trh and then reconstituted with water revealed that stress related to SFD did 
not affect the particulate nature of WIV. Presence of WIV particles with sizes of 100 
nm to 150 nm and clearly visible spikes on the viral membrane indicates that inulin, 
dextran and dex/trh are suitable stabilizers during SFD of WIV.
Hemagglutination titers
The biological activity of HA after SFD with inulin, dextran or dex/trh and subsequent 
storage at -20, 4, 30 or 40 °C for up to three months was evaluated by measuring 




















































































































Figure. 6 WIV specific humoral immune 
responses induced in mice two weeks after 
booster dose by pulmonary immunization 
of SFD vaccine powders. (a) Nasal IgA 
(b)BAL IgA and (c) serum IgG antibody 
responses induced by freshly prepared 




The activity of HA in unprocessed WIV (Figure 5a) was reduced by more than 
100-fold (log27 when stored at 30 °C or 40 °C for 1 month. In addition, there 
was a gradual loss in hemagglutination titer for samples stored at -20 and 4 °C. 
The hemagglutination titers of WIV after SFD with inulin, dextran or dex/trh were 
found to be unchanged after storage for a period of 3 months at temperatures up to 
40 °C (Figure 5b-d).
To further determine the molecular stability of the proteins present in WIV, freshly 
prepared vaccines and vaccines stored for three months at 30 °C were analyzed by 
SDS-PAGE. The gel of freshly prepared WIV showed a band pattern consistent 
with the structural proteins present in WIV (Figure 5e). Four bands associated with 
proteins of WIV were observed on the gel, viz., HA1: 47 kD, NA: 50 kD and HA2: 
29 kD. No difference was found in the band pattern between freshly prepared liquid 
or reconstituted SFD formulations and SFD formulations stored at 30 °C. Yet, the 
band color intensity was observed to be lower for the SFD formulations stored at 30 
°C. However, a larger difference was observed in the banding pattern between freshly 
prepared WIV and liquid WIV stored at 30 °C. Bands of HA1 and HA2 which 
could be easily identified  in freshly prepared WIV were almost absent in WIV stored 
at 30 °C for 3 months.
Preservation of the hemagglutinating function of HA and the unchanged protein 
patterns revealed by SDS-PAGE demonstrate that the stresses of the SFD process and 
storage of the SFD powders at 30 °C for three months did not result in aggregation 
or cleavage of the WIV proteins.
3.3 Immune response after vaccination
Evaluation of humoral immune responses evoked by SFD and 
reconstituted vaccines
To evaluate the effect of the different sugars on preservation of the immunogenic 
properties of the vaccines mice were immunized twice via the pulmonary route with 
the different SFD vaccine powders which were either freshly prepared or stored 
at 30 °C for 3 months. Nose washes, BAL and serum samples were collected one 
week after the second dose and analyzed by ELISA (Figure 6a-c). No significant 
differences were found in the immune responses evoked by  freshly prepared SFD 
vaccine powders with the different sugars except for BAL IgA which was somewhat 
lower for the SFD vaccine powder based on dextran . Comparison of IgA antibody 
responses in nose and BAL washes between mice that received freshly prepared 
and stored SFD vaccine powders showed that in all cases there was a decreased IgA 
antibody production in the mice vaccinated with the stored formulations although 
the differences were not always significant (Figure 6a-b). Similarly, evaluation of 
IgG antibody titers in serum revealed that SFD vaccine powders stored at 30 °C for 
three months induced significantly lower IgG antibody titers than freshly prepared 
SFD formulations vaccine powders (Figure 6c), and the same trend was seen for the 
HI titers of the sera (data not shown).










































































































































Figure 8. The phenotype of immune 
response induced in mice by reconstituted 
SFD vaccines determined by IgG subtypes 
analysis. Serum (a) IgG2a (b) IgG1 and 
(c) IgG2a/IgG1 antibody ratios induced by 
freshly prepared vaccines (striped bars) and 





















































































Figure 7. WIV specific humoral immune responses evoked by reconstituted SFD vaccines. 
(a) Serum IgG antibody responses and (b) Serum HI titers induced by freshly prepared 




The  lower mucosal and systemic antibody induction in mice after pulmonary 
administration of SFD vaccine powders stored at 30 °C could be due to loss of 
antigenicity of the vaccine or due to changes in physical powder characteristics after 
storage leading to less effective vaccine administration or due to both. However, 
our in vitro studies showed that both the physical powder characteristics and the 
integrity of the vaccine did not change substantially during storage. To elucidate 
this inconsistency, freshly prepared as well as stored SFD vaccine powders were 
reconstituted with water and then pulmonary administered to mice with the micro-
sprayer. The serum IgG antibody response as determined by ELISA (Figure 7a) 
showed that stored liquid WIV induced significantly lower levels of IgG antibody 
titers in mice than freshly prepared WIV or SFD vaccine powders reconstituted 
after storage. Furthermore, SFD vaccine powders, reconstituted after storage, 
induced a similar level of IgG antibody titers as SDF vaccine powders reconstituted 
immediately after preparation. HI titers were in line with the IgG antibody titers as 
the stored liquid WIV elicited significantly decreased HI titers compared to SFD 
powders reconstituted immediately after preparation or after storage or the freshly 
prepared liquid formulation (Figure 7b).
The subtypes of IgG antibodies (IgG2a and IgG1) induced after pulmonary 
administration of stored (three months at 30 °C) or freshly prepared, liquid WIV or 
reconstituted SFD vaccine powders were analyzed by ELISA. It was found that stored 
liquid WIV induced significantly lower amounts of IgG2a and IgG1 antibodies than 
freshly prepared or stored SFD vaccine powders or freshly prepared WIV (Figure 8a-
b). Furthermore, storage of the SFD vaccine powders did not affect the induction of 
IgG1 and IgG2a antibody titers. Analysis of the IgG2a/IgG1 ratio (Figure 8c) shows 
that pulmonary vaccination induced a IgG1-dominated antibody response which is 
in line with a previous study [27].
Overall, the HI titers, IgG titers and the  IgG2a and IgG1subtype titers demonstrate 
that the antigenicity of WIV stored at 30 °C for three months was better preserved in 
SFD than in liquid vaccine formulation. Furthermore, the stabilizers used for SFD 
had no effect on the preservation of the immunogenicity of the vaccines.
4. Discussion and conclusion
In this study, we prepared a dry powder influenza WIV formulation by SFD using 
inulin, dextran, or dex/trh as stabilizing excipients. The aerodynamic diameter of 
the SFD powders was about 0.8, 1.8 and 3.3 µm for X10, X50 and X90 indicating 
that almost all of the powder particles were suitable for inhalation. Furthermore, 
we showed that for all three stabilizers the SFD vaccine powders could be prepared 
without loss of the particulate nature, biochemical integrity and receptor-binding 
property of the incorporated WIV as shown by TEM, SDS-PAGE and HA assay, 
respectively.




During storage of the SFD powders for three months at temperatures up to 30 °C, 
the physical powder characteristics, i.e. particle size distribution and specific surface 
area, remained the same. However, when stored at 40 °C, the size and specific surface 
area of SFD particles of inulin and dex/trh were reduced. These results indicate 
that the inulin and dex/trh particles shrunk during storage, yet without displaying 
macroscopic viscous flow. These observation can be related to the Tg of the powders. 
The Tg of dry dextran was found to be 220 °C, whereas the Tg of dry inulin and 
dry dex/trh was in both cases 154 °C. All these Tg values are far above storage 
temperatures implying that all three sugars are suitable as stabilizers. However, it 
is to be realized that residual moisture is a potent plasticizer for sugar glasses. Thus, 
residual moisture present in the samples (although not determined) will strongly 
reduce the Tg [38]. As all powders were prepared by an identical procedure it can be 
assumed that all contained equal amounts of residual moisture. For inulin and dex/
trh this moisture might have been sufficient to reduce the real Tg values from 154 
°C to close to 40 °C. In contrast, for dextran with a high initial Tg of 220 °C, the 
residual moisture was possibly insufficient to lower the Tg to 40 °C. The shrinkage 
of the inulin and dex/trh containing particles is in line with this reasoning. The 
shrinkage indicated that there was some translational molecular mobility but not to 
such an extent that macroscopic viscous flow occurred.
Furthermore, WIV incorporated in the SFD powders retained its particulate nature, 
biochemical integrity and receptor-binding properties during three months storage 
at temperatures up to 30 °C. As expected, the unprocessed liquid WIV formulation 
was less stable. Replacing inulin by dextran and dex/trh revealed that both these 
sugars are also excellent stabilizers for WIV during SFD and subsequent storage. 
Additionally, WIV incorporated in dextran was even stable at temperatures as high as 
40 °C. Overall, WIV SFD  in the presence of all three sugars yielded a stable product 
when stored at 30 °C. Hence, the SFD vaccine powders stored at 30 °C for three 
months were selected for the immunization of mice. The pulmonary administration 
of the SFD vaccine powders induced IgA in the nose and BAL washes, serum IgG 
and serum HI titers. However, to our surprise the stored SFD vaccine powders were 
found to elicit significantly lower antibody and HI titers than the freshly prepared 
SFD vaccine powders. In contrast, immunization experiments with reconstituted 
SFD vaccines demonstrated that the immunogenicity of WIV was not decreased 
during storage of the SFD powders. This indicates that although not detected by 
laser diffraction and BET measurements, the physical properties of the SFD vaccine 
powders must have changed during storage such that delivery to the lungs was 
hampered. Possibly, the results can be explained as follows: for the determination 
of the particle size distribution by laser diffraction, the RODOS disperser was 
used. It is well known that the RODOS dispenser is a very powerful disperser [39]. 
In contrast, the dry powder insufflator was found to exhibit very poor dispersing 
capacities for the SFD powders as not only primary particles left the insufflator but 
also large agglomerates. Therefore, it could be that during storage subtle changes to 
the physical properties of the SFD powder occurred that were not significant enough 
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Enhanced pulmonary immunization with aerosolized inactivated influenza 
vaccine containing delta inulin adjuvant





Vaccination is the primary intervention to contain influenza virus spread during 
seasonal and pandemic outbreaks. Pulmonary vaccination is gaining increasing 
attention for its ability to induce both local mucosal and systemic immune responses 
without the need for invasive injections. However, pulmonary administration of 
whole inactivated influenza virus (WIV) vaccine induces a Th2 dominant systemic 
immune response while a more balanced Th1/Th2 vaccine response may be preferred 
and only induces modest nasal immunity. This study evaluated immunity elicited 
by pulmonary versus intramuscular (i.m.) delivery of WIV, and tested whether the 
immune response could be improved by co-administration of delta (δ)-inulin, a 
novel carbohydrate-based particulate adjuvant. After pulmonary administration both 
unadjuvanted and δ-inulin adjuvanted WIV induced a potent systemic immune 
response, inducing higher serum anti-influenza IgG titers and nasal IgA titers than 
i.m. administration. Moreover, the addition of δ-inulin induced a more balanced 
Th1/Th2 response and induced higher nasal IgA titers versus pulmonary WIV 
alone.  Pulmonary WIV alone or with δ-inulin induced hemagglutination inhibition 
(HI) titers > 40, titers which are considered protective against influenza virus. In 
conclusion, in this study we have shown that δ-inulin adjuvanted WIV induces a 




Influenza vaccines are important in controlling virus infection and spread during 
seasonal and pandemic outbreaks. Conventionally, inactivated influenza vaccines are 
administered by subcutaneous or intramuscular injection, with just live attenuated 
vaccines being administered by intranasal spray. However, non-invasive routes of 
inactivated influenza vaccine administration, including intranasal, sublingual, 
intradermal and pulmonary delivery have gained increasing attention [1–4]. 
The pulmonary route is an attractive route given its non-invasive nature, ease of 
administration and lack of need for trained health care workers. A further potential 
advantage of pulmonary immunization is the ability to induce local mucosal 
immune protection in the respiratory tract, e.g. via secretory IgA production [5]. 
However, there are also some short comings of pulmonary route of vaccination 
including a propensity to induce a dominant Th2 immune response [6,7]. A more 
balanced Th1/Th2 vaccine response is preferred as the combination of cellular with 
humoral immunity protects the host better against invading influenza viruses [8]. 
Furthermore, although pulmonary influenza vaccines elicit local immune responses 
in the respiratory tract, their ability to induce intranasal IgA antibody titers are only 
modest [6,7,9]. A strong mucosal response in the nose and lungs is desired to provide 
maximal protection at the port of entry for the influenza virus [10]. 
Addition of a suitable adjuvant to a pulmonary influenza vaccine could help improve 
vaccine immunogenicity and thereby its ability to protect against a viral infection. 
Carbohydrate-based adjuvants have gained recent attention with their ability to 
combine a high level of efficacy, tolerability and safety [11]. The lack of reactogenicity 
of carbohydrate-based adjuvants namely δ-inulin and δ-inulin, as demonstrated in 
both animal models and human vaccine trials [12], suggests their suitability for 
pulmonary use although to date they have predominantly been used by i.m. and 
s.c. routes [13]. δ-inulin, the most immunologically active inulin polymorph [14], 
was shown to have potent adjuvant activity when co-administered i.m. with seasonal 
or pandemic inactivated or recombinant influenza vaccines in the form of Advax™ 
adjuvant [12,15,16]. Therefore, we hypothesized that δ-inulin might similarly 
be able to enhance influenza vaccine immunogenicity when administered via the 
pulmonary route. This study therefore set out to compare mucosal and systemic 
WIV immunogenicity when administered by pulmonary versus i.m. routes with or 
without δ-inulin adjuvant.
2. Material and method
2.1 Vaccine
The WIV antigen (A/California/7/2009 (H1N1)) was produced and inactivated 
as previously reported [6]. After inactivation and dialysis, the protein content of 
the vaccine was determined by the micro Lowry assay [6]. The adjuvanted vaccine 
was prepared by mixing 200 µg of δ-inulin adjuvant (Advax™ adjuvant, 1 mg/ml, 
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Vaxine Pty Ltd, Adelaide, Australia) with WIV equivalent to 5 µg of HA (0.1 µg/µl) 
immediately prior to vaccination.
2.2 Immunization studies and sample analysis
The local animal welfare and use committee of the University of Groningen approved 
all animal experiment handling and work protocols. The study was carried out in 
6-8 week old female BALB/c mice (Harlan, Zeist, The Netherlands). Mice were 
immunized twice at a two week interval (day 0 and 14) with WIV formulations 
containing 5 µg HA with or without 200 µg of δ-inulin adjuvant. For pulmonary 
immunization, mice were anesthetized by inhalation of isoflurane/O2 then intubated 
in vertical position with a modified Autograde catheter (Becton Dickinson, Breda, 
The Netherlands). 50 µl of vaccine was delivered to the lungs of the mice using a 
IA-1C micro-sprayer attached to a FMJ-250 high-pressure syringe (Penn-Century 
Inc., Wyndmoor, USA). For i.m. immunization, 50 µl of vaccine was administered 
by dividing the dose equally between both hind limbs. Mice were then placed in a 
recovery incubator at a temperature of 25 °C for 2 hours, and then placed back in 
the housing facility.
Two weeks after the first dose, blood samples were withdrawn by facial vein technique 
for evaluation of the immune response. Two weeks after the second dose, the mice 
were sacrificed. After sacrifice, blood samples were withdrawn by heart puncture. 
Serum was stored at -20 °C until used. Nose wash was obtained using 1 ml PBS, 
pH 7.4, containing complete protease inhibitor cocktail tablets (Roche, Almere, 
The Netherlands). The collected samples were analyzed by ELISA to evaluate anti-
influenza IgG, IgG1, IgG2a, and IgA antibody titers. Serum samples were also 
analyzed for anti-influenza HI titers, as previously described [7].
2.3 Statistical analysis
Immunoglobulin and HI titers are reported as geometric mean ± standard error 
mean. The differences in titers were analyzed by two-tailed Mann Whitney U-test at 
a confidence interval of 95 % (P≤0. 05). The significance level in figures is denoted 
by an increase in the number of “*” symbols: one symbol (P≤0.05); two symbols 
(P≤0.01) and three symbols (P≤0.001).
3. Results
3.1 Anti-influenza IgG responses 
The immune responses evoked in mice by i.m. or pulmonary immunization with 
or without δ-inulin adjuvant were first evaluated by measuring total serum anti-
influenza IgG titers 14 days after the first and second immunization. Both i.m. and 
pulmonary immunization with or without δ-inulin adjuvant induced potent IgG 
responses even after the first immunization with further increases in anti-influenza 
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IgG titers seen after the second immunization (Figure 1). While after just a single 
immunization, anti-influenza IgG titers were significantly lower in the group 
receiving WIV alone by the pulmonary route when compared to WIV alone given 
by i.m injection, this reduced immunogenicity in the singe dose pulmonary group 
was more than compensated for by the addition of δ-inulin adjuvant, with the 
single dose WIV+ δ-inulin pulmonary group achieving higher IgG titers than the 
equivalent single dose i.m. groups. 
Furthermore, while after the second immunization in the i.m groups the increases 
in anti-influenza IgG were relatively modest (approximately 1 log), the increases 
in IgG titers after the second immunization in the pulmonary groups were much 
greater (approximately 3 logs for the WIV alone group and 1.5 logs for the WIV+ 
δ-inulin adjuvant group). Hence after two immunizations pulmonary immunization 
with or without δ-inulin adjuvant induced significantly higher IgG antibody titers 
than two doses of i.m. vaccine, either with or without adjuvant. Two weeks after 
the second vaccination, the mice that received i.m. vaccine with δ-inulin adjuvant 
achieved a significantly higher anti-influenza IgG response than mice that received 
i.m. WIV vaccine alone (P=0.0002), whereas two weeks after the second vaccination, 
there were no longer significant differences in anti-influenza IgG titers in mice that 
received pulmonary WIV vaccine with δ-inulin adjuvant compared to those that 









































Figure 2. WIV specific serum IgG subtypes, 
IgG1 (gray bars) and IgG2a (black bars) 
antibody titers induced on day 28 after i.m. 










































Figure 1. WIV specific serum IgG 
antibody titers induced on day 14 (gray 
bars) and day 28 (black bars) after i.m. 
and pulmonary vaccination on day 0 
and day 14.




























































Figure 3. WIV specific serum HI levels 
induced on day 14 (gray bars) and day 
28 (black bars) after i.m. and pulmonary 
vaccination on day 0 and day 14. The HI 
titers were measured in triplicate. Since no 
differences in HI titers were found no error 
bars are shown
Figure 4. WIV specific nose IgA 
antibody levels induced by unadjuvanted 
(gray bars) and adjuvanted WIV (black 
bars) vaccine on day 28 after i.m. and 
pulmonary vaccination on day 0 and 
day 14.
Phenotype of i.m versus pulmonary vaccine responses 
Anti-influenza IgG subtypes were evaluated two weeks after the second vaccination 
(Figure 2). Pulmonary immunization with WIV alone induced primarily an IgG1 
response, consistent with a Th2 dominant immune response, consistent with the 
results of previous studies [6,7].  This compared to the i.m groups with or without 
adjuvant where the titers of IgG1 and IgG2a were approximately equal (Figure 2), 
consistent with a more balanced Th1/Th2 response. The addition of δ-inulin adjuvant 
to the pulmonary immunization group significantly increased the IgG2a antibody 
titers when compared to WIV alone given pulmonary without compromising the 
IgG1 antibody titers, thereby resulting in a more balanced Th1/Th2 response. 
This was interesting as by contrast the addition of δ-inulin adjuvant to the i.m 
immunization group resulted in primarily in enhancement of the IgG1 rather than 
IgG2a response.
Hemagglutination inhibition titers after i.m. and pulmonary 
vaccination
Hemagglutination inhibition (HI) antibody titers reflect the subfraction of anti-
influenza immunoglobulin that is able to block influenza virus attachment to 
mammalian sialic acid receptors and thereby more directly measures the amount 
of neutralizing antibodies induced by an influenza vaccine, with an HI titer of 40 
considered to be protective [17]. After the second immunization, all groups whether 
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i.m and pulmonary, achieved an HI titer > 40, consistent with protection (Figure 
3). There were no significant difference between the i.m WIV alone group and both 
pulmonary vaccine groups, with the only group having significantly higher HI titers 
than the i.m WIV alone group being the δ-inulin adjuvanted i.m. vaccine group 
(Figure 3).
Mucosal response after i.m. versus pulmonary immunization
The production of local secretory IgA at relevant mucosal respiratory surfaces was 
shown to be an important first line of defense against influenza virus attachment and 
infection. In general, mucosal IgA is not seen after intramuscular immunization. 
The mucosal immune response to i.m. or pulmonary immunization was therefore 
evaluated by measuring anti-influenza IgA levels in nasal washings of immunized 
mice (Figure 4). WIV vaccine given pulmonary with or without adjuvant induced 
significantly higher anti-influenza IgA titers in nasal washings than obtained 
with the i.m. vaccine. Furthermore, δ-inulin adjuvant significantly enhanced the 
anti-influenza IgA titers in nasal washings compared to WIV vaccine alone given 
pulmonary (P=0.02) (Figure 4). 
4. Discussion and conclusions
To our knowledge, this is the first study to confirm that δ-inulin maintains its vaccine 
adjuvant activity when administered via the pulmonary route. Mice receiving δ-inulin 
adjuvanted influenza vaccine administered via the pulmonary route demonstrated 
a more balanced Th1/Th2 immune response whereas pulmonary administration 
of WIV alone demonstrated a marked Th2 bias in their antibody response. This 
Th1 enhancement of the antibody response to a pulmonary vaccine by δ-inulin is 
in contrast to the results seen when it was given i.m where it primarily enhanced 
IgG1 production consistent with a more Th2 action, and suggests that the immune 
pathways activated in the lung by δ-inulin may differ from the pathways it activates 
after i.m. injection. Another feature of δ-inulin when given pulmonary was its ability 
to enhance mucosal anti-influenza IgA titers. The most marked pulmonary effect of 
δ-inulin adjuvant on IgG titers was seen after a single immunization, when it enabled 
higher anti-influenza IgG titers to be achieved than obtained after even two i.m 
immunizations with WIV alone, or a single i.m immunization with WIV + δ-inulin. 
Previously, pulmonary or intranasal vaccines have generally required multiple booster 
vaccine doses to achieve satisfactory immunogenicity [6,18]. Based on these findings 
it may be possible to utilize δ-inulin adjuvant along with antigen dose optimization 
and delivery strategies to achieve single dose pulmonary vaccine protection, and this 
will be tested in future influenza challenge studies. While pulmonary delivery of WIV 
when compared to i.m. delivery induced a broader antibody isotype response than 
included IgA, and after two doses achieved HI titers considered protective, for as yet 
unexplained reasons there was a divergence such that whilst the anti-influenza IgG 
titers were substantially higher, the HI titers induced by pulmonary vaccination were 
Pulmonary  influenza vaccination with δ-inulin adjuvant
4
58
substantially lower than those induced by i.m. vaccination. Typically, WIV vaccines 
induce a Th1-biased immune response upon i.m. vaccination while Th2 dominant 
responses have usually been seen after pulmonary vaccination suggesting that the lung 
may have an innate Th2 bias [6,19]. The Th2 immune response helps to neutralize 
the virus whereas the Th1 immune response assists in clearing virally-infected cells 
from the host [8]. Hence, a balanced Th1/Th2 type of immune response should be 
optimal for influenza virus neutralization and clearance. Our results show that the 
δ-inulin adjuvanted pulmonary vaccine was capable of inducing a more balanced 
Th1/Th2 immune response than the WIV alone pulmonary vaccine. Furthermore, 
mucosal IgA is beneficial because it neutralizes the influenza virus at the port of entry 
and thus enhances protection [20,21]. Moreover, IgA antibodies are known for their 
broad spectrum protection, i.e. they are cross-protective against a range of drifted, 
heterologous influenza strains [22]. The results of this study show that significant 
anti-influenza IgA was only induced by pulmonary but not i.m. vaccination and 
was further improved by the δ-inulin adjuvant. Future studies will test the extent 
to which this enhanced mucosal IgA production might contribute to enhanced 
protection against influenza infection. 
A wide variety of adjuvants including cholera toxins, squalene oil emulsions, 
saponins, CpG oligonucleotides, and ISCOMS have been tested for efficacy in 
animal models of intrapulmonary or intranasal immunization with variable results 
[23–28]. However, the single most important consideration for an adjuvant to be 
administered to the lung, nose or other mucosal surfaces is safety, given previous 
mucosal adjuvant misadventures most particularly the occurrence of facial nerve 
palsy in human trials of a Escherichia coli heat-labile toxin adjuvanted intranasal 
inactivated influenza vaccine [29], an event later shown to be directly attributable 
to the Escherichia coli heat-labile toxin adjuvant [30]. With these safety issues in 
mind, it is reassuring that δ-inulin has a strong safety and tolerability record when 
administered by the i.m. route in multiple preclinical and human clinical studies 
[12,15,16]. Of course, this i.m administration data does not guarantee against an 
unforeseen effect specific to lung administration and hence formal preclinical safety 
studies of δ-inulin’s intrapulmonary use will be required to exclude such a possibility, 
prior to any commencement of any human studies. However, no differences in 
animal well-being, e.g. weight loss, were observed between the pulmonary groups 
with or without adjuvant and the i.m groups (data not shown). The absence of 
any obvious pulmonary or systemic adverse events in mice in this study receiving 
δ-inulin adjuvant is reassuring and supports the idea that inulin particles might be 
safely administered to the lung as part of an intrapulmonary vaccine formulation.
In conclusion, our results clearly indicate that δ-inulin has adjuvant activity when 
administered through the pulmonary route with an inactivated influenza vaccine, 
inducing changes to the balance of IgG isotypes resulting in a more balanced Th1/
Th2 response and promoting the production of secretory IgA in the nose. The 
extent to which this contributes to protective immunity will need to be clarified in 
future influenza virus challenge studies. These studies will also look at the effect of 
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changes in the dose of either the influenza antigen, the δ-inulin adjuvant or both 
on optimization of the anti-influenza immune response, with the ultimate goal of 
testing whether protection against influenza with a single dose of intrapulmonary 
vaccine is in fact achievable.
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Abstract
Prophylaxis against influenza could be improved by the development of a stable, 
easy to deliver, potent mucosal vaccine. In this study, we spray-freeze-dried 
(SFD) whole inactivated virus influenza vaccine (WIV) alone or supplemented 
with monophosphoryl lipid A (MPLA) using inulin as a lyoprotectant. Physical 
characterization revealed that the SFD powder consisted of highly porous particles 
with a size distribution suitable for pulmonary administration. The receptor-binding 
properties of WIV and the immunostimulatory properties of MPLA were preserved 
after spray-freeze-drying as indicated by unchanged hemagglutination titers and a 
retained ability of the vaccine to activate NFkB after incubation with a reporter 
cell line, respectively. Pulmonary vaccination of mice with MPLA-adjuvanted 
liquid or powder WIV resulted in induction of higher mucosal and systemic 
antibody concentrations than vaccination with non-adjuvanted formulations. When 
exposed to influenza virus, mice immunized with MPLA-adjuvanted pulmonary 
vaccine showed similar protection in terms of reduction in lung virus titers and 
prevention of weight loss as mice immunized intramuscularly with subunit vaccine. 
Characterization of the antibody response revealed a balanced IgG2a-to-IgG1 profile 
along with induction of both memory IgA- and IgG-producing B cells in mice 
immunized with MPLA-adjuvanted vaccine. These studies suggest that the mucosal 
and systemic immune responses to pulmonary delivered influenza vaccines can be 
significantly enhanced by using MPLA as adjuvant. MPLA-adjuvanted SFD vaccine 
was particularly effective implying that delivery of adjuvanted vaccine powder to the 




Influenza virus spreads via aerosols and is therefore easily transmitted from person to person. 
According to the World Health Organization (WHO), around 250,000 to 500,000 
people yearly die because of influenza infections, and around 3 to 5 million people 
suffer from severe illness[1]. During a pandemic, this number can increase by several-
fold, as demonstrated by the 1918 Spanish Flu with 40 to 50 million deaths[2,3]. 
Today, the spread of a virus would be much faster than in previous pandemics because 
of global travel and contacts, and therefore vaccine distribution and administration 
should be similarly rapid. Hence, in the context of pandemic preparedness there is 
a need for a vaccine which can be stockpiled for years[4,5], is easy to administer, 
and when administered, evokes a serum IgG antibody response along with a robust 
mucosal IgA antibody response which neutralizes the virus at the port of entry and 
provides some degree of cross-protection[6]. 
Inactivated influenza vaccines available today are administered by intramuscular 
(i.m.) injection. These formulations have several disadvantages for use as a pandemic 
vaccine. First, current vaccines are liquid and require a cold chain until vaccine delivery, 
making vaccine distribution difficult in remote areas. Second, for administration 
of needle-based vaccines trained medical personnel is required[6]. Third, vaccine 
injection is time consuming, especially when dealing with people suffering from 
needlephobia[7-9]. Finally, current inactivated influenza vaccine, being administered 
parenterally, induce serum IgG  but no mucosal IgA. Pulmonary vaccination is an 
attractive method for vaccine delivery. This vaccination strategy targets the lungs 
which are highly vascularized organs and offer a large surface area with strategically 
located dendritic cells and macrophages for antigen capture and presentation [6,10]. 
Pulmonary immunization can be performed with aerosolized liquid vaccine or with 
vaccine formulated as dry powder. Dry powder influenza vaccines are particularly 
attractive since they offer higher stability than liquid vaccine at low as well as at 
elevated temperatures [11,12]. Pulmonary delivery strategies have been successfully 
employed for several vaccines. The development of this strategy is most advanced 
for the live attenuated measles vaccine which has been successfully tested in several 
field trials [13]. In the context of influenza vaccines, early studies by Waldmann 
et al and Haigh et al[14,15] indicated the feasibility of pulmonary immunization 
strategies in a clinical setting but pulmonary influenza vaccination has been studied 
most extensively in mice. Immunization with liquid or dry powder subunit or split 
influenza vaccine formulations resulted in immune responses comparable to or 
higher than those induced by i.m. immunization[11,16,17]. Moreover, pulmonary 
immunized mice showed the same level of protection against virus growth in the 
lungs as mice that were conventionally immunized by the i.m. route[18]. 
However, despite these promising results immune responses achieved by pulmonary 
immunization need further optimization. While pulmonary immunization with 
unadjuvanted influenza subunit or WIV vaccines did result in induction of IgA 
antibodies in the lungs, only some of the immunized  mice mounted measurable IgA 
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responses in the nose and in those that did antibody titers were low[17,18]. Next to 
IgA also IgG participates in protection from influenza[19]. In mice the Th1 related 
IgG subtype IgG2a is particularly effective[20]. Yet, antibody responses observed in 
mice after pulmonary vaccination with whole inactivated virus (WIV) or subunit 
influenza vaccine were dominated by the Th2-related antibody subtype IgG1[21]
[18]. Although the relevance of different IgG subtypes for protection in humans is 
so far unclear we expect a Th1 type response to be favorable for protection.  One 
potential solution to the above mentioned problems might involve the addition of 
an adjuvant to the vaccine in order to steer the immune response to the desired Th1 
phenotype and to enhance the stimulation of mucosal immune responses. Initiation 
of Th1 response leads to activation of pro-inflammatory cytokines which promotes 
IgG2a antibody production. Toll-like receptor (TLR) ligands are acknowledged for 
their ability to induce potent immune responses to antigen with which they are 
co-administered[22]. One such TLR ligand is monophosphoryl lipid A (MPLA), 
a low toxicity derivative of lipopolysaccharide (LPS) derived from the cell wall of 
gram-negative bacteria. As LPS, MPLA is a ligand of TLR 4 which is expressed on 
immune as well as on respiratory epithelial cells[23,24]. MPLA is recognized for its 
ability to skew responses towards Th1 thus promoting IgG2a antibody production 
in mice. In addition, MPLA has been shown to effectively stimulate IgA antibody 
responses against mucosally administered Hepatitis B surface antigen, tetanus toxoid, 
respiratory syncytium virus (RSV) vaccine and influenza subunit vaccine[25,26] . 
MPLA, together with alum is part of the adjuvant AS04, which is FDA approved and 
commercially used in the Hepatitis B vaccine Fendrix and in the Human Papilloma 
Virus (HPV) vaccine Cervarix[27,28]. Moreover, the combination of MPLA and a 
TLR7 ligand, as also present in WIV in the form of single stranded viral RNA,  is 
particularly effective in inducing long-lasting immune responses[29].
In the present study, we investigated whether inclusion of MPLA as an adjuvant 
in liquid or dry powder influenza vaccine promotes mucosal and systemic (Th1-
skewed) immune responses after pulmonary vaccination. To this end, WIV influenza 
vaccine and a mixture of WIV and MPLA were either used as such or spray-freeze-
dried using inulin as a lyoprotectant. Our results indicate that MPLA is a suitable 
adjuvant for use in liquid as well dry vaccine formulations and enhances systemic 
and mucosal immune responses upon pulmonary delivery together with influenza 
vaccine.
2. Material and Methods
2.1. Virus preparation
A/Hiroshima/52/2005 (A/Hir/H3N2) influenza virus was kindly provided by Abbott 
(Weesp, The Netherlands). A/PR/8/34 H1N1 viruses were cultured in embryonated 




For preparation of WIV, live A/Hir/H3N2 or A/PR/8/H1N1 viruses were 
inactivated by overnight incubation at room temperature under continuous rotation 
in 0.1 % β-propiolacton prepared in sterile citrate buffer (125 mM citrate, 150 mM 
NaCl, pH 8.2). The inactivated virus was then dialysed overnight at 4 °C against 
hepes buffered saline (HBS; 145 mM NaCl, 5 mM Hepes, pH 7.4). Subunit 
vaccine was produced by solubilizing WIV for 3 hours at 4 °C under continuous 
rotation at a final concentration of 800 µg/ml in sterile HBS containing 12 mg/
ml Tween 80 (Sigma-Aldrich Chemie B.V., Zwijndrecht, The Netherlands) and 
6 mg/ml hexadecyltrimethylammonium bromide (Sigma-Aldrich Chemie B.V., 
Zwijndrecht, The Netherlands). Virus solubilization was followed by centrifugation 
at 50000 RPM at 4 °C for 30 minutes in a TLA100.3 rotor. The supernatant was 
recovered and detergents were removed using absorbent Bio-Beads SM-2 (Bio-Rad, 
Veenendaal, The Netherlands). Vaccine protein content was determined by micro-
Lowry assay and purity was analyzed by SDS PAGE followed by silver staining. The 
hemagglutinin (HA) content was assumed to be one third of the total protein weight 
of the whole inactivated virus (based on the known protein composition of influenza 
virus and the molecular weight of the viral proteins) and to be equal to the total 
amount of protein for subunit vaccine (based on the SDS analysis). WIV-MPLA was 
obtained by mixing WIV with MPLA (InvivoGen, Toulouse, France) at a weight 
ratio of 8:1 (HA of WIV: MPLA) prior to spray-freeze-drying or immunization.
2.3. Spray-freeze-drying
Spray-freeze-drying by mixing WIV or a solution containing WIV and MPLA (in a 
ratio of 0.125 µg MPLA/µg HA)  with a 5 % (w/v) solution of inulin 4 kD (Sensus, 
Roosendaal, The Netherlands) in HBS, pH 7.2 to a final HA:inulin weight ratio of 
1:200. The mixture was pumped at a flow rate of 5 ml/min through a two-fluid nozzle 
(diameter 0.5 mm) of a Büchi 190 Mini Spray Dryer (Büchi, Flawil, Switzerland), 
and sprayed using an atomizing airflow of 500 l/hr in liquid nitrogen. The liquid 
nitrogen was evaporated in a Christ Epsilon 2-4 freeze dryer precooled at a shelf 
temperature of -55 °C. Drying was performed at a pressure of 0.220 mBar with a 
condenser temperature of -85 °C. The shelf temperature was steadily increased from 
-55 °C to 4 °C over a time period of 32 hours. The pressure was decreased to 0.055 
mBar and the shelf temperature was gradually increased to 20 °C in a time period of 
11 hours. The vaccine powder was collected in a cabinet with a relative humidity less 
than 10 % and stored at 4 °C under air tight conditions.
2.4. Analysis of influenza WIV
The size of WIV derived from A/PR/8/H1N1 before and after addition of MPLA 
was analyzed using a nanoparticle tracking system (LM-14, NanoSight, Wiltshire, 
United Kingdom). One dose of vaccine corresponding to 5 µg HA of WIV and 
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0.626 µg MPLA was diluted with 5 ml PBS (Gibco Life Technologies B.V., Bleiswijk, 
The Netherlands) to a final concentration 1 µg/ml and 0.125 µg/ml, respectively. 
Particle size analysis was done using Nanoparticle Tracking Analysis (NTA) software 
(NanoSight) and particle size distribution plots were obtained.
Transmission electron microscopy (TEM) was performed using a Philips CM 12 
transmission electron microscope (Philips, Eindhoven, The Netherlands). SFD 
vaccines were rehydrated using sterile-filtered water. Liquid and reconstituted SFD 
formulations were dialysed against ammonium acetate buffer (75 mM ammonium 
acetate, 2.5 mM Hepes, pH 7.4) overnight at 4 °C. Dialyzed samples were added to 
glow-discharged 200 mesh copper grids covered with Formvar film. Samples were 
stained with 3% ammonium molybdate, pH 7.2 and analyzed.
The capacity of WIV derived from A/PR/8/H1N1 to bind to cells was assessed by a 
hemagglutination assay, performed as described previously[18]. WIV was dissolved 
in PBS to a final concentration of 0.1 µg HA/µl and 50 µl was added to 96-well 
V-bottom plates containing 50 µl of PBS. Two-fold dilutions were performed 
followed by addition of 50 µl of a 1% guinea pig red blood cell (RBC) suspension 
prepared in PBS. Hemagglutination was read 2 hours after incubation at room 
temperature. Hemagglutination titers were expressed as log2 of the highest dilution 
showing agglutination of RBC.
Activation of NFκB by the vaccines was detected using the RAW-BlueTM cell line 
(InvivoGen, Toulouse, France). RAW-BlueTM cells are reporter cells expressing a 
range of pattern recognition receptors and secreting embryonic alkaline phosphatase 
(SEAP) upon induction of NfκB following ligand binding to one of these receptors. 
The assay was performed according to the manufacturer’s protocol. Briefly, 
RAW-BlueTM cells were maintained in DMEM with high glucose (Gibco Life 
Technologies BV, Bleiswijk, The Netherlands) containing 10 % Fetal Bovine Serum 
(FBS, Lonza, Basel, Switzerland), 100 µg/ml NormocinTM (InvivoGen, Toulouse, 
France), 2 mM L-glutamine. For stimulation, 1 x 105 RAW-BlueTM cells were added 
to flat bottom 96-well plates (Corning Incorporated, Corning, USA). Cells were 
stimulated with 1.25 µg MPLA (6.25 µg/ml) or with liquid vaccine or reconstituted 
vaccine powder containing 5 µg (25 µg/ml) of HA of A/PR/8 H1N1 WIV with 
or without 1.25 µg MPLA and were incubated at 37 °C with 5 % CO2 for 16 
hours. 40 µl of cell supernatant was collected in a 96-well ELISA plate (Greiner 
Bio One, Alphen a/d Rijn, The Netherlands) to which 160 µl/well QUANTI-
BlueTM (InvivoGen, Toulouse France) was added. The plate was incubated at 37˚C 
for 1 hour. Secreted embryonic alkaline phosphatase (SEAP) levels from cells were 
determined by measuring absorbance at 620 nm.
2.5. Physical characterization of vaccine powders
Scanning electron microscopy (SEM) was performed with a JEOL JSM 6301-F microscope 
(JEOL Ltd., Tokyo, Japan). Samples were prepared by placing powders onto double-
sided sticky carbon tape on a metal disk. Then particles were coated with 30 nm 
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of gold using a Balzer’s 120B sputtering device (Balzer UNION, Liechtenstein, 
Austria). Images were taken at magnification of 1000x and 5000x.
Geometric particle sizes of SFD vaccine powders were measured using a HELOS 
compact model KA laser diffraction apparatus (Sympatec GmbH, Germany). The 
RODOS dispersing system (Sympatec GmbH, Clausthal-Zellerfeld, Germany) was 
used to disperse vaccine powders at a pressure of 1 bar.
The specific surface area of vaccines powders was determined using a Tristar surface 
analyser (Micrometrics Instrument Corp., Norcross, USA). The specific surface area 
was determined using the multipoint BET method from the nitrogen adsorption 
isotherm at 77 K as described previously [11].
2.6. Immunization and challenge of mice
Animal experiments were approved by The Institutional Animal Care and Use 
Committee of the University of Groningen (IACUC-RuG), The Netherlands. In-
vivo experiments were carried out in 8-10 weeks old female BALB/c mice obtained 
from Harlan (Zeist, The Netherlands).
Mice received two immunizations with an interval of 3 weeks using vaccine 
formulations containing 5 µg HA of A/Hir/H3N2 or A/PR/8/H1N1 WIV. Subunit 
vaccine was administered via the i.m. route. 50 µl of vaccine containing 5 µg of HA 
was divided over both hind legs. 
For pulmonary vaccination, mice were anaesthetized by subcutaneous injection of 
dormitor (0.75 mg/kg body weight) and ketamine (50 mg/kg body weight). Then 
mice were brought to a vertical position and intubated with a modified Autograde 
catheter (Becton Dickinson, Breda, The Netherlands). 50 µl of liquid vaccine was 
administered using an IA-1C Microsprayer Aerosolizer for mice attached to a 
FMJ-250 High Pressure Syringe (Penn-Century Inc., Wyndmoor, USA). Vaccine 
powders were delivered using a dry powder insufflator (DPI), (Penn-Century Inc.). 
Approximately 1 mg of vaccine powder containing 5 µg HA was delivered to the 
lungs by applying 3 puffs of 200 µl. Antisedan (0.75 mg/kg body weight) was 
administered subcutaneously for awakening mice. Before they were brought back to 
the housing facility after awaking, mice were placed in a recovery incubator with a 
temperature of 25 °C for 2 hours.
One week after the second vaccine dose, mice (n=4) were sacrificed for evaluation of 
the immune response. After sacrifice, blood was obtained by heart puncture. Serum 
was collected and stored at -20 °C until use. Nose washes and bronchioalveolar 
lavages (BAL) were obtained using 1 ml PBS (pH 7.4), containing Complete 
protease inhibitor cocktail tablets (Roche, Almere, The Netherlands) as described 
previously[17].
The protective efficacy of the vaccines was determined by challenge of the immunized 
mice (n=6) with live virus (A/PR/8/H1N1) 4 weeks after the booster vaccination. 
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Briefly, mice were anaesthetized with isoflurane/O2 and 40 µl of HBS containing 
200 plaque forming units (PFU) A/PR8/H1N1 viruses were slowly administered 
via the nostrils. Mice were observed daily for weight loss followed by sacrifice on 
three days after challenge by heart puncture under the anesthesia with isoflurane/O2. 
Nose wash, lungs and spleens were collected and processed for further use.
2.7. ELISA
Nose washes, BAL and serum samples were used for ELISA and HA-specific IgG, 
IgG1, IgG2a and IgA antibodies were determined. ELISA plates (Greiner Bio One, 
Alphen, The Netherlands) were coated with 200 ng/well of A/Hir/H3N2 or A/PR/8 
H1N1 subunit vaccine overnight at 37 ˚C. ELISA was performed as previously 
described[18] except that the substrate solution consisted of  citrate phosphate 
buffer, pH 5, containing 0.04 % (w/v) o-phenylenediamine and 0.012 % (v/v) 
H2O2. The enzymatic reaction was allowed to proceed at room temperature for 30 
minutes and stopped using 50 µl of 2 M H2SO4. Absorbance was measured at 492 
nm using a Synergy HT reader (BioTek, Winooski, USA). Average IgG titers were 
determined as log10 of the reciprocal of the sample dilution corresponding to an 
absorbance at 492 nm of 0.2. IgA levels are presented as average of the maximum 
absorbance of 1:1 diluted nose and lung washes. IgG1 and IgG2a concentrations 
were determined using calibration curves made by overnight coating of ELISA plates 
with 0.1 µg anti IgG (Southern Biotech, Birmingham, USA) at 37 °C. Following 
extensive washing increasing concentrations of 100 µl of IgG1 or IgG2a (Southern 
Biotech, Birmingham, USA) were added to the plates. Average influenza HA-specific 
IgG1 or IgG2a responses are presented as concentration (µg/ml). 
2.8. Hemagglutination inhibition
Hemagglutination inhibition (HI) assay was performed as described previously with 
minor changes[18]. The changes were as follows: pooled sera from vaccinated mice 
were used for determining HI titers, and 4 Hemagglutination units (HAU) live virus 
was added to the diluted serum samples. HI titers are expressed as the highest serum 
dilution preventing hemagglutination.
2.9. Virus titration
Lungs collected after challenge were homogenized in PBS (pH 7.4) and centrifuged 
at 1200 rpm for 10 minutes, supernatants were snap-frozen in liquid nitrogen and 
stored at -80 °C until use. Lung virus titers were determined by infecting MDCK cells 
grown in 96-well plates with serial dilutions of the lung homogenate supernatants 




2.10. Determination of influenza specific antibody secreting 
cells
 The number of influenza-specific antibody secreting cells (ASC) was 
determined using the protocol as described previously [30]. Spleens collected 
in Iscove’s Modified Dulbecco’s Medium (IMDM) complete medium (Gibco, 
Life Technologies B.V., Bleiswijk, The Netherlands) containing 5 % FBS (Lonza, 
Basel, Switzerland), 100 U/ml penicillin, 100 mg/ml streptomycin and 0.05 M 
2-mercaptoethanol (Invitrogen, Breda, The Netherlands) were processed to single 
cell suspensions using cell strainers (BD Biosciences, Breda, The Netherlands) 
followed by RBC lysis using hypotonic medium (0.83 % NH4Cl, 10 mM KHCO3, 
0.1 mM EDTA, pH 7.2). After extensive washing, 1 x 106 splenocytes, pooled per 
experimental group, were added to 6-well plates (Corning incorporated, New York, 
USA) followed by incubation at 37 °C with 5 % CO2 for 6 days in complete IMDM 
medium with or without subunit vaccine (5 µg/ml) in the presence of imiquimode 
(5 µg/ml, InvivoGen, Toulouse, France). After incubation, cells were recovered 
and washed with complete IMDM medium followed by addition of 5 x 105 cells 
to MultiScreenHTS-HA filter plates (Millipore, Billerica, Massachusetts) coated 
with subunit vaccine 0.5 µg /well. Memory IgA or IgG ASC were detected using 
alkaline phosphatase labeled anti-mouse IgA antibody (Sigma-Aldrich Chemie B.V., 
Zwijndrecht, The Netherlands) or horse radish peroxidase labeled anti-mouse IgG 
antibody (Southern Biotech, Birmingham, USA). Plates were washed and memory 
influenza-specific IgA ASC spots were stained using 3-amino-9-ethylcarbazole 
substrate (Sigma-Aldrich Chemie B.V., Zwijndrecht, The Netherlands). Plates were 
washed with PBS again and memory influenza-specific IgG ASC spots were stained 
using 5-Bromo-4-chloro-3-indolyl phosphate/Nitro blue tetrazolium substrate 
(Roche, Almere, The Netherlands). Spots were allowed to develop and the reaction 
was stopped by washing plates with tap water. Spots were counted manually using a 
microscope (Wild Heerbrugg, Gais, Switzerland).
2.11. Cytokine ELISA
To determine IFNγ levels in the lungs of the challenged mice, lung supernatants 
were obtained as described above. Lung supernatants were stored at -80 °C until use. 
IFNγ levels in lung supernatants were determined using Ready-SET-Go ELISA kits 
(Ebioscience, Vienna, Austria) according to the manufacturer protocols.
2.12. Statistical analysis
Mann Whitney U-test was used for data analysis. One-tailed tests were performed 
for comparison of data from groups immunized with non-adjuvanted vs adjuvanted 
vaccines. For other comparisons two-sided tests were employed. P values less than 
0.05 were considered to represent statistically significant differences. *, **, *** 
represent p<0.05, p<0.01, p<0.001 respectively.
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Figure 1. Characterization of virus particles in liquid and SFD vaccine. (a) Number 
size distribution of WIV, WIV in combination with MPLA, and MPLA only (c) 
Transmission electron microscope images of WIV and WIV MPLA before and after spray-
freeze-drying (bar represents 200 nm). (d) Hemagglutination activity of WIV and WIV 
MPLA before and after spray-freeze-drying (e). NfκB activation by MPLA, WIV, and 


























































































































3.1. Analysis of effects of MPLA on the structure and biological 
properties of whole inactivated virus influenza vaccine
In order to further improve immune responses elicited by pulmonary administered 
WIV influenza vaccine we decided to evaluate MPLA as an adjuvant. MPLA is an 
amphiphilic molecule which potentially could interact with the membrane of the 
WIV particles. To determine the effect of MPLA on morphology and size of WIV, 
the particle size of WIV derived from A/Hir/H3N2 was evaluated before and after 
addition of MPLA using NanoSight, a microscope-based nanoparticle tracking 
system, to characterize and measure nanoparticles in liquid dispersion. The size 
distribution of plain and adjuvanted virus particles showed that liquid WIV and 
liquid WIV-MPLA consisted of a relatively homogenous population of virus particles 
as indicated by a single narrow peak at 115 nm and 114 nm respectively (Figure 1a). 
No particles were observed when MPLA was analyzed alone. Cumulative undersize 
curves showed virus particles had a size range between 80 to 300 nm and that the 
distribution of sizes was very similar for non-adjuvanted and adjuvanted WIV. This 
result suggests that addition of MPLA did not affect virus particle size.
In order to further assess whether addition of MPLA to WIV and stress of spray-
freeze-drying induced structural changes in the virus particles, WIV derived from 
A/Hir/H3N2 was SFD with or without addition of MPLA using inulin as a lyo-
protectant. The morphological integrity of the virus particles in non-treated and 
reconstituted SFD WIV and SFD WIV-MPLA was evaluated by TEM (Figure 1b). 
The morphology of liquid WIV-MPLA was similar to that of liquid WIV. Moreover, 
the morphology of WIV and WIV-MPLA reconstituted from SFD formulations was 
similar to that of the non-spray freeze-dried counterparts. The virus structure was 
intact with clearly visible spikes protruding from the virus membrane. These results 
suggest that addition of MPLA to WIV did not have effects on the structure of the 
virus particles in WIV vaccine.
To evaluate whether addition of MPLA or spray-freeze-drying or both affected the 
biological activity of HA, in particular its capacity to bind to its cellular receptor, a 
hemagglutination assay was performed using the reconstituted vaccines prepared from 
A/PR/8/H1N1 and guinea pig RBCs. Evaluation of liquid WIV and liquid WIV-
MPLA suggests that addition of MPLA to WIV did not affect the hemagglutinating 
properties of the virus particles (Figure 1c). Moreover, after spray-freeze-drying, the 
haemagglutination activity of the reconstituted vaccine formulations was similar to 
that of the liquid vaccine formulations, indicating that the capacity of WIV to bind 
to RBC was fully preserved after spray-freeze-drying.
We next evaluated in how far spray-freeze-drying had any effect on the biological 
activity of MPLA. For this purpose, adjuvanted liquid and reconstituted powder 
vaccine formulations were tested for their capacity to activate NFκB using RAW-















































Figure 2. Physical characterization of spray freeze dried vaccine powder. 
(a) X10, X50 and X90 undersize values of the cumulative geometric volume size 
distributions of SFD particles containing inulin alone or in combination with WIV or 
WIV-MPLA. (b) Specific surface area of SFD particles containing inulin alone or in 
combination with WIV or WIV-MPLA. Scanning electron microscope images at 1000X 




BlueTM cells (Figure 1d). Unexpectedly, WIV derived from A/PR/8/H1N1 by 
itself was poorly capable of activating NFκB. MPLA-adjuvanted A/PR/8/H1N1 
WIV activated NFκB to a significantly higher extent than WIV alone. The capacity 
of MPLA to activate NFκB was fully retained after spray-freeze-drying, suggesting 
that stress during the drying procedure did not affect MPLA’s efficacy to bind and 
activate TLR4. MPLA-adjuvanted WIV tended to have a higher capacity to activate 
RAW-BlueTM cells than MPLA alone; this trend was significant for SFD WIV-
MPLA.
The above results demonstrate that addition of MPLA to WIV did neither change 
the physical nor the biological characteristics of WIV. Moreover, spray-freeze-drying 
had no detrimental effect on the physical and biological properties of WIV or MPLA.
3.2. Physical characterization of the vaccine powder
We next evaluated whether addition of MPLA to WIV derived from A/Hir/H3N2 
affects the characteristics of the SFD vaccine powder particles. The particle size 
distribution was measured by laser diffraction. The X10, X50 and X90 values were 
determined from cumulative undersize curves. The X50 values for SFD inulin, SFD 
WIV and SFD WIV-MPLA were found to be 7.64 µm, 7.56 µm and 7.87 µm 
respectively with span [span = (X90 – X10)/X50] of 1.52, 1.49 and 1.64 (Figure 
2a-2b). These results reveal that addition of MPLA to WIV did not noticeably 
change the particle size of the SFD powder. Laser diffraction measurements yield 
the geometric particle size, while for pulmonary administration the aerodynamic 
particle size is more relevant. The aerodynamic particle size (Table 1) was calculated 
from the geometric particle size using an approach described earlier[17,31]. From 
this calculation it can be concluded that powder particles obtained after spray-freeze-
drying had aerodynamic diameters within the limits for pulmonary vaccination (1-5 
µm)[32,33]. 
Table 1. Aerodynamic particle size of SFD powder vaccines
Sample X10 (µm + SD) X50 (µm + SD) X90 (µm + SD)
Inulin 0.768 + 0.007 1.701 + 0.009 3.166 + 0.007
SFD WIV 0.651 + 0.002 1.663 + 0.004 3.135 + 0.002
SFD WIV MPLA 0.669 + 0.009 1.731 + 0.009 3.509 + 0.011
Porosity is important for dispersion of the powder from the DPI and for the solubility 
of the powder particles. As a measure of porosity, the specific surface areas of the SFD 
inulin, SFD WIV and SFD WIV-MPLA powders were determined. The specific 
surface areas were found to be 93.76 m2/g, 102.67 m2/g and 82.38 m2/g for the three 
formulations, respectively. These readings indicate that addition of MPLA to WIV 
had some effect on the specific surface area of the SFD powder; yet, the effects on 








































































































































































































Figure 3. Systemic and mucosal antibody 




Mice were immunized on day 0 and day 21 with 5 µg subunit vaccine (i.m.) or 5 µg 
HA of whole inactivated A/Hir/H3N2 with or without MPLA in liquid or powder form 
(pulmonary). Control mice received HBS (total respiratory track). Systemic responses were 
evaluated from serum three weeks after the first (white bars) and one week after the second 
immunization (black bars). (a) IgG titers of individual mice. (b) HI titers in sera pooled 




the overall particle architecture were limited. These findings were further confirmed 
by analysis of the vaccine powders using SEM (Figure 2c,d). SEM analysis revealed 
highly porous structures with interconnected pores with little difference in particle 
architecture between SFD WIV and SFD WIV-MPLA. The geometric particle size 
ranged between 1 µm and 10 µm in both SFD WIV and SFD WIV-MPLA. The size 
of the particles, as seen in the SEM images, correlated well with the particle sizes as 
determined by laser diffraction. In line with the high porosity, all powders dissolved 
very easily within seconds when brought in contact with water. 
Overall, the physical characterization of the vaccine powders highlighted that the 
addition of low amounts of MPLA to WIV did not affect the size and structure of the 
powder particles obtained by spray-freeze-drying in the presence of inulin.
3.3. Immune responses induced by pulmonary immunization 
of mice with plain or MPLA-adjuvanted WIV vaccines
To evaluate the adjuvant activity of MPLA upon pulmonary vaccination, BALB/c 
mice were immunized twice with non-adjuvanted or MPLA-adjuvanted WIV vaccine 
(derived from A/Hir/H3N2 virus) in liquid or SFD powder form. Evaluation of 
serum samples for IgG antibodies after the first and second immunization showed 
that all immunized mice developed detectable serum IgG titers after a single dose 
(Figure 3a). These titers were further enhanced after the booster. Mice vaccinated 
with MPLA-adjuvanted formulations showed significantly increased IgG antibody 
titers after a single or after the booster dose compared to mice receiving non-
adjuvanted vaccines. However, mice vaccinated with liquid WIV-MPLA and SFD 
WIV-MPLA showed lower levels of IgG antibody than mice which received a 
standard i.m. immunization with subunit vaccine. Analysis of HI titers (Figure- 
3b) revealed that all formulations induced HI titers greater than 40 (regarded as 
protective in humans[34,35]) after the first immunization dose. These titers were 
further enhanced following the booster immunization. HI titers detected in the 
liquid WIV-MPLA and the SFD WIV-MPLA group on day 21 and 28 were two-
fold higher than those in the corresponding groups vaccinated with non-adjuvanted 
vaccines. Moreover, HI titers in mice receiving liquid WIV-MPLA and SFD WIV-
MPLA were comparable to those in mice vaccinated i.m. with subunit vaccine. 
Mucosal immune responses were analyzed on day 28 and one week after the second 
immunization. Evaluation of nose washes (Figure 3c) showed induction of nose IgA 
antibodies in mice immunized with powder formulations whereas little IgA antibody 
induction was observed in nose washes of mice vaccinated with liquid formulations. 
In contrast to the effect of MPLA on systemic antibody titers, no adjuvant effect 
of MPLA was observed on nasal IgA titers. However, in BAL (Figure 3d-3e), both 
liquid WIV-MPLA and SFD WIV-MPLA vaccines induced significantly higher 
levels of  IgA and IgG antibody than non-adjuvanted liquid WIV and SFD WIV 
vaccine. Levels of BAL IgA were similar for mice immunized with WIV-MPLA or 
SFD WIV-MPLA and were significantly higher than those found in mice vaccinated 
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Figure 4. Effect of vaccine formulation on 
protection against lethal virus challenge.
 Mice were immunized on day 0 and day 21 
with 5 µg subunit vaccine (i.m.) or 5 µg HA 
of whole inactivated A/PR/8/H1N1 with or 
without MPLA in liquid or powder form 
(pulmonary). Control mice received HBS 
(total respiratory track). Four weeks after the 
second vaccine dose, mice were infected with 
200 PFU A/PR8/H1N1 viruses. (a) Post 
challenge, mice were scored for weight loss for 
3 days until sacrifice (85% weight loss, dotted line, was used as humane end point). (b) 
Three days upon challenge, lungs from mice were harvested and lung supernatants were 
evaluated for virus titers. Virus titers are expressed at log10 per ml of lung supernatant. 
Levels of significance are presented as *p<0.05, **p<0.01.
i.m. with subunit vaccine. As expected, i.m. administered subunit vaccine failed to 
induce IgA antibody responses in nose and BAL while IgG was clearly detectable in 
BAL.
Overall, the data suggest that supplementation of pulmonary vaccines with 
MPLA adjuvant results in increased serum IgG antibody and HI titers along with 
enhanced IgA and IgG antibody levels in BAL. However, MPLA adjuvantation of 
the pulmonary administered vaccines did not improve nose IgA titers. The immune 
responses evoked by SFD vaccines tended to be higher than those evoked by the 
liquid versions but this trend was significant for nose IgA only.
3.4. Protection after influenza virus challenge
To compare the protective efficacy of MPLA-adjuvanted and non-adjuvanted, 
liquid or powder WIV or subunit vaccine derived from A/PR8/H1N1, mice were 
vaccinated twice on day 0 and 21 with 5 µg HA of WIV followed by a challenge 
with 200 PFU virus 5 weeks after the booster. The control group received plain HBS 
through the pulmonary route. Three days post infection, none of the mice in the 
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immunized and control groups showed more than 15 % body weight loss which 
was set as humane end point in this experiment (Figure 4a). However, control mice 
showed significantly more weight loss at day 3 than mice which received MPLA-
adjuvanted liquid (p=0.0411) or powder (p=0.0087) vaccine formulations. Mice 
immunized with non-adjuvanted SFD WIV showed more weight loss on day 3 than 
mice immunized with SFD WIV-MPLA, though the difference was not significant 
(p=0.0660).
 We next determined lung virus titers to assess the ability of infected mice to clear 
influenza virus from the lungs (Figure 4b). On day 3 after challenge, all immunized 
groups showed lower lung virus titers than the non-immunized control group and 
this difference was significant for all groups except the group that received non-
adjuvanted WIV. Mice vaccinated with the adjuvanted formulations showed reduced 
virus titers compared to mice that received non-adjuvanted formulations. MPLA-
adjuvanted pulmonary vaccines and i.m. administered subunit vaccine resulted in the 
best protection. In the SFD WIV-MPLA group, the virus levels were below detection 
level for two mice. These results indicate that the adjuvanted powder vaccine elicits 
a more potent protection against influenza infection than the adjuvanted liquid 
vaccine.
In non-immune mice with a primary influenza infection, production of IFNγ by 
NK cells is an early response of the innate immune system to the infection and an 
indication of active virus replication[36-38]. We, therefore, determined IFNγ levels 
3 days post challenge in lung supernatants as a measure for active viral replication 
(Figure 4c). ELISA revealed substantial amounts of IFNγ in the lung supernatants 
of the control group and of mice vaccinated with non-adjuvanted vaccines. Lower 
levels of IFNγ were found in mice which received MPLA-adjuvanted formulations 
or i.m. subunit vaccine. In line with our expectation the observed IFNγ levels were 
proportional to the measured lung virus titers. These results imply that strong (local) 
immune responses effectively control virus replication in the lungs.
To evaluate systemic immune responses after virus infection, IgG antibody in 
serum (Figure 5a) and serum HI (Figure 5b) titers were determined in the virus-
challenged mice. In line with the previous observations (Figure 3), IgG antibody 
and HI titers were higher in mice immunized with MPLA-adjuvanted A/PR/8 WIV 
formulations than in mice immunized with non-adjuvanted formulations. For the 
MPLA-adjuvanted vaccines, IgG and HI titers were similar to those induced by i.m. 
administered subunit vaccine. Analysis of nose washes revealed that nose IgA titers 
(Figure 5c) after immunization with A/PR/8 WIV were generally low except for the 
SFD WIV-MPLA group. In the lungs, increased IgA (Figure 5d) and IgG (Figure-
5e) antibody titers were observed in mice immunized with MPLA-adjuvanted 
formulations, compared to mice immunized with non-adjuvanted vaccine. Lung 
IgG antibody responses were in line with serum IgG responses. IgG1 and IgG2a 
responses were increased in mice immunized with MPLA-adjuvanted vaccines as 
compared to mice immunized with non-adjuvanted vaccine (Figure 5f ). However, 




























































































































































































































































































































































Figure 5. Effect of 
vaccine formulation 
on recall of immune 
response.Blood, nose 
wash, lungs and spleens 
from the mice described 
in the legend of Figure 
4 were collected after 
vaccination and 
challenge and analyzed 
for (a) serum IgG (b) 
serum HI titers (c) 
nose IgA (d) lung IgA 
(e) lung IgG (f ) serum 
IgG2a and IgG1 
response. Serum and 
lung IgG antibody 
titers are expressed as 
log10 titers. Nose and 
lung IgA responses 
are represented 
as absorbance at 
OD492. HI titers 
after vaccination and 
challenge are expressed 
as reciprocal of the 
highest dilution of sera 
resulting in complete 
h e m a g g l u t i n a t i o n 
inhibition. Splenocytes 
were pooled per 
experimental group 
and IgA (g) and IgG 
(h) ASCs specific 
for A/PR/8 HA 
were enumerated 
by ELISPOT assay. 
Bars represent the 
number of ASCs per 
5x105 cells +/- SD 
of quadruplicate 
measurements.   Levels 
of significance are 




the differences reached statistical significance only for the groups immunized with 
liquid vaccine.
We next evaluated HA-specific memory B cells from immunized and challenged 
mice (Figure 5g). Spleens of mice vaccinated via the pulmonary route with MPLA-
adjuvanted vaccines contained significantly higher numbers of influenza-specific 
memory IgA-secreting B cells than spleens of mice vaccinated with non-adjuvanted 
formulations. Splenocytes from mice which received liquid WIV-MPLA showed 
approximately eight fold more memory IgA B cells compared to mice immunized 
with non-adjuvanted liquid WIV. Similarly, IgA-secreting memory B cells were 
approximately 3 times more frequent in splenocytes of mice immunized with SFD 
WIV-MPLA than in those of mice immunized with non-adjuvanted SFD WIV. 
Two-fold more memory IgA B cells were seen in spleens of in mice that received 
MPLA-adjuvanted pulmonary vaccines than in spleens of mice immunized i.m. 
with subunit vaccine. The number of memory IgG-secreting B cells (Figure 5h) was 
similar for all groups except for the group which received non-adjuvanted WIV via 
the pulmonary route. In this group the frequency of HA-specific memory IgG B cells 
was about 6 times lower than in the other groups.
Taken together, these results indicate that MPLA-adjuvanted vaccine formulations 
elicit more robust immune responses and protection, therefore causing less 
recruitment of IFNγ-producing NK cells to the lungs, than non-adjuvanted liquid 
WIV or SFD WIV. Across all parameters studied, SFD WIV-MPLA was found to be 
the best vaccine for its ability to induce more potent mucosal and systemic responses 
along with better protection than other vaccines.
4. Discussion
 In the current study, we evaluated whether inclusion of MPLA as 
adjuvant in a liquid or powder influenza vaccine for pulmonary administration has 
advantageous effects on the immune response. WIV was chosen as basic vaccine 
formulation, since it is known to be superior to split or subunit vaccine formulations 
in inducing immune responses[39]. Analysis of liquid WIV and liquid WIV-MPLA 
by nanoparticle tracking and TEM highlighted that MPLA did not have any adverse 
effect on the size and structure of the inactivated virus particles in WIV. Dry powder 
vaccines were produced by spray-freeze-drying liquid WIV and liquid WIV-MPLA 
using inulin as stabilizer. Analysis of SFD WIV or SFD WIV-MPLA revealed that the 
stress encountered during spray-freeze-drying did not affect the biological activity of 
either MPLA or HA. Characterization of the vaccine powders showed that particle 
size, specific surface area and morphology of SFD WIV and SFD WIV-MPLA were 
comparable and both vaccine powders were found to be suitable for pulmonary 
immunization. In vivo studies demonstrated that pulmonary administration with 
MPLA-adjuvanted formulations, in particular the SFD formulation, resulted in 
superior antibody responses compared to non-adjuvanted formulations. Moreover, 
in mice, vaccinated with MPLA-adjuvanted formulations, decreased weight loss 
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and lower lung virus titers were observed after challenge with live influenza virus. 
Pulmonary immunization with MPLA-adjuvanted vaccines was at least as effective 
as i.m. immunization in reducing lung virus titers.
MPLA is an amphiphilic molecule and as such may have detrimental effects on the 
structure of the inactivated virus particles, like WIV. The structural integrity of the 
virus particles is important as only intact virus particles will provide protection for 
the ssRNA present in WIV; viral ssRNA has been shown to be recognized by TLR7 
and to act as an intrinsic adjuvant in WIV[40]. Evaluation of the size and structure 
of the WIV virus particles by the nanoparticle tracking system and TEM did not 
reveal any effect of MPLA on these properties. Thus, addition of MPLA did not 
interfere with the structural integrity of the virus particles. HA-mediated binding of 
the WIV virus particles to cellular receptors is important for vaccine internalization 
by antigen-presenting cells. Moreover, a proper natural conformation of the HA 
would also be important to induce antibodies that recognize conformational epitopes 
and thus are able to interact with the native HA on infectious virus. We observed 
that the hemagglutination properties of WIV with and without MPLA were similar 
indicating that MPLA had no effect on the biological activity of HA. Thus, neither 
the structural integrity nor the cell-binding properties of the WIV virus particles 
were affected by addition of MPLA.
MPLA is known to retain its adjuvant activity but to be less toxic when integrated 
in a membranous environment[41]. Furthermore, LPS, the molecule from which 
MPLA is derived, was described to be more active when integrated into a virosomal 
membrane than when being present freely in solution[42]. Whether or not MPLA 
added to WIV in our experiments did integrate in the membrane of the virus 
particles remains elusive. MPLA easily inserts into lipid membranes of liposomes 
and virosomes when added during constitution of these structures[21,41]. If not 
inserted MPLA will form micelles when present in sufficiently high concentration 
(> 5 µM, [34]). We did not find evidence for either incorporation or the presence 
of micelles in our studies. The amount of MPLA used per vaccine dose (0.35 nmol) 
equals about 7% of the viral lipids in the vaccine. This amount is insufficient to 
increase the size of virus particles to an extent detectable by the nanoparticle tracking 
system or TEM. Indeed, we did not observe an increase in mean diameter of the 
WIV particles. We did not detect MPLA micelles either which might be due to the 
high dilution used for analysis by the nanoparticle tracking system by which the 
MPLA concentration was lower than its critical micelle concentration. The fate of 
MPLA added to WIV thus remains to be determined.  
Earlier we reported that spray-freeze-drying is an effective technique to produce 
subunit or WIV vaccine powders suitable for pulmonary delivery[6,12,18]. Particle 
size distribution and specific surface area are key parameters for pulmonary delivery 
of the vaccine powder. The aerodynamic particle size determines the distribution of 
the powder vaccine in the respiratory tract while surface area, indicative of porosity, 
determines dispersion of powder particles from the DPI. Moreover, porous particles 
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dissolve instantaneously when they come in contact with aqueous solutions making 
them ideal for pulmonary vaccine delivery. These parameters may get affected by the 
presence of amphiphilic molecules like MPLA in vaccine formulations during spray-
freeze-drying. Our data shows that the characteristics of powder particles generated 
from WIV in absence or presence of MPLA are similar. Possibly, the detrimental 
effects of MPLA are limited because we used a very high inulin to MPLA weight 
ratio (1600:1). Alternatively, interaction of the MPLA acyl chains with inulin may 
be prevented due to insertion of MPLA into the lipid bilayer of WIV. 
After evaluating SFD vaccine powders for their physical characteristics, immune 
responses induced by pulmonary administered MPLA-adjuvanted or non-
adjuvanted WIV were determined. MPLA-adjuvanted vaccine formulations induced 
significantly higher IgG and HI titers in serum than non-adjuvanted formulations, 
indicating a beneficial effect of including MPLA in pulmonary vaccines. These 
results are in agreement with previous observations demonstrating enhancement of 
immune responses to Hepatitis B surface antigen, tetanus toxoid, influenza subunit 
vaccine or RSV-derived virosomes administered to the total respiratory tract when 
MPLA was used as adjuvant[25,26,43].
A major aim of pulmonary vaccination is the induction of IgA responses at the site 
of virus entry. As expected, subunit delivered i.m., used as a golden standard in 
our experiments, was a rather poor inducer of lung IgA and failed to induce IgA in 
the nose. Pulmonary immunization with MPLA-adjuvanted vaccine as compared to 
non-adjuvanted formulations resulted in significantly increased IgA antibody levels 
in lung but not in nose. The low amounts of IgA in the upper respiratory tract 
may be explained by the fact that the antigen was directly delivered to the lungs, 
thus bypassing the nasal mucosa and its associated lymphoid tissue. Indeed, MPLA-
adjuvanted RSV virosomes delivered to the total respiratory tract via the nose were 
found to effectively induce IgA in the lung as well as in the nose[26,44]. Another 
explanation could be that the amount of MPLA used in the vaccine was insufficient 
to induce nasal IgA upon pulmonary immunization. Based on in vitro experiments 
using the NFκB reporter cell line RAWBlueTM, we chose a dose of 0.625µg MPLA 
per vaccine dose of 5 µg HA. This amount was obviously sufficient to stimulate 
production of IgA in the lungs, the site of vaccine administration, but not in the nose. 
In the studies on RSV virosomes, a much higher dose of MPLA was employed, i.e. 
5 µg versus 0.625 µg used in the present study[26,44]. Thus, MPLA adjuvantation 
of pulmonary administered vaccines is capable of stimulating IgA production in the 
lungs but higher amounts of adjuvant may be necessary to also induce nasal IgA. 
Analysis of lung virus titers and lung IFNγ levels upon influenza virus challenge 
revealed that MPLA-adjuvanted vaccines induced better protection in mice than 
non-adjuvanted formulations. For challenge, 200 PFU virus in 40 µl of buffer were 
inoculated in mice through the nasal route. In this model, the whole respiratory tract 
is challenged but most of the virus particles are delivered to the lungs because of 
the relative large volume used[45]. In mice immunized with the MPLA-adjuvanted 
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vaccines higher levels of IgA and IgG antibodies were produced in the lungs and 
might have played a vital role in neutralization of influenza virus and therefore 
reduction of virus titers. In addition, serum IgG antibody transuding into the lungs 
might have further helped in virus clearance[46]. Furthermore, MPLA-adjuvanted 
vaccines induced higher amounts of IgG2a than non-adjuvanted vaccines. In mice 
it has been shown that IgG2a antibody provides better protection than IgG1 against 
influenza virus upon challenge[20]. Thus, induction of higher levels of antibody 
and of the superior antibody subtype IgG2a probably contributed to the improved 
protection of mice immunized with MPLA-adjuvanted vaccine as compared to mice 
that received non-adjuvanted formulations. 
In conclusion, our data indicate that MPLA is an effective adjuvant for pulmonary 
vaccines. When delivered together with WIV influenza vaccine MPLA improves 
local and systemic immune responses as well as the protective capacity of the vaccine. 
A stable adjuvanted vaccine can be formulated by spray-freeze-drying in the presence 
of inulin. In fact, among the vaccine formulations studied SFD WIV-MPLA was 
the most potent, inducing the highest serum and mucosal antibody responses and 
providing the best protection against virus challenge. To our knowledge, this is the 
first study to demonstrate that MPLA can be SFD along with an antigen formulation, 
in this case WIV, with full retention of its adjuvant activity. MPLA adjuvantation of 
pulmonary administered WIV certainly had a positive effect on humoral response 
induction and the effect can probably be further improved by using higher amounts 
of the adjuvant, especially with respect to nasal IgA titers. Pulmonary immunization 
with SFD WIV-MPLA was equally effective as i.m. immunization with subunit 
vaccine, used as golden standard in our study, in inducing humoral immune 
response and was better in inducing mucosal antibodies and protection. Pulmonary 
administration of adjuvanted influenza vaccines is therefore a promising approach 
for induction of protective immune responses by user-friendly inhalation.
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Influenza virus is transmitted by aerosols and accordingly the presence of IgA 
antibodies in the upper respiratory tract plays an important role in preventing 
initial infection and spread of the virus to the lower respiratory tract. Parentally 
administered influenza vaccines do not induce IgA antibody production and thus 
do not provide protection at the port of virus entry. Previously, we showed that 
non-adjuvanted inactivated influenza vaccines administered as a dry powder to the 
lungs successfully induce IgG antibody in serum but are poorly effective in eliciting 
nose IgA antibody responses. Here we investigated the suitability of a range of Toll-
like receptor (TLR) ligands and a non-pattern recognition receptor (PRR)-binding 
compound, GPI-0100, to serve as pulmonary adjuvant in a whole inactivated virus 
(WIV) dry powder influenza vaccine formulation. For this purpose, adjuvants were 
spray freeze dried (SFD) along with WIV using inulin as cryoprotectant. In vitro 
analysis of the SFD vaccine formulations on a NFkB reporter cell line showed that 
the immune stimulating properties of the adjuvants were not affected by stress 
during spray freeze drying. Comparative in vivo immunization revealed that the TLR 
ligands palmitoyl-3-cysteine-serine-lysine-4 (Pam3CSK4), Monophosphoryl lipid A 
(MPLA) and CpG oligodeoxynucleotides (CpG ODN) did not stimulate potent 
mucosal immune responses to a pulmonary delivered WIV vaccine in mice although 
all except Pam3CSK4 did increase systemic IgG responses. In contrast, vaccination 
with WIV adjuvanted with GPI-0100 induced robust mucosal antibody responses 
in nose and lungs and resulted in the strongest systemic immune responses of all 
vaccines studied. Moreover, in the GPI-0100 group but not in the other vaccination 
groups partial protection against lethal heterologous influenza virus challenge 
was obtained as confirmed by reduced lung virus titres. These data highlight that 
adjuvants can be SFD along with WIV without loss of adjuvant function. Moreover, 
they underline that a properly adjuvanted dry powder influenza vaccines delivered 
directly to the lungs is capable of inducing effective mucosal IgA and systemic IgG 




Influenza virus is well known for its ability to cause seasonal epidemics and occasional 
pandemics. The virus is transmitted by aerosols and binds to and infects epithelial 
cells in the respiratory tract[1,2]. Pre-existing secretory IgA (S-IgA) antibodies in 
the nose play a vital role in preventing binding of influenza virus to its cellular 
receptor and further spreading of the virus in the respiratory tract[3-5]. Moreover, 
IgA antibodies are known for their ability to provide cross protection against 
heterologous influenza virus[4,6]. Together with IgG antibodies, IgA antibodies were 
shown to inhibit infectivity of influenza virus in the respiratory tract[5,7]. To prevent 
influenza infection and further dissemination of the virus to the lower respiratory 
tract or to the environment, it is therefore important that a vaccine induces IgA 
antibody responses. However, currently available inactivated influenza vaccines that 
are administered by the intramuscular, subcutaneous or intradermal route do not 
induce mucosal immunity[8,9]. 
To induce mucosal IgA antibody production as well as systemic immunity, mucosal 
vaccine delivery is mandatory. In this context, the lung is a particularly attractive target. 
Upon interaction with respiratory viruses, airway epithelial cells produce cytokines 
and chemokines promoting recruitment of inflammatory cells and help directing 
the adaptive immune response according to stimuli received[10]. Antigen presenting 
cells (APC) like dendritic cells (DC) that are present beneath the epithelial layer and 
alveolar macrophages (AM) that are present in the lumen constantly protect the large 
surface area of the lung[11-13]. Upon activation by pathogens, these epithelial cells, 
DC and AM effectively bypass the steady state anti-inflammatory T helper 2 (Th2) 
responses in the lung and initiate innate and adaptive immunity against the invading 
pathogen[13]. 
We previously showed that pulmonary delivery of spray freeze dried (SFD) whole 
inactivated virus (WIV) influenza vaccine induced the production of systemic IgG 
antibody to the levels similar to those evoked by standard intramuscular (i.m.) 
immunization without causing inflammation in the lungs[14-16]. Pulmonary 
vaccination also resulted in induction of IgA antibody in nose and lungs. However, 
the levels of IgA in the respiratory tract and the amount of systemic IgG2a antibodies, 
the protective antibody subtype in mice, were low[14]. An approach to overcome this 
drawback is addition of a potent adjuvant to the pulmonary administered vaccine. 
Toll like receptor (TLR) ligands are pathogen associated molecular patterns or 
substances mimicking such patterns that are recognised by TLR present on the 
host cells. Binding of TLR ligands to TLR activates signals that are important for 
initiation of innate and adaptive immune responses[17]. Our previous study showed 
that addition of a low amount (0.625 μg) of monophosphoryl lipid A (MPLA), 
a TLR 4 agonist, to pulmonary delivered WIV improved IgA levels in the  lung, 
but had little effect on IgA titers in the nose[18]. Therefore to find a more effective 
pulmonary adjuvant a head-to-head comparison of several candidate adjuvants 
is needed. TLR ligands like palmitoyl-3-cysteine-serine-lysine-4 (Pam3CSK4, 
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recognised by TLR 1 and TLR 2), MPLA (TLR 4) and CpG oligodeoxynucleotide 
(CpG-ODN-1826, TLR 9) are attractive adjuvant candidates. They have been 
described to improve humoral responses against parenterally administered split or 
subunit influenza vaccines [19-22]. The semi-synthetic saponin adjuvant GPI-0100 
is not recognised by known pattern recognition receptors (PRR). Yet, we earlier 
showed that pulmonary vaccination with GPI-0100-adjuvanted influenza subunit 
vaccine induced potent mucosal and systemic antibody responses as well as efficient 
protection against virus challenge[23].
To find an optimal adjuvant that effectively enhances systemic and mucosal immune 
responses to pulmonary administered dry powder vaccine, WIV was SFD along with 
minimal concentrations of above mentioned adjuvants using inulin as stabilizer[14]. 
The SFD vaccines were used for pulmonary immunization of mice. Our results show 
that all adjuvants tolerated the stresses encountered during spray freeze drying well. 
All adjuvants except Pam3CSK4 enhanced systemic influenza-specific antibody 
levels. Yet, only GPI-0100-adjuvanted vaccine effectively induced mucosal antibody 
titres and provided partial protection from heterologous virus challenge. To our 
knowledge, this is the first study comparing different adjuvants for their suitability 
to be used in SFD, pulmonary administered vaccine.
2. Material and methods:
2.1. Virus 
A/PR/8 H1N1 was cultured in embryonated eggs by inoculation of the seed virus into 
the allantoic fluid. Allantoic fluid was harvested 4 days post seed virus inoculation 
and virus was purified as described previously[14]. 
2.2. Vaccine preparation.
WIV derived from A/California/07/2009 (H1N1) was kindly provided by Solvay 
Biologicals (Weesp, The Netherlands). WIV was dialysed overnight at 4 ˚C against 
HBS, pH 7.2, and protein content was determined by micro-Lowry assay. Purity of 
the WIV was confirmed by SDS PAGE followed by silver staining. The hemagglutinin 
(HA) content was assumed to be one third of the total protein for whole inactivated 
virus (based on the known protein composition of influenza virus and the molecular 
weight of the viral protein). Adjuvanted vaccine solutions were made by adding to 
WIV the minimum amount of adjuvant recommended for one dose in mice based 
on the literature. The amount of adjuvants used per vaccine dose, i.e. 2.5 µg HA of 





Spray freeze-drying of vaccine solutions was performed using 5 % (w/v) inulin from 
dahlia tubers, MW ~5000 (HA of WIV: inulin = 1:200) (Sigma-Aldrich Chemie 
B.V. Zwijndrecht, The Netherlands) as described before[15,14].
2.4. Analysis of adjuvants after spray freeze drying
NFkB activation was detected using the NFκB reporter cell line RAW-BlueTM 
cell line (InvivoGen, Toulouse, France) following the manufacturer’s protocol. 
For stimulation, 1 x 105 RAW-BlueTM cells were added to flat bottom 96-well 
plates (Corning Incorporated, Corning, USA). Cells were stimulated with 5 µg/
ml lipopolysaccharide (LPS) or adjuvants or liquid or dissolved powder vaccines 
containing 2.5 µg of HA of WIV obtained from A/California/07/2009 (H1N1) with 
or without adjuvants. The amount of adjuvant which was present in one vaccine dose 
(see above) was used for stimulating cells. Following stimulation, cells were incubated 
at 37 °C with 5% CO2 for 16 hours. 40 µl of cell supernatant was collected in 96-
well ELISA plates (Greiner Bio One, Alphen a/d Rijn, The Netherlands) to which 
160 µl QUANTI-BlueTM (InvivoGen, Toulouse France) was added. The plates 
were incubated at 37 °C for 1 hour. Secreted embryonic alkaline phosphatase (SEAP) 
levels were determined by measuring absorbance at 620 nm. NFkB activation is 
expressed as the activity of the adjuvants or vaccine relative to that of LPS.
2.5. Physical characterization of powder vaccine
Scanning electron microscope (SEM) images of powder vaccines were taken 
using a JEOL JSM 6301-F microscope (JEOL Ltd., Tokyo, Japan) as described 
previously[15]. Images were taken at magnification of 1000x.
Geometric particle size distribution of powder vaccines was measured using a HELOS 
compact model KA laser diffraction apparatus (Sympatec GmbH, Germany) and the 
RODOS dispersing system (Sympatec GmbH, Clausthal-Zellerfeld, Germany) as 
described previously[15]. The aerodynamic size distribution was calculated from the 
geometric particle size distribution using the equation  from[24] 
where dae= aerodynamic diameter, de= geometric diameter, ρp= density of powder 
particles (0.05 g/cm3), ρ0 = unit density (1g/cm
3), χ = dynamic shape factor which is 
1 for spherical particles[25]. 
The specific surface area of powder vaccines was measured using a Tristar 
surface analyser (Micrometrics Instrument Corp., Norcross, USA) as described 
previously[15].
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2.6. Immunization and challenge of mice
Animal experiments were approved by The Institutional Animal Care and Use 
Committee of the University of Groningen (IACUC-RuG), The Netherlands. 
In vivo experiments were performed in female BALB/c mice (Harlan, Zeist, The 
Netherlands) which were 6-8 weeks old. 
Mice (n=6) were vaccinated via the pulmonary route twice, with an interval of 3 
weeks. Each dose of unadjuvanted or adjuvanted powder vaccine contained 2.5 µg 
HA of WIV derived from A/California/07/2009 (H1N1). Non-treated mice served 
as naive controls. 
For pulmonary vaccination, mice were anaesthetised with isoflurane/O2. Mice were 
brought to a vertical position and intubated with a modified Autograde catheter 
(Becton Dickinson, Breda, The Netherlands). Powder vaccine was delivered 
using a dry powder insufflator (DPI), (Penn-Century Inc., Wyndmoor, USA). 
Approximately 500 µg of powder vaccine containing 2.5µg HA was delivered to 
the lungs by applying a single puff of 200 µl. Before mice were brought back to the 
housing facility after anesthesia, mice were placed in a recovery incubator with a 
temperature of 25 ˚C for 2 hours.
The protective efficacy of the vaccines was determined by challenge of the immunized 
mice with live virus of a heterologous strain (A/PR/8/H1N1) one month after the 
booster vaccination. Briefly, mice were anaesthetised with isoflurane/O2 and 40 µl 
of HBS containing 200 PFU A/PR8/H1N1virus were slowly administered via the 
nostrils. Mice were observed daily for weight loss and ruffled fur. Three days post 
challenge, mice were sacrificed under isoflurane/O2 anesthesia. Blood, nose washes, 
lungs and spleens were collected and processed for further use. Nose washes were 
obtained using 1 ml PBS (pH 7.4), containing Complete protease inhibitor cocktail 
tablets (Roche, Almere, The Netherlands) as described previously[26]. Lungs were 
collected in 1 ml Iscove’s Modified Dulbecco’s Medium (IMDM) complete medium 
(Gibco, Life Technologies BV, Bleiswijk, The Netherlands) containing 5 % FBS 
(Lonza, Basel, Switzerland), 100 U/ml penicillin, 100 mg/ml streptomycin and 0.05 
M 2-mercaptoethanol (Invitrogen, Breda, The Netherlands) after perfusion with 10 
ml PBS containing 0.1 µg/ml heparine. Spleens were collected in 5 ml complete 
IMDM medium.
2.7. ELISA
Nose washes, lung supernatants and serum samples were used for evaluation of 
humoral responses after vaccination. For detection of influenza-specific IgG, IgG1, 
IgG2a and IgA antibodies, ELISA plates (Greiner Bio One, Alphen, The Netherlands) 
were coated with 500 ng/well of WIV derived from A/California/07/2009 (H1N1) 
or A/PR/8 (H1N1) overnight at 37 ˚C. ELISA was performed as previously 
described[15]. Average IgG titres were determined as log 10 of the reciprocal of the 
sample dilution corresponding to an absorbance at 492 nm of 0.2. IgA levels are 




Heamagglutination inhibition (HI) assay was performed as described previously 
with minor changes[14] using pooled sera of mice from each experimental group. 
Four heamagglutination units (HAU) inactivated A/California/07/2009 (H1N1) 
virus was added to the diluted serum samples. HI titres are expressed as log2 values 
of the highest dilution preventing heamagglutination.
2.9 FACS staining
Spleens were collected in complete IMDM medium three days after the second 
immunization and were processed to single cell suspension as described previously[15]. 
Briefly, spleens collected in IMDM were processed to single cell suspensions using 
GentleMACS C tubes along with a GentleMACS dissociator (Mitenyi Biotec B, 
Leiden, The Netherlands). RBCs were lysed using ACK buffer (0.83% NH4Cl, 1 
mM KHCO3, 0.1 mM EDTA, pH 7.2).  Similarly, lungs were collected in complete 
IMDM medium and were processed as described previously[27]. After extensive 
washing 1 x 106 cells were added to FACS tubes (Corning Incorporated, New York, 
USA). Cells were centrifuged at 1200 rpm for 5 min at 4 ˚C. Pelleted cells were 
resuspended and stained with Alexa Fluro 647 anti-GL7 (0.1 µg/100µl) and PE 
anti-B220 PE (0.2 µg/100 µl) in FACS buffer (1% Bovine serum albumin (BSA) in 
PBS, pH 7.4) at 4 ˚C for 60 min. Cells were then washed three times with FACS 
buffer and analysed on a MACSQuant flow cytometer (Miltenyi Biotec B, Leiden, 
The Netherlands). Data was analysed using Kaluza flow cytometry analysis software 
version 1.2 (Beckman Coulter, Woerden, The Netherlands)
2.10 IFNγ or IL4 ELIspot
The numbers of influenza specific IFNγ- and IL4-producing cells were determined 
using ELIspot. IFNγ was performed using a murine IFNγ ELIspot kit (Gen-Probe 
Diaclone SAS, Besancon Cedex, France) according to the manufacturer’s protocol. 
IL4 ELIspot was performed using an in-house made protocol. After extensive washing, 
5 x 105 splenocytes or lymphocytes from lungs were added to MultiScreenHTS-HA 
filter plates (Millipore, Billerica, Massachusetts) coated with anti IFNγ or anti IL4 
(BD Biosciences, Breda, The Netherlands) antibodies. Splenocytes were incubated 
overnight at 37 ˚C with 5 % CO2 in IMDM complete medium with or without 
WIV obtained from A/California/07/2009 (H1N1) (10 µg/ml). Lymphocytes from 
lungs were incubated at 37 ˚ C with 5 % CO2 in IMDM completed medium without 
WIV. IFNγ- or IL4-producing cells were detected using alkaline phosphatase (AP)-
labelled anti-mouse IFNγ or IL4 antibodies (eBioscience, Vienna, Austria). Plates 
were washed and IFNγ- or IL4-specific spots were detected using BCIP/NBT 
substrate (Roche, Almere, The Netherlands). Spots were allowed to develop and the 
reaction was stopped by washing plates with tap water.




5 x 105 splenocytes were added to round bottom 96-well plates (Corning incorporated, 
New York, USA) and were incubated for 72 hours at 37 ˚ C with 5 % CO2 in IMDM 
complete medium with or without WIV obtained from A/California/07/2009 
(H1N1) (10 µg/ml). Cell supernatant was collected and stored at -20 ˚C until used. 
IFNγ and IL-4 levels in samples were determined using Ready-SET Go ELISA kit 
(Ebioscience, Vienna, Austria) according to manufacturer protocol.
2.12 Virus titration
Perfused lungs collected after challenge were homogenised in PBS (pH 7.4) and 
centrifuged at 1200 rpm for 10 minutes. Supernatants were collected, snap-frozen 
in liquid nitrogen and stored at -80 ˚C until use. Lung virus titers were determined 
by infecting MDCK cells grown in 96-well plates with serial dilutions of the lung 
homogenate supernatants as described previously [14]. Virus titers are presented as 
10log titre per gram of lung.
2.13 Statistical analysis
Mann Whitney U-test was used for data analysis. One-tailed tests were performed for 
comparison of data from groups immunized with non-adjuvanted vs adjuvanted 
vaccines. For other comparisons two-sided test was employed. P values < 0.05 were 
considered to represent statistically significant differences. *, **, *** signify p<0.05, 
p<0.01, p<0.001 respectively.
3. Results
3.1 Physical characterization of SFD powder vaccines
In order to evaluate whether addition of adjuvants to WIV prior to spray freeze 
drying affects the physical characteristics of the obtained powder particle size, surface 
area and morphology of powder vaccines were analysed. Firstly, the geometric 
particle size distribution of vaccine powders was studied by laser diffraction (Figure-
1a).  X10, X50 and X90 values of the geometric diameter were determined from 
cumulative undersize curves and the span [span = (X90 – X10)/X50] was calculated 
(Table 1). It was found that 90 % of the powder particles had a geometric size < 17 
µm with a narrow size distribution (stated as span) between 1.4 and 2.1 µm. These 
results demonstrate that addition of the adjuvants did not substantially affect the 
geometric particle size of obtained powder particles.
For pulmonary delivery the aerodynamic diameter is more relevant than the geometric 
diameter since it determines the behaviour of particles in an air stream like during 
inhalation. It has been earlier demonstrated that particles having an aerodynamic 

























































































































































Figure 1. Physical characterization of SFD 
powder vaccines
WIV derived from A/California/07/2009 
(H1N1) was mixed with different adjuvants 
and SFD using inulin as stabilizer. 
Evaluation of (a) geometric particle size 
[X10 (white bars), X50 (grey bars) and 
X90 (black bars)] and (b) aerodynamic 
particle size of SFD powder vaccines by laser 
diffraction using RODOS. (c) Analysis of the surface area of SFD vaccine formulations. 
Scanning electron microscope images of SFD vaccines at 1000X magnification representing 
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aerodynamic size showed (Figure 1b) that the diameter of 90 % of the particles 
was < 5 µm for all the vaccine powders. These powders thus have the dimensions 
required for pulmonal delivery. Analysis of the surface area of SFD vaccines revealed 
that all vaccine formulations had high specific surface areas > 60 m2/g proving that 
the obtained powder vaccines were highly porous as desired for pulmonary delivery 
(Figure 1c). Among the SFD vaccines, WIV-Pam3CSK4 had the lowest surface area 
(65 m2/g) while WIV-GPI-0100 had the highest (97 m2/g). The surface area of WIV-
MPLA and WIV-CpG was 87 m2/g and 84 m2/g respectively. 
The physical appearance of the powder particles was further investigated by scanning 
electron microscopy (SEM). SEM images revealed that all adjuvanted powder 
formulations consisted of spherical particles with interconnected pores (Figure 1 
d-h). For each powder there was some minor variation in particle size distribution. 
Yet, the general appearance of the powders was very similar. 
Overall the results of the physical characterization of the SFD powders indicate that 
addition of the adjuvants had negligible effects on the powder size and porosity.




































Figure 2. Biological activity of vaccine 
components in vitro
Analysis of NFκB activation by SFD 
vaccines on RAW-BlueTM cells. Relative 
absorbance was calculated by dividing 
OD620 values of supernatants from 
cells incubated with the vaccines by the 
OD620 value of the supernatant from cells 
incubated with LPS. Relative absorbance 
for adjuvants (white bars), non SFD 
vaccines (grey bars) and SFD vaccines 
(black bars).
Table 1. Analysis of powder vaccines by laser diffraction for geometric size distribution. 
Particle diameters are indicated in µm. X10, X50, X90 gives the average size of 10, 50, 
90%, respectively, of the powder particles after spray freeze drying. 
Vaccines Laser diffraction (µm) Span
X10 X50 X90
SFD WIV 1.93 5.637 13.953 2.133
SFD WIV Pam3CSK4 2.617 6.263 15.04 1.984
SFD WIV MPLA 3.537 8.66 16.46 1.492
SFD WIV CpG ODN 1826 1.82 5.747 16.16 2.495
SFD WIV GPI-0100 1.893 5.497 12.98 2.017
Chapter 6
99
To study in how far spray freeze drying affects the biological activity of adjuvants 
and vaccines, different adjuvants, untreated or SFD together with WIV and then 
reconstituted, were analysed on RAW-BlueTM cells for their capacity to activate 
NFκB (Figure 2). Analysis of adjuvants alone demonstrated that all adjuvants except 
GPI-0100 were able to activate NFkB in RAW-BlueTM cells, with Pam3CSK4 and 
MPLA being somewhat more active in this respect than CpG. NFkB activation 
was further increased when cells were incubated with adjuvant/WIV formulations. 
WIV itself had little effect and when present in adjuvanted formulations had an 
additive but not a synergistic effect on NFκB activation. Spray freeze drying did not 
affect the capacity of the WIV-adjuvant combinations to induce NFκB activation 
in a negative way. Indeed, for Pam3CSK4-adjuvanted and CpG-adjuvanted WIV 
the SFD formulations were more potent in activation of RAWBlue cells than the 
non-SFD formulations. SFD inulin alone had no effect on RAWBlue cells (results 
not shown) proving the absence of LPS contamination from inulin. These results 
indicate that the stresses encountered by the adjuvants during spray freeze drying did 
not have an adverse effect on their immune stimulating capacities.
3.3 Systemic antibody responses after pulmonary vaccination
The immunological properties of the adjuvanted powder vaccines were evaluated 
in BALB/c mice that received two doses of 2.5 µg HA (approximately 8 µg total 
viral protein) by the pulmonary route. We compared the humoral immune response 
generated by mice vaccinated with SFD adjuvanted WIV with that generated by 
administration of plain SFD WIV. For this purpose blood was collected 21 days after 
the first immunization or 7 and 30 days following the second immunization (i.e. day 
28 and 51 after the first immunization, respectively). Analysis of heamagglutination 
inhibition (HI) activity (Figure 3a) revealed that after a single immunization only 
mice immunized with WIV-GPI-0100 developed HI titres greater than 40. An 
HI titre > 40 is considered as protective in humans[30,31]. This titre was further 
boosted to >4000 after the second immunization with WIV-GPI and was the highest 
among all immunized groups. The other adjuvanted vaccine formulations, except 
WIV-Pam3CSK4+, also induced HI titres higher than unadjuvanted WIV but 
titres greater than 40 were reached only after the second immunization. These titres 
remained constant for a month after booster. 
Determination of IgG antibody titres in serum (Figure 3b) showed that mice 
immunized with WIV-MPLA, WIV-CpG or WIV-GPI-0100 produced significantly 
higher influenza specific IgG titres after the first immunization than mice that 
received WIV alone. Following the second immunization, the IgG titres were further 
increased 10-fold and remained at the same level for at least one month. Among the 
adjuvanted formulations studied WIV-Pam3CSK4 induced the lowest IgG titres and 
no difference in IgG titres was found as compared to non-adjuvanted WIV. Mice 
immunised with CpG or GPI-0100-adjuvanted vaccines had significantly higher 
titres on day 21, 28 and 51 than mice that received non-adjuvanted WIV. However, 





































































































































































































































Figure 3. Systemic antibody responses after pulmonary vaccination
Mice (n=6) were vaccinated via the pulmonary route on day 0 and 21 with powder 
vaccines containing 2.5µg HA of WIV derived from A/California/07/2009 (H1N1) 
alone or with adjuvants. Influenza virus specific humoral responses were evaluated in 
serum. (a) HI titres from pooled sera (b) IgG titres (c) IgG1 titres and (d) IgG2a titres 
and (e) IgG2a to IgG1 ratios on day 21 (white bar), day 28 (grey bars) and day 51 (black 
bars) following immunizations. HI titres after vaccination are expressed as reciprocal 
of the highest dilution of sera resulting in complete heamagglutination inhibition. IgG 
antibody levels are expressed as 10log titres. IgG1 and IgG2a levels are shown as µg per 








mice immunized with GPI-0100 adjuvanted vaccine displayed the highest IgG titres. 
Quantification of influenza specific IgG subclasses (Figure 3c-d) demonstrated that 
mice receiving adjuvanted formulations, except the one containing Pam3CSK4, 
developed significantly higher IgG1 levels than mice immunized with unadjuvanted 
vaccine. By far the highest IgG1 titres were measured in mice immunized with 
WIV-GPI-0100. Differences with titres in mice immunized with plain WIV were 
significant for d21, d28 and d51. Analysis of serum for IgG2a antibody revealed 
that after the first vaccination WIV-GPI-0100 induced higher IgG2a levels than 
any of the other vaccine formulations. However, after the second immunization 
mice vaccinated with WIV CpG displayed similar levels of IgG2as WIV-GPI-0100-
immunised mice. Other vaccine groups also showed increased IgG2a amount after 
the second immunization, however, the levels were lower than those observed for 
WIV-CpG or WIV-GPI-0100 immunized mice. Calculation of the IgG2a/IgG1 
(Figure 3e) ratio showed that at least on day 51 all powder formulations induced 
IgG2a as the predominant antibody subtype (IgG2a/IgG1 ratio in the range of 
1.1626 to 8.326) except for WIV GPI-0100 (IgG2a/IgG1 ratio = 0.281).
3.4 Mucosal antibody responses after pulmonary vaccination
Earlier we described that pulmonary immunization with non-adjuvanted WIV 
induced lung IgA but rather little IgA in the nose[14]. To find out whether the use 
of one of the adjuvants improved the mucosal immune response, nose washes and 
lung supernatants of the vaccinated and challenged mice were evaluated for antibody 
responses. Nose IgA responses in mice immunized with non-adjuvanted SFD WIV 
were higher than in our previous experiment, possibly due to some changes in 
vaccination technique. None of the adjuvanted vaccines induced significantly higher 
nose IgA titers than non-adjuvanted WIV (Figure 4a); yet, there was a trend towards 
higher nose IgA titers in mice immunized with WIV-CpG or WIV-GPI-0100. In 
contrast, mice vaccinated with WIV-Pam3CSK4 or WIV-MPLA had (significantly) 
lower levels of nose IgA than mice vaccinated with non-adjuvanted WIV. 
Evaluation of lung supernatants for IgA antibody (Figure 4b) showed that mice 
immunised with WIV-GPI-0100 developed approximately 250-fold higher IgA 
titres than mice administered with unadjuvanted WIV. A trend towards higher IgA 
induction in the lungs was also observed in mice vaccinated with WIV-CpG, but 
was not statistically significant. Conversely, mice immunised with WIV-Pam3CSK4 
showed lower lung IgA levels, while WIV-MPLA-immunised mice developed similar 
levels of IgA compared to mice that received non-adjuvanted WIV. Determination 
of IgG titres in the lungs supernatants demonstrated that all adjuvants except 
Pam3CSK4 significantly stimulated lung IgG responses. The IgG titres were highest 
in mice vaccinated with WIV-GPI-0100.







































































































































Figure 4. Mucosal antibody responses 
after pulmonary vaccination
Nose wash and lungs from the mice 
described in the legend of Figure 3 were 
collected after vaccination and challenge 
and analysed for (a) nose IgA (b) lung 
IgA and (c) lung IgG. Nose IgA responses 
are presented as absorbance at OD492 
while lung IgA and IgG antibody levels 
are expressed as log10 titres. Levels of 





3.5 Germinal centre formation after pulmonary vaccination
Formation of germinal centres in the spleens was analysed 3 days post influenza 
virus challenge in immunized mice. For this purpose, splenocytes were analysed by 
flow cytometry for the presence of B cells expressing the germinal center marker 
GL7[32,33]. About 50 % of splenocytes were B220-positive and no difference in the 
percentage of B cells was found between vaccinated and control mice (Figure 5a). 
However, all pulmonary vaccinated mice except those administered with WIV-CpG 
had significantly higher numbers of GL7+ B cells in the spleens than in the spleens 
of the control mice (Figure 5b). There was no difference in GL7+ B cell numbers 
between the mice that received unadjuvanted or adjuvanted vaccine. 
To investigate to which extent formation of iBALT takes place upon pulmonary 
administration of adjuvanted vaccine, lymphocytes were isolated from the lungs of 
Chapter 6
103
immunized mice, pooled per experimental group and analysed for GL7+ B cells by 
flow cytometry (Figure 5c). In control mice (non-immunized, 3 days after challenge) 
about 1% of the lung lymphocytes were positive for B220 and GL7. In mice 
immunized with WIV-GPI-0100 the amount of GL7+B220+ lung lymphocytes was 
2.2 times higher indicating an effect of the immunization on local B cell populations. 
The other adjuvants had little effect on the percentage of the size of the germinal 
centre B cell population.
3.6. Cellular responses after pulmonary vaccination
Cellular immune responses were assessed three days after virus challenge in 
immunised mice. Splenocytes obtained from the immunized and challenged mice 
were stimulated with influenza virus for 16 hours for performing ELIspot and for 72 
hours for determination of the levels of secreted cytokines. Analysis of the number of 
IL4-producing cells (Figure 6a) demonstrated that the H1N1 specific T cell response 
was robust in mice immunized with WIV-GPI-0100. H1N1-specific IL4-forming 


























































































































































Figure 5. Germinal centre formation after 
pulmonary vaccination
Spleens and lungs from the mice described 
in the legend of Figure 3 were collected after 
vaccination and challenge. Formation of 
germinal centres was evaluated by staining 
106 cells for GL7 and B cells using anti-GL7 
Alexa647 and anti-B220 PE respectively. (a) 
Percentage of B cells in spleen (b) GL7+ B 
cells per 106 splenocytes and (c) Percentage of 
GL7+ B cells in lymphocytes from lungs.
c
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alone or WIV together with one of the other adjuvants. However, the numbers were 
significantly lower than those from mice immunised with WIV-GPI-0100. In line 
with the increased numbers of IL4-producing T cells, the supernatants of splenocyte 
cultures from mice immunised with WIV-GPI-100 also showed significantly 
increased levels of IL5 compared to those from mice that were immunized with 
any of the other formulations (supplementary Fig. 1a). IL-5 secretion was also 
high in the splenocyte cultures from the mice immunised with WIV alone although 
these mice did not possess large numbers of IL4 producing splenocytes. The other 
vaccines did not induce much production of IL5. Evaluation of splenocyte cultures 






















































































































































Figure 6. Cellular responses after pulmonary 
vaccination
Effects of adjuvants on the number of 
influenza-specific T cells were evaluated 
three days after heterologous challenge. 
Splenocytes isolated were stimulated 
overnight with or without subunit vaccine 
derived from A/California/07/2009 
(H1N1). (a) IL4- and (b) IFNγ-producing 
influenza-specific cells were calculated by 
subtracting spots formed by non-stimulated 
cells from spots formed by stimulated cells. 
Similarly, effects of adjuvants on cytokine-
producing cells in lungs were evaluated 
three days after heterologous challenge. (c) 
Lymphocytes from the perfused lungs were 
pooled and analysed for IL4- (white bars) and IFNγ- (black bars) producing cells. The 
results are expressed as spot forming cells per 5 x 105 cells. Levels of significance are 





in the number of H1N1-specific IFNγ spot-forming cells compared to those from 
mice that received non-adjuvanted formulations (Figure 6b). However, splenocytes 
cultures from vaccinated mice had significantly higher numbers of IFNγ producing 
cells than those from control mice. A similar trend was observed when supernatants 
of splenocyte cultures were analysed for secreted IFNγ (supplementary Fig. 1b). 
Irrespective of the immunising agent, stimulated splenocytes from all mice produced 
more of the Th1-related cytokine IFNγ than of the Th2-related cytokines IL4 or 
IL5 (compare supplementary Fig. 1a and b). The dominance of IFNγ was least 
pronounced for the mice immunized with WIV-GPI-0100.
Cellular immune responses in immunized and challenged mice were also analysed 
in the lungs. Higher numbers of IL4-producing cells were observed in the lungs of 
vaccinated and challenged mice than in the lungs of control mice which had only 
been challenged. Among the vaccinated mice the highest number of IL4 producing 
cells was seen in the lungs of mice that had received WIV GPI-0100. Not much 
difference was found between IL4-forming cells from the mice that received plain 
vaccine or vaccine supplemented with MPLA or CpG.  
Analysis of lung lymphocyte cultures showed that influenza-specific IFNγ-producing 
T cells were present in the lungs of all mice, with the highest frequencies in WIV, 
WIV-MPLA and WIV-CpG-immunized mice and the lowest frequency in WIV-





























































































Figure 7. Cross protection after pulmonary vaccination
One month after the second vaccination, mice (n=6) were given a heterologous challenge 
with 200 PFU A/PR/8 (H1N1). Three days post challenge, mice were sacrificed. Serum 
samples were analysed for A/PR/8 (H1N1) specific (a) IgG. Lung supernatants were 
evaluated for (b) virus titres. IgG antibody levels are expressed as 10log titres per ml. HI 
titres after vaccination and challenge are expressed as reciprocal of the highest dilution 
of sera resulting in complete heamagglutination inhibition. Virus titres are expressed as 
10log titres per gram lung. Levels of significance are presented as *p<0.5, **p<0.01.
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formulations, irrespective of their composition, induced IL4- and IFNγ-producing 
cells in the lungs. The variation in the number of cytokine-producing T cells induced 
by the various formulations was higher for IL4- than for IFNγ-producing T cells.
 3.7 Cross protection after pulmonary vaccination
In our earlier studies we proved that pulmonary vaccination is capable of providing 
protection against homologous virus challenge[14]. Now we investigated in how far 
pulmonary immunized mice were protected against challenge with a heterologous 
virus strain and whether adjuvants contributed to this protection. To this end, mice 
were immunized with (adjuvanted) SFD vaccines derived from A/California/07/2009 
(H1N1pdm) and were challenged with a lethal dose of A/PR/8/34 (H1N1) one 
month after the second vaccination.
Analysis of serum samples for IgG titres post virus challenge revealed that pulmonary 
delivery of either of the SFD A/Cal vaccines induced IgG antibody cross-reactive 
with A/PR/8/34 (Fig. 7a). Adjuvantation of the vaccine with GPI-0100 but not with 
any of the other adjuvants significantly increased the titre of the cross-reactive IgG. 
Despite the presence of cross-reactive IgG antibodies in all experimental groups, only 
mice vaccinated with WIV-GPI-0100 had a detectable A/PR/8/34 (H1N1)-specific 
HI titer which was however low viz. 8. 
Titration of lung supernatants for presence of virus showed that none of the 
vaccinated mice was able to completely clear the virus (Figure 7b). Yet, in mice 
vaccinated with WIV-GPI-0100 the lung virus titre was reduced by more than 1 log 
(>90%) as compared to the virus titre in mice vaccinated with unadjuvanted WIV 
and this difference was statistically significant. In contrast, mice immunised with 
any of the other adjuvanted vaccines did not show reduced virus load in the lungs in 
comparison with the control group.
4. Discussion
The aim of this study was to investigate the suitability of different adjuvants to 
enhance immune responses to pulmonary delivered whole inactivated virus (WIV) 
dry powder influenza vaccine. For this, WIV supplemented with different TLR 
ligands or the non-PRR binding, saponin-derived semi synthetic compound GPI-
0100 was SFD using inulin as stabilizer. Physical characterization of SFD vaccines 
showed that all adjuvanted vaccines were ideally suitable for pulmonary delivery. 
NFκB activation in RAW-BlueTM cells confirmed that spray freeze-drying did not 
affect the immune stimulating properties of the adjuvants. A comparative pulmonary 
immunization study in mice highlighted that all adjuvants, except Pam3CSK4, 
enhanced the induction of systemic IgG. However, only GPI-0100 was capable of 
stimulating mucosal IgA responses. The enhanced humoral response in WIV-GPI-
0100-immunised mice was associated with increased numbers of influenza-specific 
IFNγ- or IL4-secreting T cells. Mice immunised with GPI-0100-adjuvanted WIV 
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were partially protected against heterologous virus challenge while mice immunised 
with any of the other adjuvanted vaccines were not.
Our study aimed at delivering the WIV-adjuvant vaccines to the lungs as dry 
powder. For effective pulmonary delivery particle size, surface area and porosity of 
the powder vaccines are important parameters[24]. The particle properties of SFD 
vaccines are determined by the compounds present in the dried material, the sugar 
(disaccharide or polysaccharide) used for stabilization and the conditions employed 
for spray freeze-drying[14]. We therefore evaluated whether addition of any of the 
adjuvants to the vaccine/inulin mixture affected the powder properties. Our data 
indicates that addition of adjuvants to WIV had no adverse effects on the particle 
size of SFD powder vaccine. Also, all adjuvanted vaccines consisted of spherical and 
porous particles as desired for pulmonary immunization. 
After analysing the SFD vaccines for their physical characteristics and the vaccine 
compounds for their biological activity, the systemic immune response induced 
by the adjuvanted pulmonary vaccines was evaluated. Our results show that most 
adjuvants stimulated the induction of HI titres to levels greater than those induced 
in mice vaccinated with unadjuvanted WIV. Yet, Pam3CSK4 performed poorly as 
an adjuvant. In a previous study, Pam3CSK4 administered i.m. along with influenza 
subunit vaccine did stimulate IgG antibody responses with IgG2a as the dominant 
antibody subtype[20]. Moreover, when administered to the total respiratory tract 
together with RSV virosomes, Pam3CSK4 elicited potent cellular and humoral 
responses[19].  The reason for a suboptimal humoral response in our study may be 
the combination of Pam3CSK4 and WIV. WIV contains ssRNA that is recognised 
by TLR7[34]. It has been shown that a combination of TLR2 and TLR7 ligands 
is not able to induce IL12 or IFNγ in human peripheral blood mononuclear 
cells[35]. IL12 is an important cytokine for induction of IgG as well as mucosal IgA 
antibody[36]. Furthermore, in the previous studies 5 or 10 µg Pam3CSK4 were used, 
these amounts exceeded earlier literature data. The lower amount of Pam3CSK4 in 
our study (2.5 µg) might have resulted in insufficient stimulation of APCs.
Another TLR ligand that was shown to be a safe and potent mucosal adjuvant is 
MPLA[37][38]. In our study, pulmonary delivery of MPLA together with WIV in 
powder form evoked effective serum and lung IgG responses but antibody subtype 
analysis revealed that the MPLA adjuvanted vaccine induced more IgG1 than IgG2a. 
Similar results were observed when 0.625 µg MPLA along with 5 µg of HA of WIV 
was delivered via the pulmonary route . Moreover these results are in line with 
immune responses induced when Mycobacterium tuberculosis antigen 85A together 
with MPLA was delivered to the total respiratory tract (TRT)[39]. However, these 
results contradict observations where TRT delivery of MPLA along with antigen 
stimulated Th1 responses and thus resulted in high IgG2a antibody titers[38]. The 
first reason for these contradictory results could be strict pulmonary delivery of 
vaccine as opposed to TRT delivery. In TRT delivery, APCs in nasal cavity, trachea as 
well as conducting airways gets activated because the vaccine flows from nasal cavity 
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to the lungs; while in strict pulmonary delivery only DCs (CD103+ CD11c+CD11b-
langerin+)in the conducting airways along with alveolar macrophages(F4/80+ 
CD11c+CD11b+) might get activated[40,41]. Alveolar macrophages are thought 
to be immune suppressive and to have an anti-inflammatory role[42,43]. A second 
reason could be the use of a rather low amount of WIV and MPLA in the vaccine 
formulations used in our study. Antibody responses were shown to be dependent on 
the stimulation of innate immunity[44], and insufficient stimulation due to a low 
amount of MPLA might  be the reason for low IgA induction in nose and lungs. 
Similar to MPLA, CpG enhanced IgG antibody responses in lungs and serum upon 
pulmonary immunisation. Moreover, pulmonary delivery of CpG-adjuvanted WIV 
induced four times more IgG2a than IgG1. These results are in line with previous 
observations where CpG along with bovine RSV successfully evoked production of 
IgG antibodies upon pulmonary delivery[45]. In this study it was also shown that 
CpG-adjuvanted pulmonary vaccine elicits highly skewed Th1 responses resulting 
in predominant induction of IgG2a antibodies in serum. This phenomenon was not 
only true for inactivated viruses but also for subunit antigen. For example, delivery 
of CpG together with Mycobacterium tuberculosis antigen 85A resulted in Th1-
dominant cellular and humoral responses[39]. However, pulmonary delivery of 
CpG stimulated moderate IgA responses in nose and lungs. One way to increase IgA 
responses could be to increase the amount of CpG in the vaccine; a second way could 
be conjugation of CpG with a nanoparticle[46].
In contrast to the other adjuvanted vaccines, GPI-0100-adjuvanted vaccine induced 
robust HI and IgG titres upon pulmonary vaccination at all studied time points. 
These results are in line with previous observations where pulmonary delivery of 
ISCOMATRIX (IMX), another saponin-based adjuvant, with influenza split vaccine 
in sheep promoted robust systemic IgG responses[47]. However, analyses of serum 
antibody subtype and enumeration of cytokine-producing cells showed that GPI-
0100 was unable to overcome the predominant Th2 microenvironment in the lungs: 
GPI-0100 stimulated a 25-fold increase in IgG1 as opposed to a 10-fold increase in 
IgG2a compared to unadjuvanted WIV. These results are in agreement with previous 
findings where GPI-0100-adjuvanted influenza subunit vaccine resulted in skewed 
Th2 responses after pulmonary immunisation[23]. Though GPI-0100 induced a 
Th2-dominant response, it enhanced both lung IgG and IgA titers by approximately 
20 and 1600 fold respectively. Moreover, usage of GPI-0100 showed a trend towards 
increase of nose IgA demonstrating its potential to boost mucosal immunity. 
Earlier studies on mucosal immunity indicated that the microenvironment in the 
respiratory tract favours the development of a Th2-dominated immune response 
which is the result of anti-inflammatory cytokines such as IL4, IL5 and IL13[48-
50]. These cytokines stimulate IgG1 antibody production and suppress production 
of the Th1-associated IgG2a antibody subtype[51,52]. This phenomenon has been 
observed in our previous studies where pulmonary immunisation with WIV resulted 
predominantly in production of IgG1 antibody although upon i.m. immunization 
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WIV induces a Th1-dominated immune response[34]. In the current study, use of 
adjuvants, except GPI-0100, resulted in a dominant Th1 response, the hallmarks of 
which are a high IgG2a/IgG1 ratio and high numbers of IFNγ producing cells. The 
vaccine formulation containing CpG induced robust IgG2a antibody production 
and relatively little production of IgG1 and the Th2-related cytokines IL4 and 
IL5. The amount of IgG2a antibody produced in mice immunized with GPI-
0100-adjuvanted vaccine was equivalent to the amount produced in WIV-CpG-
immunized mice. Yet, the amount of IgG1 in these mice was very high leading to 
an ‘unfavourable’ IgG2a/IgG1 ratio of 0.281. Previous studies show that both the 
IgG1 and the IgG2a antibody subtype play a role in controlling influenza spread 
in the host. IgG1 controls influenza by virus neutralisation while IgG2a performs 
the task by helping in clearance of influenza virus from the host by activation of the 
complement system and by stimulating uptake of opsonized virus by Fc receptor-
bearing cells[53]. A study of Huber et al demonstrates that IgG2a alone can protect 
against influenza infection as effectively as a IgG1/IgG2a mix, while IgG1 is much 
less effective in protection[53,54]. Thus IgG2a is the more important isotype for 
protection and the IgG2a/IgG1 ratio is not that important as long as sufficient IgG2a 
is available.  Therefore, though GPI-0100 adjuvanted vaccine gave rise to a dominant 
IgG1 response, it effectively evoked high IgG2a antibody levels resulting in control 
of influenza virus infection as seen from this and from previous studies[23,55]. 
The aim of pulmonary vaccination is to raise IgA antibody titers at the mucosal 
surfaces so that immediate neutralization of influenza virus is obtained at the port 
of entry. In our study pulmonary immunisation with any of the vaccines stimulated 
rather moderate levels of IgA in the nose but high levels in the lungs. The reason 
could be that the vaccine was directly delivered to the lungs and the nasal mucosa 
with its antigen-presenting cells was bypassed. Upon antigen re-encounter, memory 
T and B cells from the draining lymph nodes were shown to preferentially home 
back to the earlier site of stimulation and then to the adjacent mucosa[56-58]. Thus, 
antigen-specific lymphocytes stimulated in the lungs would preferentially home back 
to the lungs and only to a limited extent to the nose. Another factor could be tissue-
resident memory T and B cells which stay at the place of activation. For primary 
influenza infection it has been shown that, rather than homing to adjacent organs 
or the bone marrow, influenza-specific memory B and T cells remain in the lungs 
where they can provide immediate protection upon influenza re-encounter and do 
not home to adjacent organs[59]. Moreover, the surface area of the nasal mucosa is 
much smaller than that of the lower respiratory tract (20 mm2 upper respiratory tract 
v/s 480 mm2 lower respiratory tract) which probably contributes to moderate IgA 
levels in the nose.
In addition to antibody responses, we evaluated the ability of the adjuvanted vaccines 
to provide cross protection upon heterologous challenge. Upon doing ELISA, we 
found that pulmonary immunisation with A/California (H1N1) alone or with any 
of the adjuvants resulted in production of antibodies which cross-reacted with A/
PR/8 (H1N1). However, a measurable HI titre (HI=8) against A/PR/8 (H1N1) was 
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only observed in mice immunised with GPI-0100 adjuvanted WIV. These results 
are in agreement with lung virus titers where only GPI-0100 immunised mice had 
significantly reduced virus in the lungs. However, these results contradict previous 
observations where i.m. administration of fusion-active, non-adjuvanted WIV was 
shown to provide protection against infection with a heterologous influenza virus 
strain[27]. In those experiments, protection could be attributed to CTLs rather 
than to antibodies [60]. The same paper shows that TRT immunisation does not 
elicit robust CTL responses. Instead, moderate cross-protective efficacy of TRT 
immunisation with WIV could be attributed to mucosal IgA[60]. Therefore, in 
our study the reason for reduced virus titres in the lungs of mice immunised with 
GPI-0100 could be the presence of IgA in lungs and serum (supplementary Fig. 
2). The conditions of the virus challenge experiment were severe. Non-immunized 
mice challenged with 200 PFU of the used challenge virus are known to reach the 
humane endpoint (15% weight loss) by day 4 (unpublished observations). This 
severe challenge might have prevented better control of virus growth by vaccine-
induced immune responses and thus lead to an under-estimation of the potency of 
pulmonary vaccination.
Taken together, our data show that all studied adjuvants tolerated the stresses 
associated with spray freeze drying and the use of all adjuvants was compatible with 
the production of powder particles as desired for pulmonary administration. Yet, the 
adjuvants differed in their capacity to enhance systemic and particularly mucosal 
immune responses, with GPI-0100 being clearly more effective than the other 
adjuvants in this respect. To our knowledge this is the first study which evaluates in 
a head-to-head comparison the capacity of different adjuvants to improve immune 
responses to pulmonary administered vaccine in vivo and does so by using dry powder 
vaccine formulations. The results are very encouraging and warrant further studies 
to determine the minimal amount of adjuvant and vaccine required for protection. 
In conclusion, pulmonary delivery of stable adjuvanted powder vaccine is a feasible 
approach for the production of potent mucosal vaccines suitable for preventing 
spread of seasonal and pandemic influenza infections.
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Supplementary Figure 1. Level of cytokine production in stimulated splenocytes. 
Splenocytes were cultured overnight with or without subunit vaccine derived from A/
California/07/2009 (H1N1). Cell supernatants from stimulated and non-stimulated 
splenocytes were analysed for (a) IL5 and (b) IFNγ. Results are presented as the difference 
in cytokine levels between stimulated and unstimulated splenocytes. Levels of significance 
are presented as *p<0.5, **p<0.01.
Supplementary Figure 2. Serum IgA responses.
Mice (n=6) were vaccinated via the pulmonary route on day 0 and 21 with powder 
vaccines containing 2.5 µg HA of WIV derived from A/California/07/2009 (H1N1) 
alone or with adjuvants. Influenza virus specific IgA response was evaluated from serum 
on (a) day 21 and (b) day 28.
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Abstract
The best approach to control the spread of influenza virus during a pandemic is 
vaccination. Yet, an appropriate vaccine is not available early in the pandemic since 
vaccine production is time consuming. For influenza strains with a high pandemic 
potential like H5N1, stockpiling of vaccines has been considered but is hampered 
by rapid antigenic drift of the virus. It has, however, been shown that immunization 
with a given H5N1 strain can prime the immune system for a later booster with 
a drifted variant. Here we investigated whether whole inactivated virus (WIV) 
vaccine can be processed to tablets suitable for sublingual (s.l.) use and whether 
s.l. vaccine administration can prime the immune system for a later intramuscular 
(i.m.) boost with a heterologous vaccine. In vitro results demonstrate that freeze-
drying and tableting of WIV did not affect the integrity of the viral proteins or 
the hemagglutinating properties of the viral particles.  Immunization experiments 
revealed that s.l. priming with WIV (prepared from the H5N1 vaccine strain 
NIBRG-14) four weeks prior to i.m. booster immunization with the same virus 
strongly enhanced hemagglutination inhibition (HI) titers against NIBRG-14 
and the drifted variant NIBRG-23. Moreover, s.l. (and i.m.) immunization with 
NIBRG-14 also primed for a subsequent heterologous i.m. booster immunization 
with NIBRG-23 vaccine. In addition to HI serum antibodies, s.l. priming enhanced 
lung and nose IgA responses while i.m. priming enhanced lung IgA but not nose 
IgA levels. Our results identify s.l. vaccination as a user-friendly method to prime 




Influenza is an infectious disease responsible for morbidity and mortality during 
yearly epidemics and occasional pandemic outbreaks. Vaccination is an efficient tool 
in containing the virus by stimulating the immune system and will be of eminent 
importance in case of a pandemic. However, the immediate availability of influenza 
vaccine during a pandemic is hindered by the laborious vaccine production process 
[1]. For this reason it is desirable to stockpile influenza vaccines for future pandemics, 
at least for influenza strains like H5N1 which have a high pandemic potential [2,3]. 
Yet, limited shelf life of current vaccine formulations and ongoing antigenic drift of 
the H5N1 virus hamper the stockpiling process [4–6]. Therefore, new strategies have 
to be developed to improve pre-pandemic preparedness.
H5N1 virus circulates mainly in aquatic birds and in poultry in South-east Asia 
and occasionally infects humans who are in close contact with the infected birds. 
Human to human transmission is rare and very few cases have been reported until 
today [7,8]. Yet, recent studies have shown that a very limited number of mutations 
may allow for efficient human to human transmission in the future [9–11]. Hence, 
H5N1 poses a constant threat of causing a new pandemic  
Much effort has been put in the development of H5N1 vaccines. It appeared that 
unlike other influenza A vaccines, the H5N1 subtype requires two vaccine doses for 
effective protection [12,13]. The need for two doses of vaccine creates an obstacle 
to pre-pandemic preparedness and may contribute to a high risk of vaccine shortage 
during pandemic outbreaks. Furthermore, H5N1 viruses display distinct antigenic 
drift; currently 9 clades and several sub-clades are distinguished [14,15]. In some 
cases, influenza vaccines from one clade may provide cross protection against another 
clade(s). Yet, in other cases cross-reactivity is very limited [16]. Interestingly, a 
recent clinical study has demonstrated that immunization with one H5N1 virus 
strain, i.e. A/Vietnam/1203/2004 can prime for boosting with another strain, i.e. 
A/Indonesia/05/2005 and that the resulting antibodies can neutralize both the 
virus strains [17]. The heterologous boosting of immune responses with vaccines 
from drifted H5N1 virus has paved the way to pandemic preparedness. Indeed, 
several countries including the USA have currently stockpiled pre-pandemic H5N1 
vaccines.
The instability of liquid influenza vaccine is an important problem in stockpiling 
of H5N1 vaccines [18].  Influenza vaccines can be stabilized by incorporating them 
into a glassy matrix of a sugar, e.g. inulin, dextran or trehalose, for example by means 
of freeze-drying techniques [19–22]. Dried vaccines can be reconstituted prior to 
intramuscular (i.m.) injection. Yet, ideally they would be used in dry form, e.g. as 
powder or formulated in a unit-dosage form like tablets. Tablets are easy to distribute 
and administer during challenging situations like the outbreak of an avian influenza 
pandemic. 
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Unfortunately, delivery of influenza vaccines to the gastro-intestinal tract as such 
induces suboptimal immune responses [23]. Recently, s.l. delivery of influenza 
vaccine has raised interest. Preclinical studies in mice have shown promising results: 
s.l. administered influenza vaccine is capable of inducing hemagglutination-inhibiting 
antibodies in serum as well as a local immune response in the upper respiratory 
tract [24–29]. Secreted IgA in the mucosa provides a local immune protection. IgA 
antibodies in the nose have an added advantage because they can neutralize the virus 
at the port of entry [21,30].
In this study, we tested the possibility of formulating a whole inactivated virus 
(WIV) H5N1 vaccine into a stable s.l. tablet and the suitability of such a tablet to 
prime for an immune response which can be boosted by i.m. immunization with 
a conventional vaccine formulation. We used inactivated A/Vietnam/1203/2004 
vaccine virus (NIBRG-14) belonging to clade 1 for production of the s.l. tablets 
and NIBRG-14 or A/turkey/Turkey/1/2005 vaccine virus (NIBRG-23), a clade 2.1 
virus, for the subsequent i.m. boost.
 2. Materials and methods
2.1 Materials
The NIBRG-14 (a reassortant strain of A/PR/8/34 (H1N1) and A/Vietnam/1194/2004 
(H5N1)) and NIBRG-23 (a reassortant strain of A/PR/8/34 (H1N1) and A/turkey/
Turkey/1/2005 (H5N1)) vaccines strains were obtained from the National Institute 
for Biological Standards and Controls (NIBSC), Potters Bay, UK and were propagated 
on embryonated chicken eggs. Inulin 4 kD was procured from Sensus (Roosendaal, 
The Netherlands). The tablet excipients i.e. Avicel PH 102 (microcrystalline cellulose) 
and Ac-Di-Sol (cross-linked sodium carboxymethylcellulose) were purchased from 
FMC, Biopolymers (Philadelphia, USA), and mannitol from Bufa (Uitgeest, The 
Netherlands).
2.2 Vaccine
Whole inactivated influenza virus (WIV) was derived from NIBRG-14 and 
NIBRG-23 viruses by inactivating them with β-propiolactone as described previously 
[21]. Thereafter, WIV was purified by dialyzing overnight against HBS (2 mM 
Hepes, 125 mM NaCl, 0.9 mM CaCl2, and 0.5 mM MgCl2, pH 7.4). The protein 
concentration of the inactivated vaccine solution was determined by micro-Lowry 
assay [31]. The HA content of the vaccine was considered to be one third of the total 
protein content. 
2.3 Freeze-drying
The NIBRG-14 vaccine was freeze-dried as described previously [19]. In brief, the 
vaccine was mixed with an aqueous inulin solution at a HA: inulin weight ratio 
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of 1:500 and a final inulin concentration of 5 % w/v. Subsequently, 10 ml glass 
vials were charged with 2 ml of the vaccine dispersion. The samples were frozen 
by immersing the vials in liquid nitrogen for 10 minutes. After freezing, they were 
placed on the shelf of a freeze dryer (Christ Epsilon 2-4 freeze dryer; Salm and 
Kipp, Breukelen, The Netherlands). The shelf and condenser temperature were set at 
-35 °C and -85 °C, respectively. The freeze-drying process was initiated by reducing 
the pressure to 0.180 mBar and the shelf temperature was gradually increased to 4 
°C over 32 hours. Thereafter, the pressure was further reduced to 0.05 mBar while 
the temperature was gradually increased to 20 °C over 11 hours. Freeze-drying was 
continued under these conditions for another 24 h. After freeze-drying, glass vials 
were closed in a nitrogen atmosphere with a controlled relative humidity of less than 
10 % and stored at room temperature until further use.
2.4 Formulation and evaluation of s.l. vaccine tablets
S.l. tablets weighing 30 mg were formulated by mixing freeze-dried NIBRG-14 
vaccine (25 % w/w) with Avicel PH 102 (55 % w/w), mannitol (10 % w/w) and 
Ac-Di-Sol (10 % w/w). The powder mixture was compressed using a single (6 
mm x 2 mm capsule shaped die) tablet press with a compaction force of 10 kN, 
which was reached within 5s. The crushing strength of the tablet in radial direction 
was evaluated using a tablet tester (MODEL 6D (SG), Pharmatron, Switzerland). 
The tablet disintegration test recommended by pharmacopoeia could not be used, 
because the size of the tablets was too small for the meshes of the basket. Hence, we 
adopted a simple method as described by Rawas-Qalaji et al [32]. Briefly, the tablet 
was immersed into a test tube filled with 2 ml of water and the time required for 
breakdown of the tablet into smaller fragments was recorded by visual inspection.
2.5 SDS-PAGE 
The biochemical integrity of proteins in freeze-dried NIBRG-14 vaccine was analyzed 
by SDS-PAGE under non-reducing conditions and compared with unprocessed 
NIBRG-14 vaccine. The freeze-dried samples and the tablets were reconstituted in 
water. The reconstituted and unprocessed samples and a pre-stained protein ladder 
(Page Ruler 10-170K, Thermo Scientific, USA) were incubated at 37 °C for 10 
minutes. Thereafter, the samples were mixed with sample buffer (Novagen® 4X SDS 
Sample Buffer, Millipore Corporation, USA). Each sample was then loaded on a 
pre-cast gel (12 % polyacrylamide Mini-PROTEAN TGX Pre-cast Gels, Bio-Rad, 
USA) and resolved at 100 V for 1.5 hrs. Subsequently, the polyacrylamide gel was 
subjected to silver staining as reported earlier [33]. The gel was dried and scanned 
using an HP scanner. 
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2.6 Hemagglutination assay 
The hemagglutination capacity of the unprocessed NIBRG-14 and NIBRG-23 
vaccines, reconstituted freeze-dried vaccines and solubilized tablets was determined 
as described earlier [34]. In brief, a dispersion of the vaccine containing 5 µg of 
hemagglutinin (HA) in 50 µl phosphate buffer saline (PBS) was prepared and 
added to the first well of a V-bottom micro-titer plate (Corning Constar, USA). 
Subsequently, the solution was serially diluted twofold in PBS (pH 7.4). Subsequently, 
50 µl of 1 % guinea pig red blood cells, (RBC) suspension was added to the wells 
and hemagglutination was allowed to proceed for 2 h at room temperature. The 
highest dilution of vaccine capable of agglutinating the RBC was recorded as 1 
hemagglutination unit (HAU). The measurements were performed in triplicate.
2.7 Immunization studies
Animal experiments were evaluated and approved by the Committee for Animal 
Experimentation (DEC) of the University of Groningen, The Netherlands. Female 
Balb/c mice (6-8 weeks old) were purchased from Harlan (Zeist, The Netherlands). 
All procedures in mice were performed under Isofluran/ O2 (inhalation) anesthesia.
The mice were immunized on day 0 and day 56 according to the immunization 
schedule depicted in Table 1. To ensure proper s.l. vaccination the dry vaccine 
powder was reconstituted in 10 µl PBS and pipetted carefully under the tongue 
of anesthetized mice. The freeze-dried vaccine powder was used for reconstitution 
because it was found that the reconstitution of the formulated tablet required more 
than 10 µl of water while the sublingual cavity of a mouse can only accommodate 
maximally 10 µl of liquid. After s.l. immunization the mice were placed on a flat 
surface for 30 minutes under anesthesia to ensure effective immunization. Mice were 
sacrificed on day 84.
Group Prime (day 0) Boost (day 56) n
1 s.l. (NIBRG -14) i.m. (NIBRG -23) 8
2 i.m. (NIBRG -14) i.m.(NIBRG -23) 8
3 s.l. (NIBRG -14) i.m. (NIBRG -14) 8
4 i.m. (NIBRG -14) i.m. (NIBRG -14) 8
5 s.l. (PBS) i.m. (NIBRG -23) 8
Table I. Immunization schedule
Blood samples were taken twice, i.e. on day 28 by orbital vein puncture and on 
day 84 via cardiac puncture. The samples were centrifuged and the serum was 
collected. Serum samples were stored at -20 °C until further analysis. Nasal wash 
and bronchoalveolar lavage (BAL) were performed as described earlier [34].
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2.8 Hemagglutination inhibition assay
The antigen neutralizing capacity of the collected sera was evaluated by HI assay and 
was performed according to the procedure used by Audouy et al [21]. In short, serum 
was inactivated by incubating it with kaolin suspension at 56 °C for 20 minutes. 
Subsequently, after centrifugation at 1200 rpm the samples were transferred to the 
first well of a V-bottom 96 well plate in duplicate and serially diluted twofold in PBS 
(pH 7.4). Then, 50 µl of either NIBRG-14 or NIBRG-23 vaccine containing 4 HAU 
was added to the wells. After 40 minutes of incubation at room temperature, 50 µl of 
1 % guinea pig erythrocyte in PBS was added to wells. After 2 h of incubation at room 
temperature, the highest serum dilution capable of preventing hemagglutination of 
RBCs was scored as HI titer. By convention titers below the detection limit (<8) were 
assigned a titer of 4 for calculation purposes. An HI titer of ≥ 40 is considered to be 
effective in reducing the chance of influenza infection by 50 % [35–37]. HI titers are 
presented in log2 scale; a titer of 40 equals a 2log titer of 5.3.
2.9 ELISA
ELISA was performed as described previously [34]. Briefly, ELISA plates (Greiner 
Bio-One, Alphen a/d Rijn, The Netherlands) were coated overnight with WIV 
(NIBRG-14 or NIBRG-23) containing 500 ng of total protein (WIV) and then 
blocked with a 2.5 % aqueous solution of milk powder in PBS at 37 °C. The plates 
were washed and then charged with pre-diluted samples (serum, nasal or lung 
lavages), which were serially diluted till the last well of the plate (12 times) and the 
plates were incubated for 1.5 h at 37 °C. Then, 100 µl of horseradish peroxidase 
(HRP) conjugated antimouse IgG, anti-mouse IgG1, anti-mouse IgG2a or anti-
mouse IgA (Southern Biotech, Birmingham, USA) diluted 1:5000 in PBST was 
added followed by incubation at 37 °C for 60 minutes for the detection of IgG, 
IgG1, IgG2a and IgA, respectively. Thereafter, the antibodies were detected using 
1,2-phenylen-diamine-dihyrochloride (Sigma Aldrich, USA) as substrate in the 
phosphate-citrate buffer. The absorbance at 492 nm was measured with a micro-plate 
reader (Synergy HT, BioTek, USA). IgG  antibody titers are given as the reciprocal 
of the sample dilution calculated to correspond to A492 = 0.2 after background 
correction and IgA levels are presented as average of the maximum absorbance of 
1:1 diluted nose and lung washes. The measurements were performed in duplicate.
2.10 Statistical analysis
The titers are given as the geometric mean ± standard error of the mean (SEM), 
unless stated otherwise. The differences in titers between groups were analyzed by 
Mann-Whitney U test at 95 % confidence interval (P<0.05). Significance is denoted 
by one symbol (P≤0.05) or two symbols (P≤0.01).




3.1 Formulation of WIV as s.l. tablet and 
evaluation of tablet properties 
In order to assess whether formulation of WIV influenza vaccine as tablet for s.l. 
administration is feasible, the inactivated NIBRG-14 was freeze-dried using inulin 
as stabilizer, mixed with other tablet ingredients and compressed. During this 
procedure, the vaccine encounters stress related to freeze-drying and tableting. 
Therefore, to investigate the stability of the vaccine in s.l. tablets the unprocessed 
vaccine, the freeze dried vaccine and the tablets were subjected to different tests such 
as SDS-PAGE and HA activity assay. Furthermore, the crushing strength and the 
disintegration time of the tablet were determined.
Stability during drying and tableting
First, the proteins in WIV (NIBRG-14) were investigated to establish that they 
remained intact during freeze-drying and tablet formulation. WIV proteins i.e. 
HA, neuraminidase (NA), matrix protein (M1), and nuclear export protein (NS2) 
of processed WIV were compared with those of unprocessed WIV by SDS-PAGE 
analysis under non-reducing conditions. Knowing their molecular weights, the WIV 
proteins could be identified by comparison with the standard protein mixture. The 
band patterns of HA, NA, M1 and NS2 did not change after processing of WIV by 
freeze-drying and subsequent compression into tablets (Figure 1a, compare lanes 
2, 3 and 4). The faintness of bands in lane 3 may be due to adsorbent properties 















Figure 1. Stability of NIBRG-14 WIV vaccine. (a) SDS-PAGE of unprocessed and 
processed WIV proteins under non-reducing conditions. Lane 1: molecular weight 
standard, lane 2: unprocessed WIV, lane 3: WIV freeze dried and subsequently processed 
into a formulated tablet, lane 4: freeze dried WIV. (b) HA titers of unprocessed WIV 
(black bar), freeze-dried WIV (dark gray bar) and freeze-dried WIV which was processed 
into a formulated tablet (light gray bar). The HA assay was performed in triplicate. As no 
differences in HA titers were found there are no error bars.
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of Avicel PH 102 and Ac-Di-Sol (which are insoluble) included in the tablet 
formulation. This result confirms the biochemical integrity of WIV proteins after 
freeze-drying and formulation. 
Next, the structural stability of inactivated NIBRG-14 was investigated in vitro 
by determination of the hemagglutination activity. As shown in Figure 1b, the 
NIBRG-14 vaccine did not lose any hemagglutinating capacity during freeze-drying 
and processing of the freeze-dried powder into a tablet.
Tablet crushing strength and disintegration time
 The tablets should have good mechanical stability in order to withstand the 
stress related to packaging and transport. The crushing strength of the formulated 
tablets was found to be 41.80 ± 0.92 N (n=10), which is high for these small tablets. 
In addition, the s.l. tablet should disintegrate rapidly to efficiently deliver the enclosed 
antigen and to prevent swallowing of the vaccine released from the tablet [38]. The 
disintegration time of the formulated s.l tablet was found to be 2 ± 1 sec (n = 10). 
It can be concluded that inulin sugar glass technology can be successfully applied to 
prevent deterioration of WIV during stressful process conditions like freeze-drying 
and compression. The formulated tablets fulfilled requirements regarding strength 
and disintegration for s.l. tablets. Hence, a stable influenza vaccine in the form of 
sublingual tablet can be made using inulin glass technology.
3.2. Effect of s.l. priming on the immune 
response to i.m. immunization 
In order to evaluate whether s.l. immunization can prime for a subsequent i.m. boost, 
mice were immunized s.l. with NIBRG-14 (20 µg HA) on day 0 followed by an i.m. 
booster immunization with NIBRG-14 or the drift variant NIBRG-23 on day 56 (5 
µg HA). Control groups received prime and boost via the i.m. route (5 µg HA each) 
or received PBS on day 0 followed by i.m. immunization with NIBRG-23 (5 µg HA) 
on day 56. Serum antibodies towards NIBRG-14 and NIBRG-23 were evaluated 
on day 28 (after prime only) and on day 84 (28 days after the final immunization), 
respectively. Mucosal antibody responses in lung and nose were determined on day 
84 after termination of the animals. 
Hemagglutination inhibition titers
On day 28 after a single immunization with NIBRG-14 WIV serum HI titers against 
the homologous virus were below the detection limit (log2 3), irrespective of whether 
the immunization was given via the s.l. or the i.m. route (Figure 2a and 2b, left parts, 
day 28). Similarly, no HI titer against the heterologous drift variant NIBRG-23 was 
observed 28 days after s.l. or i.m. immunization with NIBRG-14 (Figure 2a and 2b, 
right parts, day 28). However, HI titers towards NIBRG14 were readily observed 
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upon i.m. boosting of the s.l. or i.m. primed mice and exceeded the titer of 40 (log 2 
5.3), regarded as protective in humans (Figure 2a left part, day 84). Priming via the 
s.l. route (dark gray bar) was somewhat less effective than priming via the i.m. route 
(light grey bar) in this respect. The NIBRG-14 prime/boost immunization regimens 
resulted in comparable levels of HI antibodies directed against NIBRG-14 (Figure 
2a, left part, day 84) and NIBRG-23 (Figure 2a, right part, day 84). 
Interestingly, s.l. (or i.m.) immunization with NIBRG-14 primed not only for a 
homologous i.m. boost with NIBRG-14 but also for a heterologous i.m. boost 
with NIBRG-23 vaccine (Figure 2b, day 84). Priming with NIBRG14 followed 
by boosting with NIBRG23 resulted in log2 HI titers of 6 (s.l. priming) and 8 (i.m. 
priming) against NIBRG14 and NIBRG23. In contrast, i.m. immunization with 
NIBRG23 alone was not capable of inducing HI titers above the detection limit 
(Figure 2b, black bars). 
Serum IgG antibody titers and IgG subclasses
In contrast to HI antibodies, influenza-specific IgG (reacting with NIBRG-14 
as well as NIBRG-23) could already be detected on day 28 after priming of the 
immune response with NIBRG-14 vaccine administered by the s.l. route (Figure 3a 
and 3b, day 28, dark gray bars). These results clearly indicate that s.l. vaccination 
with WIV influenza vaccine induced a systemic immune response. Not surprisingly, 
the response elicited by s.l. priming was of somewhat lower magnitude than the 
response induced by i.m. priming (Figure 3a and 3b, day 28, light gray bars). An 
i.m. boost with either NIBRG-14 (Figure 3a) or NIBRG-23 (Figure 3b) further 




























Figure 2. NIBRG-14 and NIBRG-23 specific HI titers of pooled sera after one or two 
immunizations with H5N1 WIV. (a) Mice were primed on day 0 with NIBRG-14 WIV 
given via the s.l. (dark gray bars) or the i.m. (light gray bars) route and boosted with 
NIBRG-14 WIV via the i.m. route on day 56. HI titers were measured in blood collected 
on day 28 and 84 against NIBRG-14 (left part) and NIBRG-23 (right part). (b) Mice 
were primed on day 0 by s.l. (dark gray bars) or i.m. (light gray bars) immunization 
with NIBRG-14 WIV and boosted i.m. with NIBRG-23 WIV on day 56. Control mice 
received PBS on day 0 and NIBRG-23 WIV via the i.m. route on day 56 (black bars). 





























Figure 4. NIBRG-14 and NIBRG-23 specific IgG1 and IgG2a titers of sera after one or 
two immunizations with H5N1 WIV. (a) Mice were primed on day 0 with NIBRG-14 
WIV given via the s.l. (dark gray bars) or the i.m. (light gray bars) route and boosted with 
NIBRG-14 WIV via the i.m. route on day 56. IgG1 and IgG2a titers were measured in 
blood collected on day 84 against NIBRG-14 (left part) and NIBRG-23 (right part). (b) 
Mice were primed and boosted as outlined in the legend to Fig. 2b. IgG1 and IgG2a in 
sera of individual mice was determined on day 84.
























Figure 3. NIBRG-14 and NIBRG-23 specific IgG titers of sera after one or two 
immunizations with H5N1 WIV. (a) Mice were primed on day 0 with NIBRG-14 WIV 
given via the s.l. (dark gray bars) or the i.m. (light gray bars) route and boosted with 
NIBRG-14 WIV via the i.m. route on day 56. IgG titers were measured in blood collected 
on day 28 and 84 against NIBRG-14 (left part) and NIBRG-23 (right part). (b) Mice 
were primed and boosted as outlined in the legend to Fig. 2b. IgG in sera of individual 
mice was determined on day 84.
a b
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increased the IgG titers in s.l. primed mice (Figure 3a and 3b, compare day 28 
day 84 titers), and had an even greater effect in i.m. primed animals (Figure 3a and 
3b, compare dark with light gray bars). IgG titers in s.l. primed and i.m. boosted 
animals were significantly larger (p = 0.0008) than in animals which received a single 
i.m. immunization (Figure 3b, day 84, compare dark grey bars with black bars). 
However, the difference was by far not as large as that between the i.m. primed and 
boosted and the i.m. immunized group (Figure 3b, day 84, compare light grey 
bars with black bars). 
IgG subtypes (IgG1 and IgG2a) were determined on day 84 to elucidate which 
type of T-helper cell response, i.e. Th1 (IgG2a) or Th2 (IgG1) was predominantly 
induced by the different vaccination regimens (Figure 3c and 3d). In line with 
the IgG titers, IgG1 and IgG2a titers were lower for s.l. primed mice than for i.m. 
primed mice. For the NIBRG14/NIBRG14 scenarios (Figure 4a) both regimens 
induced balanced responses with equal amounts of IgG1 and IgG2a. In contrast, 
for the heterologous NIBRG-14 prime/NIBRG-23 boost scenarios IgG2a responses 
were clearly lower than IgG1 responses especially when tested against NIBRG-14 
(Figure 4b). This effect was more pronounced for s.l. primed mice than for i.m. 
primed mice indicating that s.l. priming of IgG2a is somewhat less effective than 
i.m. priming. Still, IgG1 and IgG2a responses were higher for the mice immunized 
following a prime/boost regimen than for mice immunized only once i.m. with 
NIBRG-23 (except for NIBRG-23-specific IgG2a).


























Figure 5. NIBRG-14 and NIBRG23 specific IgA responses in BAL and nasal washes 
(a) Mice were primed and boosted as outlined in the legend to Fig. 2a. IgA in BAL 
and nose of individual mice was determined on day 84. (b) Mice were primed and 
boosted as outlined in the legend to Fig. 2b. IgA in BAL and nose of individual mice was 
determined on day 84.
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3.3 Mucosal immune response
The mucosal immune responses on day 84 were determined by measuring IgA levels 
against NIBRG-14 and NIBRG-23 in BAL and nasal washes. IgA reactive against 
both viruses was observed in the BAL of all experimental groups except the group 
which received a single i.m. immunization with NIBRG-23 vaccine (Figure 5a and 
5b). There was a trend towards higher levels of lung IgA in the i.m. prime/i.m. 
boost groups as compared to the s.l. prime/i.m. boost groups but differences were 
not statistically significant (except for NIBRG-23-specific lung IgA in the groups 
primed and boosted with NIBRG-14 (Figure 5a)). In contrast to lung IgA, nose 
IgA, important for virus neutralization at the port of entry, was significantly better 
induced by the s.l. prime/i.m. boost regimens than by the i.m. prime/i.m. boost 
regimens. As expected, no IgA was detected in the nose of mice that had received a 
single i.m. immunization with NIBRG-23. 
These results indicate that s.l. priming is very effective in inducing antibody responses 
in the upper respiratory tract, the port of entry of the virus. Moreover, the induced 
IgA responses are cross-reactive across different clades and vaccine derived from one 
clade can prime for immunization with another clade.
4. Discussion and conclusion
In this study, we found that s.l. administration of NIBRG-14 WIV vaccine can prime for 
a subsequent i.m. boost. Priming was not only effective for providing a boost with 
homologous NIBRG-14 but also with heterologous NIBRG-23 WIV vaccine. 
This prime-boost regimen induced much better immune responses than an i.m. 
administration of NIBRG-14 or NIBRG-23 alone and resulted in HI titers of more 
than 40, considered as protective in humans. Moreover, mice immunized by s.l. 
priming followed by i.m. boosting showed significantly higher nasal IgA antibody 
levels than mice vaccinated by i.m. priming and boosting. Furthermore, we have 
shown that WIV vaccine can be formulated as a stable tablet with sufficient mechanical 
strength and a short disintegration time suitable for sublingual application. 
Humans are naïve to H5 antigen. Hence, a single immunization with H5N1 vaccines 
appeared insufficient to induce protective antibody levels [39] Therefore, a multi 
dose vaccination strategy is required to achieve robust immune responses. Indeed, 
the necessity of a 2-dose vaccination strategy for H5 vaccines has been proven in 
several clinical trials [40,41]. In 2008, it was shown that an immune response primed 
by one type of H5N1 vaccine can be boosted with an antigenically distinct H5N1 
vaccine for the induction of cross-clade reactive, protective antibodies [12,42,43]. 
This observation opened the way for a pandemic vaccination strategy involving 
priming with a stockpiled H5N1 vaccine (derived for example from clade 1) followed 
by boosting with an H5N1 vaccine derived from the pandemic strain (which might 
be a clade 2 virus). So far, prime-boost strategies have been tested with inactivated 
virus administered via the i.m. route and with live attenuated virus given by the 
i.n. route. In this study, we provide evidence that priming is also possible when 
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vaccine is administered via the s.l. route. Moreover, we show that s.l. priming not 
only enhances antibody titers upon i.m. boosting with a homologous virus strain but 
also effective in priming for boosting with a heterologous strain. 
In addition to enhancing serum IgG titers, s.l. priming also induced IgA responses in 
the upper respiratory tract. This in contrast to i.m. priming which could induce IgA 
in the lungs but not in the nose. IgA in the upper respiratory tract is very important 
for neutralization of influenza virus before an infection can get established and IgA 
was shown to be much more effective in this respect than IgG [44]. Thus, next to the 
advantage of ease of immunization, s.l. antigen delivery has the additional advantage 
of inducing local immunity at the port of entry of influenza virus.
Sublingual immunization has so far been performed mainly in the context of s.l. 
immunotherapy (SLIT) in which allergens are administered via the s.l. route to 
diminish an allergenic immune response. Administration of allergens via the s.l. 
route has been in use for several years and has been very successful. More recently, 
the sublingual route has also been used for the induction of immune responses. 
Generally, s.l. vaccination with influenza vaccine required high doses of antigen 
and/or use of an adjuvant to elicit robust immune response [24]. In this study, we 
tested s.l. vaccine administration as a priming strategy. Our results indicate that s.l. 
priming of immune responses can work even without an adjuvant, at least when 
performed with WIV which is known to be highly immunogenic due to the presence 
of single stranded viral RNA [45].The effectiveness of  s.l. priming can possibly be 
further enhanced by addition of suitable adjuvants to the vaccine. Recent studies 
of influenza vaccines with adjuvants including detoxified cholera toxin and c-di-
GMP demonstrate promising results [27,29,46]. Although in the animal study 
reported here liquid vaccine was given sublingually, we envisage that the WIV 
vaccine should ideally be converted into a dry and stable product and formulated 
into a s.l. tablet. Such tablets have two major advantages over the conventional 
liquid influenza vaccines. First, stockpiling is much easier because no refrigerated 
conditions are required. Secondly, administration of a s.l. tablet is much more easy 
than the conventional parenteral administration facilitating a rapid vaccination of 
the population which is imperative during a pandemic outbreak. In the present 
study, the NIBRG-14 WIV vaccine was incorporated in an amorphous inulin glass 
by freeze-drying and then compressed into tablets using appropriate excipients. The 
antigen stability after tableting was confirmed by SDS-PAGE and the HA assay. In 
previous studies, we have shown that WIV incorporated in inulin glasses shows an 
excellent storage stability [22,45]. Therefore, although not investigated in the present 
study, it can be assumed that the WIV vaccine incorporated in the s.l. tablet can be 
stored at ambient temperatures for prolonged periods of time (years) without loss 
of antigenicity, The freeze-dried WIV influenza vaccine was formulated with Avicel 
pH 102, mannitol and Ac-Di-Sol to fulfill the requirements of the s.l. tablet. The 
crushing strength (> 40 N) and disintegration time (< 3 seconds) of the formulated 
s.l. tablets were well within the limits [47]. The fast disintegration guarantees rapid 
delivery of antigen for effective immunization [38]. 
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Taken together, our results show that s.l. administration of WIV influenza vaccine 
can successfully prime for a later i.m. booster with a vaccine derived from a 
homologous but also a heterologous influenza strain. This vaccination strategy 
results in protective levels of serum antibodies as well as IgA in the upper respiratory 
tract. When incorporated into a polysaccharide matrix the vaccine can be formulated 
as a stable tablet, enabling long-term storage and easy vaccine administration. The 
results indicate that s.l. priming of influenza-specific immune response with s.l. 
tablets vaccine is an ideal strategy for pandemic preparedness with respect to H5N1 
a concept that may also be suitable for other influenza strains.
References
[1] Wyman O. Influenza Vaccine Strategies for 
Broad Global Access Key Findings and Project 
Methodology. 2007.
[2] Jennings L, Monto A, Chan P. Stockpiling 
prepandemic influenza vaccines: a new 
cornerstone of pandemic preparedness plans. 
Lancet Infect … 2008;8:650–8.
[3] Longini IM, Nizam A, Xu S, Ungchusak K, 
Hanshaoworakul W, Cummings D a T, et al. 
Containing pandemic influenza at the source. 
Science 2005;309:1083–7.
[4] Luykx DM a M, Casteleijn MG, Jiskoot W, 
Westdijk J, Jongen PMJM. Physicochemical 
studies on the stability of influenza 
haemagglutinin in vaccine bulk material. Eur J 
Pharm Sci 2004;23:65–75.
[5] Coenen F, Tolboom JTBM, Frijlink HW. 
Stability of influenza sub-unit vaccine: Does a 
couple of days outside the refrigerator matter? 
Vaccine 2006;24:525–31.
[6] Carrat F, Flahault a. Influenza vaccine: 
the challenge of antigenic drift. Vaccine 
2007;25:6852–62.
[7] Wang H, Feng Z, Shu Y, Yu H, Zhou 
L, Zu R, et al. Probable limited person-to-
person transmission of highly pathogenic avian 
influenza A (H5N1) virus in China. Lancet 
2008;371:1427–34.
[8] Ungchusak K, Auewarakul P. Probable 
person-to-person transmission of avian influenza 
A (H5N1). N Engl J Med 2005:333–40.
[9] Imai M, Herfst S, Sorrell EM, Schrauwen EJ 
a, Linster M, De Graaf M, et al. Transmission of 
influenza A/H5N1 viruses in mammals. Virus 
Res 2013;178:15–20.
[10] Russell C a, Fonville JM, Brown AEX, Burke 
DF, Smith DL, James SL, et al. The potential 
for respiratory droplet-transmissible A/H5N1 
influenza virus to evolve in a mammalian host. 
Science 2012;336:1541–7.
[11] Herfst S, Schrauwen EJ a, Linster M, 
Chutinimitkul S, de Wit E, Munster VJ, et al. 
Airborne transmission of influenza A/H5N1 virus 
between ferrets. Science 2012;336:1534–41.
[12] Stephenson I, Nicholson KGK, Hoschler 
K, Zambon MC, Hancock K, DeVos J, et al. 
Antigenically distinct MF59-adjuvanted vaccine 
to boost immunity to H5N1 New Engl J. 
2008;359:1631–3.
[13] Baz M, Luke CJ, Cheng X, Jin H, Subbarao 
K. H5N1 vaccines in humans. Virus Res 
2013;178:78–98.
[14] WHO, Updated unified nomenclature 
system for the highly pathogenic H5N1 avian 
influenza viruses. World Health Organization; 
2011.
[15] Continued evolution of highly pathogenic 
avian influenza A (H5N1): updated nomenclature. 
Influenza Other Respi Viruses 2012;6:1–5.
[16] Antigenic and genetic characteristics of 
H5N1 viruses and candidate H5N1 vaccine 
viruses developed for potential use as pre-
pandemic vaccines. 2006.
[17] Belshe RB, Frey SE, Graham I, Mulligan 
MJ, Edupuganti S, Jackson LA, et al. Safety 
and immunogenicity of influenza A H5 subunit 
vaccines: effect of vaccine schedule and antigenic 
variant. J Infect Dis 2011;203:666–73.
[18] Garmise RJ, Staats HF, Hickey AJ. Novel 
dry powder preparations of whole inactivated 
influenza virus for nasal vaccination. AAPS 
PharmSciTech 2007;8:E81.
Simplifying influenza vaccination during pandemics
7
132
[19] Amorij J-PP, Meulenaar J, Hinrichs WLJ, 
Stegmann T, Huckriede A, Coenen F, et al. 
Rational design of an influenza subunit vaccine 
powder with sugar glass technology: Preventing 
conformational changes of haemagglutinin 
during freezing and freeze-drying. Vaccine 
2007;25:6447–57.
[20] Geeraedts F, Saluja V, ter Veer W, Amorij J-P, 
Frijlink HW, Wilschut J, et al. Preservation of the 
immunogenicity of dry-powder influenza H5N1 
whole inactivated virus vaccine at elevated storage 
temperatures. AAPS J 2010;12:215–22.
[21] Audouy SAL, van der Schaaf G, Hinrichs 
WLJ, Frijlink HW, Wilschut J, Huckriede 
A. Development of a dried influenza whole 
inactivated virus vaccine for pulmonary 
immunization. Vaccine 2011;29:4345–52.
[22] Murugappan S, Patil HP, Kanojia G, ter 
Veer W, Meijerhof T, Frijlink HW, et al. Physical 
and immunogenic stability of spray freeze-dried 
influenza vaccine powder for pulmonary delivery: 
comparison of inulin, dextran, or a mixture of 
dextran and trehalose as protectants. Eur J Pharm 
Biopharm 2013;85:716–25.
[23] Boudreault A, Pavilanis V. Oral immunization 
against influenza virus. Arch Gesamte Virusforsch 
1972;182.
[24] Shim B-S, Choi Y, Cheon IS, Song 
MK. Sublingual delivery of vaccines for the 
induction of mucosal immunity. Immune Netw 
2013;13:81–5.
[25] Pedersen G, Cox R. The mucosal 
vaccine Qquandary: Intranasal vs. sublingual 
immunization against influenza . Hum Vaccin 
Immunother 2012;8:689 <last_page> 693.
[26] Kweon M-N. Sublingual mucosa: A new 
vaccination route for systemic and mucosal 
immunity. Cytokine 2011;54:1–5.
[27] Pedersen GK, Ebensen T, Gjeraker IH, 
Svindland S, Bredholt G, Guzmán CA, et 
al. Evaluation of the sublingual route for 
administration of influenza H5N1 virosomes in 
combination with the bacterial second messenger 
c-di-GMP. PLoS One 2011;6:e26973.
[28] Shim B-SS, Choi YK, Yun C-HH, Lee 
E-GG, Jeon YS, Park S-MM, et al. Sublingual 
Immunization with M2-Based Vaccine Induces 
Broad Protective Immunity against Influenza. 
PLoS One 2011;6:e27953.
[29] Song JH, Nguyen HH, Cuburu N, 
Horimoto T, Ko SY, Park SH, et al. Sublingual 
vaccination with influenza virus protects mice 
against lethal viral infection. Proc Natl Acad Sci 
U S A 2008;105:1644–9.
[30] Amorij J-P, Hinrichs WL, Frijlink HW, 
Wilschut JC, Huckriede A. Needle-free influenza 
vaccination. Lancet Infect Dis 2010;10:699–711.
[31] Bensadoun AA, Weinstein D. Assay of 
proteins in the presence of interfering materials. 
Anal Biochem 1976;250:241–50.
[32] Rawas-Qalaji MM, Estelle F, Simons R, 
Simons KJ, Simons FE. Fast-disintegrating 
sublingual tablets: effect of epinephrine load 
on tablet characteristics . AAPS PharmSciTech 
2006;7:E41.
[33] Blum H, Beier H, Gross HJ. Improved silver 
staining of plant proteins, RNA and DNA in 
polyacrylamide gels . Electrophoresis 1987;8:93–
9.
[34] Amorij J-P, Saluja V, Petersen AH, Hinrichs 
WLJ, Huckriede A, Frijlink HW. Pulmonary 
delivery of an inulin-stabilized influenza subunit 
vaccine prepared by spray-freeze drying induces 
systemic, mucosal humoral as well as cell-
mediated immune responses in BALB/c mice. 
Vaccine 2007;25:8707–17.
[35] De Jong JC, Palache AM, Beyer WEP, 
Rimmelzwaan GF, Boon ACM, Osterhaus 
ADME. Haemagglutination-inhibiting antibody 
to influenza virus. Dev Biol (Basel) 2003;115:63–
73.
[36] Hobson D, Curry RL, Beare AS, Ward-
Gardner a. The role of serum haemagglutination-
inhibiting  antibody in protection against 
challenge infection with influenza A2 and B 
viruses. J Hyg 1972;70:767–77.
[37] Research C for BE and. Guidance for 
Industry: Clinical Data Needed to Support 
the Licensure of Seasonal Inactivated Influenza 
Vaccines - ucm091990.pdf n.d.;2013.
[38] Borde A, Ekman A, Holmgren J, Larsson 
A. Effect of protein release rates from tablet 
formulations on the immune response after 




[39] Wu J, Fang H-H, Chen J-T, Zhou J-C, Feng 
Z-J, Li C-G, et al. Immunogenicity, safety, and 
cross-reactivity of an inactivated, adjuvanted, 
prototype pandemic influenza (H5N1) vaccine: 
a phase II, double-blind, randomized trial. Clin 
Infect Dis 2009;48:1087–95.
[40] Goji NA, Nolan C, Hill H, Wolff M, Noah 
DL, Williams TB, et al. Immune responses of 
healthy subjects to a single dose of intramuscular 
inactivated influenza A/Vietnam/1203/2004 
(H5N1) vaccine after priming with an antigenic 
variant. J Infect Dis 2008;198:635–41.
[41] Vemula S V, Ahi YS, Swaim A-M, Katz 
JM, Donis R, Sambhara S, et al. Broadly 
protective adenovirus-based multivalent vaccines 
against highly pathogenic avian influenza 
viruses for pandemic preparedness. PLoS One 
2013;8:e62496.
[42] Renegar KB, Small P a, Boykins LG, Wright 
PF. Role of IgA versus IgG in the control of 
influenza viral infection in the murine respiratory 
tract. J Immunol 2004;173:1978–86.
[43] Geeraedts F, Goutagny N, Hornung V, 
Severa M, de Haan A, Pool J, et al. Superior 
Immunogenicity of Inactivated Whole Virus 
H5N1 Influenza Vaccine is Primarily Controlled 
by Toll-like Receptor Signalling. - PLoS Pathog 
2008;8:e1000138.
[44] Cuburu N, Kweon M-N, Song J-H, 
Hervouet C, Luci C, Sun J-B, et al. Sublingual 
immunization induces broad-based systemic and 
mucosal immune responses in mice. Vaccine 
2007;25:8598–610.
[45] Rudnic EM, Schwartz JB. Remington: The 
Science and Practice of Pharmacy, Oral solid 
dosage forms In: Remington’s Pharmaceutical 
Sciences. 21st ed. Lippincott Williams & Wilkins; 
2006.
Simplifying influenza vaccination during pandemics
7

Summary and concluding remarks





Vaccination against influenza is the most important strategy to control the virus spread 
during seasonal epidemics and pandemics. However, there are several shortcomings 
related to current vaccines, i.e. they have to be administered parenterally (except for 
the live attenuated virus vaccine Flumist®), their production capacities are limited, 
the immune response they elicit is sub-optimal, and they are unstable. 
In this thesis, we explored two different strategies to avoid these shortcomings. In the 
first strategy, a dry and stable adjuvanted vaccine powder has been developed that can 
be administered through the pulmonary route. In the second strategy a sublingual 
(s.l.) tablet containing a stabilized vaccine of a previous strain was developed that can 
be used to prime the immune response for a booster of a vaccine prepared from the 
current drifted strain.
Hence, in this thesis we evaluated, 
1. The storage stability of powdered pulmonary vaccines. 
2. The preservation of immunogenicity of adjuvanted pulmonary influenza  
 vaccines during spray-freeze drying process, we also evaluated the adjuvant  
 effect of adjuvanted vaccines. 
3. The sublingual priming (with stabilized vaccine)  for subsequent intra  
 muscular (i.m.) boosting of immune response with heterologous influenza  
 vaccine 
In chapter 2, a literature review is given on particulate influenza vaccines. The 
particulate influenza vaccines resemble the intact influenza virus. The particulate 
nature of the vaccines holds great promise to induce better immune response than 
subunit or split vaccine. Furthermore, the review discusses about the regulatory 
challenges and perspectives of particulate influenza vaccines. 
In chapter 3, we evaluated the physical and immunogenic stability of powdered 
WIV for pulmonary vaccination. WIV was spray freeze-dried in the presence of 
inulin, dextran and mixture of dextran and trehalose. The properties of  spray freeze 
dried powders were found to be suitable for pulmonary immunization. Furthermore, 
during spray freeze drying, WIV retained its particulate nature and its antigenicity 
was maintained. The powdered vaccines were stored at -20, 2-8, 30 and 40 °C for 3 
months. The physical properties of all three vaccine powders, i.e. the particle size and 
specific surface area were maintained when stored at temperatures up to 30°C. The 
powdered vaccines stored at 30 °C for 3 months were used to evaluate their receptor 
binding capacity and immunogenicity. It was found that the receptor binding capacity 
of  dry powder vaccines was preserved which was confirmed by the maintenance of 
the hemagglutination titers. The immunogenic stability of the formulated powders 
was evaluated in mice. The results revealed that the immunopotentiating effects of 
dry powder vaccines were maintained as the immune responses elicited by the stored 
vaccines were comparable to freshly prepared spray freeze-dried vaccines. During 
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storage, however, most likely some particle-particle interaction occurred which 
interfered with a proper vaccine delivery to the lungs when using the dry powder 
insufflator. In contrast, this problem was not observed when the RODOS powder 
disperser was used. Hence, it should be noted that the stored vaccines require an 
efficient disperser for proper delivering the powder to lungs. 
In chapter 4, the adjuvant effect of δ-inulin with liquid pulmonary vaccine was 
evaluated. δ-inulin was mixed with influenza vaccine and then administered to 
mice either via i.m. injection or the pulmonary route. The immunological readouts 
including serum IgG, IgG subtypes, nose IgA and serum hemagglutination titers 
were evaluated. In terms of serum IgG and nasal IgA antibody levels, pulmonary 
vaccination induced a better immune response than i.m. vaccination. However, 
pulmonary vaccination of vaccine alone induced a Th2 dominant immune response. 
The addition of δ-inulin to vaccine induced a more balanced Th1/Th2 immune 
response without compromising the Th2 immune response. Furthermore, the δ-inulin 
adjuvanted vaccine enhanced the nasal IgA antibody levels compared to pulmonary 
vaccine alone. The adjuvanted pulmonary vaccine induced hemagglutination titers 
of > 40 which is generally considered to be protective. Thus, the addition of δ-inulin 
to the pulmonary influenza vaccine has an advantage over both the non-adjuvanted 
pulmonary vaccine  and the adjuvanted i.m. vaccine.
In chapter 5, we incorporated the adjuvant monophosphoryl lipid A (MPLA) 
together with WIV in sugar glass matrix of inulin by spray freeze-drying technique. 
The physical and immunological properties of the vaccine powder for pulmonary 
immunization were evaluated. Maintenance of the adjuvant activity of MPLA during 
spray freeze drying was confirmed by NFkB activation with RAW-BlueTM cells. The 
particle size of the vaccine powder appeared to be within the acceptable range for 
inhalation. The maintenance of the receptor binding efficacy of WIV during spray 
freeze drying was confirmed by the hemagglutination titer. The immunogenicity of 
WIV in mice was confirmed by antibody immune responses. The MPLA adjuvanted 
pulmonary vaccine induced high IgA antibody levels compared to vaccine alone. 
The incorporation of MPLA in influenza vaccines induced a more balanced Th1/
Th2 immune responses than pulmonary vaccine alone. Moreover, the adjuvanted 
pulmonary influenza vaccine equally neutralized the influenza virus as seen in the 
control (i.m.). Overall, the MPLA adjuvanted pulmonary influenza vaccine induced 
better mucosal and systemic immune responses than pulmonary vaccine alone. 
In chapter 6, various adjuvants were evaluated for pulmonary vaccine powders. The 
adjuvants include palmitoyl-3-cysteine-serine-lysine-4 (Pam3CSK4, TLR 1 and TLR 
2 ligand), MPLA (TLR 4 ligand), CpG oligodeoxynucleotide (CpG-ODN-1826, 
TLR 9 ligand) and GPI-0100 (a saponin based, non-pattern recognizing receptor 
binding compound). The adjuvants were incorporated in the vaccine powders by 
spray freeze-drying a mixture of the adjuvant, WIV and inulin as lyoprotectant. The 
NFκB reporter cell line studies confirmed the preservation of immunostimulating 
properties of these vaccine powders. All the TLR ligands were capable of inducing 
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systemic immune responses in mice, but they failed to induce potent mucosal 
immune responses. However, GPI-0100 induced both potent mucosal and systemic 
immune responses compared to the vaccine alone. The GPI-0100 also protected 
the mice from a lethal challenge of a heterologous influenza strain. Thus, GPI-0100 
holds great promise to act as a potent adjuvant for pulmonary influenza vaccines. 
In chapter 7, it was investigated whether s.l. administration of influenza vaccine 
can prime the immune system for a later i.m. boost with a heterologous influenza 
vaccine, the priming efficacy of a stabilized influenza vaccine through s.l. route for a 
heterologous i.m. booster vaccine. Ideally, the vaccine for s.l. applications should be 
administered as a tablet in which the vaccine is stable. Therefore, WIV was freeze-
dried with in the presence of inulin and then formulated as a s.l. tablet. During 
processing, the vaccine stabilized with in the sugar glass matrix remained intact, 
which was confirmed by SDS-PAGE and hemagglutination titers. The sugar-glass 
stabilized vaccine was successfully formulated into a s.l. tablet. For animal studies, 
however, we reconstituted the freeze-dried vaccine to test the priming efficacy of 
vaccine because of practical difficulties related to s.l. administration of tablets to 
mice. The i.m. boosting efficacy of heterologous vaccine was tested. The i.m. booster 
vaccine of a heterologous strain resulted in the induction of serum IgG and nasal 
IgA antibody immune responses against both new and old strains. Therefore, it was 
concluded that the s.l. vaccination can indeed prime the immune response for a 
subsequent i.m. booster vaccine.  
Concluding remarks and perspectives
In this thesis, two different strategies we explored to overcome / minimize the 
shortcomings of conventional influenza vaccines. First, a stable influenza vaccine 
powder for pulmonary administration was developed and the possibilities of adding 
adjuvants to  pulmonary vaccines were evaluated. Second, as a pre-pandemic measure, 
we tested the priming efficacy of stable s.l. vaccine for a subsequent heterologous 
i.m. booster vaccine, especially with H5N1 strains, which pose a threat for future 
pandemic.
To prepare a dry powder vaccine formulation for pulmonary administration, WIV 
was spray freeze-dried in the presence of inulin, dextran or a mixture of dextran 
and trehalose (dex/tre). Spray freeze-drying was selected as a technique to dry the 
vaccine as it can yield powder particles with proper characteristics for pulmonary 
administration. It has been shown before that WIV can be spray freeze-dried in the 
presence of inulin without loss of its antigenicity [1]. In this thesis, it has been shown 
that both dextran and dex/tre can be used as stabilizing excipients. Furthermore, it 
was found that the antigenicity of WIV incorporated in these sugars was maintained 
during storage for atleast three months at temperatures up to 40 ˚C Also the powder 
characteristics during storage were evaluated, as a change of these characteristics can 
be highly detrimental for pulmonary deposition. It was found that the particle size 
distribution and specific surface area of the inulin and dex/tre based formulations 
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did not change during storage for three months at a temperature up to 30 ˚C. 
Interestingly, the powder characteristics of the dextran based formulation was even 
stable at 40 ˚C. Hence, the inulin and dext/tre stabilized influenza vaccines have 
a potential for an excellent long term storage stability at ambient temperatures 
while the dextran based formulation even has a superior stability profile (Chapter 
3). Therefore, stockpiling of these dry powder vaccine formulations are not or less 
dependent on refrigerated conditions. Inulin, dextran and trehalose are approved for 
parenteral and oral use in humans, but not for pulmonary administration. In studies 
of Zijlstra et al. and Audouy et al. it was shown that pulmonary administration of 
inulin to the lungs of rats and mice respectively, only induced a mild inflammatory 
response [1,2]. However, further research towards the safety of administering inulin 
and the other two sugars to the lungs have to be tested in more detail in appropriate 
animal models as well as in humans. 
Previous studies indicate that pulmonary administration of WIV elicits comparable 
or higher immune responses than conventional i.m. vaccines [1,3]. However, it 
induces a Th2 skewed immune response while a balanced Th1/Th2 immune response 
is preferred [4]. In addition, the induction of nasal IgA antibodies is poor. To 
improve the quality of immune response, a range of potential vaccine adjuvants was 
incorporated by spray freeze-drying in inulin glasses together with WIV. It was found 
that the co-incorporation of adjuvants PAM3CSK, CpG ODN, monophosphoryl 
lipid A and GPI-0100 in inulin glasses did not affect their adjuvant activity. 
Pulmonary administration of these powders to mice indicated that in particular 
monophosphoryl lipid A and GPI-0100 elicit improved immune responses (Chapter 
5 and 6). Both the cellular immune response and the local immune response in nose 
were improved when compared with the vaccine alone. After a challenge with a 
heterologous influenza strain, the formulation with GPI-0100 even reduced the lung 
virus titer 10 times more than the vaccine alone. Furthermore, in a preliminary study 
δ-inulin was evaluated as adjuvant for pulmonary immunization. In this study, the 
adjuvant was ad-mixed with WIV dispersion and pulmonary administered to mice. 
This study showed that also δ-inulin improved the immune response with respect to 
cellular and local immune responses when compared to the vaccine alone (chapter 
4). Therefore, these studies clearly indicate that various adjuvants can be used to 
potentiate pulmonary influenza vaccines. The studies described in this thesis were 
performed at a fixed adjuvant dose. Thus, to further improve the immune response 
the adjuvant dose should be optimized. In these studies, also the level of protection by 
these immunizations against a virus challenge should be investigated more extensively, 
not only in mice but also in more appropriate animal models such as cotton rats and 
ferrets. More interestingly, the possibilities of dose sparing for the vaccine should 
be investigated. The δ-inulin adjuvant was evaluated as a liquid formulation. From 
previous studies it is well known that the pulmonary administration of influenza 
vaccine in  dry powder state induces a more potent immune response than in liquid 
state [1]. Thus, it would be interesting to investigate the pulmonary administration 
of dry powder formulation of a spray freeze-dried formulation containing δ-inulin 
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and WIV. Furthermore, similar to the safety aspects described above for the applied 
sugars, also the toxicity of the adjuvants in the lungs should be studied in detail 
before application in human. 
The priming efficacy of s.l. vaccine was tested for a subsequent heterologous i.m. 
booster vaccine in an animal study using mice. The immune response was primed by 
s.l. administration of WIV prepared from NIBRG-14 and booster by i.m. injection 
of WIV prepared from and NIBRG-23 to test the prime-heterologous boost strategy 
for H5N1 bird flu vaccines. The results showed that indeed s.l. immunization with 
NIBRG-14 primed for a subsequent heterologous i.m. booster immunization with 
NIBRG-23 vaccine as the serum HI titers and nasal IgA antibody titers against 
NIBRG-23 were much higher than after i,m. immunization with NIBRG-23 alone. 
In this study, WIV was also freeze-dried together with inulin as lyoprotectant and 
then formulated using appropriate excipients into a stable tablet suitable for s.l. 
administration (Chapter 7). Such tablets holds great promise for a future pandemic as 
a number of advantages: 1) They can be prepared from a previous influenza strain, thus 
reducing the risk for vaccine shortage of vaccine prepared from the virus spreading at 
that moment. 2) They are stable and can thus be stockpiled under no or less stringent 
refrigerated conditions. 3)  They are easy to distribute and administered. Therefore, 
priming of the immune response with a s.l. tablet for a booster vaccine prepared 
from heterologous drifted strain can be considered as a step forward in pandemic 
preparedness. In this thesis, the s.l. prime was administered as a liquid formulation 
due to technical problems associated with the s.l. administration of tablets to mice. 
Therefore, the s.l. tablet primer and heterologous i.m. booster strategy should be 
investigated in bigger animals e.g. cotton rats or ferrets. Furthermore, the protective 
immunity should be evaluated in challenge models. To improve the priming efficacy, 
potent adjuvants could be incorporated into the s.l. vaccine tablets. The mucosal 
adjuvants discussed in this thesis like MPLA, GPI-0100 or other potent adjuvants 
may serve as future adjuvant candidates for s.l. vaccines. Moreover, adjuvation of s.l. 
vaccines might be a step forward to further facilitate vaccination e.g. by replacing the 
s.l. prime and i.m. boost strategy with non-invasive s.l. prime and s.l. boost strategy. 
By eliminating the need for invasive (i.m.) booster vaccination, the reach of vaccine 
could be improved.
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Vaccinatie tegen griep is de belangrijkste strategie om verspreiding van het griepvirus 
te beheersen, niet alleen tijdens de jaarlijks terugkerende epidemieën maar ook 
tijdens een eventuele pandemie. De huidige vaccins hebben echter een aantal 
tekortkomingen. Ze moeten per injectie worden toegediend (met uitzondering van 
het verzwakte levende griepvirus Flumist®), de productiecapaciteit is beperkt, de 
immuunreactie die ze opwekken is niet optimaal en ze zijn niet stabiel tijdens opslag.
In dit proefschrift zijn twee verschillende strategieën onderzocht om deze 
tekortkomingen op te lossen. De eerste strategie behelst de ontwikkeling van een 
droog en stabiel poeder voor pulmonale toediening waarin behalve het vaccin 
ook een adjuvans is verwerkt. De tweede strategie richtte zich op de ontwikkeling 
van een sublinguale (s.l.) tablet waarin een gestabiliseerd vaccin is verwerkt dat 
gemaakt is van een pandemische influenzastam die eerder heeft gecirculeerd. Een 
dergelijke s.l. tablet zou mogelijk gebruikt kunnen worden als een “primer” voor een 
daaropvolgende intramusculaire (i.m.) injectie met een vaccin vervaardigd van de 
pandemische influenza stam die op dat moment circuleert (heterologe stam). Deze 
vaccinatiestrategie is aantrekkelijk omdat de s.l. tablet stabiel is en een vaccin bevat 
wat gebaseerd is op een al bekend en dus beschikbaar virus. Het product kan dus 
op voorraad geproduceerd worden en nadien tijdens een pandemie worden ingezet.
Belangrijke aandachtspunten van het onderzoek dat beschreven is in dit proefschrift 
zijn:
1. De fysische en immunologische stabiliteit gedurende opslag van 
gesproeivriesdroogde vaccinpoeders voor pulmonale toediening.
2. Het behoud van de immunogeniciteit van het adjuvans tijdens het 
sproeivriesdrogen van een waterige dispersie van het adjuvans samen met het 
influenzavaccin en stabiliserende hulpstoffen. 
3. Het behoud van het vermogen om immuunreacties op te roepen na pulmonale 
toediening van deze gesproeivriesdroogde poeders. 
4. De sublinguale “priming” van het immuunsysteem (met gestabiliseerd vaccin) 
voorafgaande aan een intramusculaire vaccinatie met een heteroloog vaccin.
Hoofdstuk 1 is algemene inleiding op het werk dat in dit proefschrift is beschreven.
In hoofdstuk 2 wordt een literatuuroverzicht gepresenteerd over griepvaccins waarin 
het antigeen is geformuleerd tot een deeltjesstructuur. Geconcludeerd werd dat deze 
vaccins de potentie hebben om een veel betere immuunreactie te induceren dan 
de conventionele “subunit”- of “split”-vaccins omdat ze veel meer op het intacte 
influenzavirus lijken. Daarnaast zijn de uitdagingen besproken met betrekking tot 
regelgeving en registratie die verbonden zijn aan de implementatie van deze vaccines. 
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In hoofdstuk 3 werd de fysische en immunogene stabiliteit van “influenza whole 
inactivated virus vaccine” (WIV) poeders voor pulmonale toediening geëvalueerd. 
WIV werd gesproeivriesdroogd in aanwezigheid van inuline, dextraan en een mengsel 
van dextraan en trehalose. Alle drie gesproeivriesdroogde poeders bleken geschikt te 
zijn voor pulmonale toediening. Bovendien bleef de antigeniciteit van het vaccin 
tijdens het sproeivriesdrogen volledig behouden. De vaccinpoeders werden gedurende 
drie maanden opgeslagen bij -20 , 2-8 , 30 en 40 °C. De deeltjesgrootteverdeling 
en het specifieke oppervlak van alle drie vaccinpoeders bleven onveranderd tijdens 
opslag bij temperaturen tot en met 30 °C. Ook het receptorbindend vermogen 
en de antigeniciteit van de vaccinpoeders bleven gedurende deze opslagcondities 
volledig behouden. De immunogene stabiliteit van de geformuleerde poeders 
werd geëvalueerd in muizen. Hieruit bleek dat ook de immunogeniciteit van de 
vaccinpoeders volledig intact bleef tijdens opslag gedurende drie maanden bij 30 
°C. Wel werd in de dierstudies gevonden dat er tijdens opslag waarschijnlijk subtiele 
veranderingen in de poederstructuur waren opgetreden. Deze resulteerden in een 
niet optimale longdepositie wanneer er gebruik werd gemaakt van een disperser die 
het poeder niet krachtig genoeg kan dispergeren. Dit probleem deed zich echter niet 
voor met dispersers die wel in staat waren om de poeders krachtig te dispergeren. 
In hoofdstuk 4 werd onderzocht of δ-inuline kan worden toepast als adjuvans 
voor pulmonale influenzavaccinatie. δ-inuline werd toegevoegd aan een vloeibare 
influenzavaccinformulering die vervolgens werd toegediend aan muizen, zowel via 
i.m. injectie als via de pulmonale route. Met betrekking tot IgG antilichaamtiters 
in het serum en nasale IgA antilichaamtiters, induceerde de pulmonale toediening 
zonder δ-inuline een betere immuunreactie dan i.m. vaccinatie. Pulmonale vaccinatie 
induceerde echter een (ongewenste) dominante Th2 immuunreactie. De toevoeging 
van δ-inuline aan het pulmonale vaccin voorkwam dit nadeel. Pulmonale toediening 
van het vaccin met δ-inuline resulteerde namelijk in een evenwichtige Th1/Th2 
immuunreactie. Een ander voordeel van het δ-inuline geadjuvanteerde pulmonale 
vaccin was dat het veel hogere nasale IgA antilichaamtiters induceerde dan het 
pulmonale vaccin zonder δ-inuline. In alle gevallen werden hemagglutinatietiters 
van > 40 gevonden. Algemeen wordt aangenomen dat hemagglutinatietiters boven 
deze grens leiden tot een goede bescherming tegen het virus. Uit de resultaten kan 
geconcludeerd worden dat toevoeging van δ-inuline aan het pulmonale vaccin leidt 
tot een betere immuunreactie dan van het niet-geadjuvanteerde pulmonale vaccin of 
van het geadjuvanteerde i.m. vaccin.
In hoofdstuk 5 werd het adjuvans monophosphoryl lipide A (MPLA) samen met 
WIV ingesloten in een matrix van inulineglas door middel van sproeivriesdrogen. 
Vervolgens werden de fysische en immunologische eigenschappen van het 
vaccinpoeder voor pulmonale immunisatie onderzocht. Laserdiffractiemetingen 
toonden aan dat de deeltjesgrootteverdeling van het verkregen vaccinpoeder 
geschikt was voor inhalatie. Het behoud van de adjuvansactiviteit van MPLA 
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tijdens sproeivriesdrogen werd bevestigd in experimenten waarbij de NFkB 
activatie van RAW-Blue™ cellen werd bestudeerd. Daarnaast is met het bepalen 
van de hemagglutinatietiter aangetoond dat het receptorbindend vermogen van 
het vaccin tijdens sproeivriesdrogen niet was veranderd. Voorts werd het behoud 
van de immunogeniciteit van WIV bevestigd in muizenstudies. Het MPLA 
geadjuvanteerde pulmonale vaccinpoeder induceerde hogere IgA antilichaamtiters 
dan het vaccinpoeder zonder MPLA. Insluiting van MPLA in het vaccinpoeder 
induceerde ook een meer evenwichtige Th1/Th2 immuunreactie dan het pulmonale 
vaccinpoeder zonder MPLA. Ten slotte is gevonden dat muizen die gevaccineerd 
werden met het geadjuvanteerde vaccinepoeder via de pulmonale route even goed 
beschermd waren tegen een infectie met het virus als muizen die i.m. gevaccineerd 
waren met het “subunit” vaccin. Geconcludeerd werd dat het MPLA geadjuvanteerde 
pulmonale vaccinpoeder betere mucosale en systemische immuunreacties induceerde 
dan het pulmonale vaccin zonder MPLA.
In hoofdstuk 6 werden verschillende adjuvantia geëvalueerd voor pulmonale 
vaccinpoeders. De onderzochte adjuvantia zijn palmitoyl-3-cysteïne-serine-lysine-4 
(Pam3CSK4 , een TLR-1 en TLR-2 ligand) , MPLA (een TLR-4 ligand) , CpG 
oligodeoxynucleotide (CpG- ODN-1826 , een TLR-9 ligand) en GPI-0100 (een 
saponine dat geen TRL receptorbinding vertoont). Door middel van sproeivriesdrogen 
werden poeders verkregen met daarin ingesloten de verschillende adjuvantia, WIV en 
inuline als stabilisator. Experimenten met de NFκB reporter cellijn toonden aan dat 
de immuunstimulerende eigenschappen van de TLR liganden en het WIV tijdens 
het sproeivriesdrogen behouden bleven. Alle TLR liganden induceerden systemische 
immuunreacties bij muizen, maar geen substantiële mucosale immuunreacties. GPI-
0100 daarentegen induceerde zowel sterke systemische als mucosale immuunreacties 
in vergelijking tot het vaccin zonder adjuvans. Ook bleken muizen die pulmonaal 
waren gevaccineerd met de GPI-0100 formulering gedeeltelijk beschermd tegen een 
infectie met een virus van een heterologe stam. De conclusie was dat GPI-0100 een 
veelbelovend adjuvans is voor pulmonale griepvaccins.
In hoofdstuk 7 werd onderzocht of de s.l. toediening van het griepvaccin kan 
fungeren als “primer” voor een latere i.m. “boost” met een heteroloog griepvaccin. Het 
zou ideaal zijn als een dergelijke “primer” toegediend zou kunnen worden in de vorm 
van een stabiele s.l. tablet. Daarom werd WIV gevriesdroogd in de aanwezigheid van 
inuline als stabilisator. Met SDS-PAGE en het bepalen van de hemagglutinatietiters 
werd aangetoond dat het vaccin tijdens vriesdrogen intact bleef. Het met suikerglas 
gestabiliseerde vaccin kon vervolgens worden geformuleerd tot een s.l. tablet met 
gewenste eigenschappen met betrekking tot oplossnelheid en mechanische sterkte. 
Bij proeven met muizen werden echter geen tabletten s.l. toegediend maar werd 
het gevriesdroogde vaccin gereconstitueerd en werd de verkregen waterige dispersie 
vervolgens s.l. toegediend. De reden hiervoor was dat de s.l. toediening van tabletten 
aan muizen praktische problemen oplevert. Na s.l. vaccinatie kregen de muizen een 
heteroloog vaccin i.m. toegediend. Deze immunisatiestrategie leidde tot de inductie 
van serum IgG en nasale IgA antilichaamtiters tegen zowel homologe als heterologe 
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influenzastammen. De conclusie was dat de s.l. vaccinatie inderdaad kan dienen als 
een “primer” van de immuunreactie voor een daaropvolgende i.m. booster met een 
heteroloog vaccin.
In dit proefschrift is aangetoond dat het mogelijk is om door middel van 
sproeivriesdrogen een vaccinpoeder te produceren dat geschikt is voor pulmonale 
toediening en dat gedurende lange tijd buiten de koelkast bewaard kan worden. 
Pulmonale toediening van het griepvaccin heeft grote voordelen boven de 
gebruikelijke i.m. injectie onder andere omdat het een naaldvrije toedieningsvorm 
is en omdat het eenvoudig toe te dienen is. Daarnaast heeft pulmonale toediening 
de potentie om naast een immuunreactie in de algemene circulatie ook een 
immuunreactie in de luchtwegen te induceren. Dit zou tot een betere bescherming 
tegen griep kunnen leiden aangezien het virus ook via de luchtwegen het lichaam 
binnendringt. Muizenstudies toonden aan dat pulmonale toediening van het 
vaccin inderdaad lokale immuunreacties induceerden. De nasale immuunreacties 
waren echter niet optimaal en bovendien werd een dominante Th2 immuunreactie 
gevonden en niet een evenwichtige Th1/Th2 immuunreactie. Deze nadelen 
konden ondervangen worden door de toevoeging van verschillende adjuvantia. 
De verbetering van de immuunreactie door pulmonale griepvaccin formuleringen 
waarin ook geschikte adjuvantia zijn opgenomen zou kunnen leiden tot een 
verlaging van de vaccindosis. Dit vermindert de druk op de productiefaciliteiten van 
het griepvaccin tijdens een epidemie of pandemie. In inleidende experimenten werd 
aangetoond dat de pulmonale toediening van het inuline-gestabiliseerd vaccin een 
milde ontstekingsreactie induceerde. Uitgebreide toxiciteitstudies zullen nog moeten 
worden uitgevoerd om de veiligheid van de pulmonale vaccinpoeders (met adjuvantia) 
te kunnen garanderen. Voor de pulmonale toediening werden enkel muizenstudies 
uitgevoerd. Voordat de stap naar de mens kan worden gemaakt zullen eerst nog 
uitgebreide onderzoeken in grotere proefdiermodellen, bijvoorbeeld katoenratten en 
fretten, moeten worden uitgevoerd waarbij ook de bescherming tegen het griepvirus 
nader moet worden bestudeerd.
In dit proefschrift is verder aangetoond dat s.l. toediening van het griepvaccin (in 
tabletvorm) kan dienen als een “primer” voor een daaropvolgende i.m. injectie 
met een heteroloog vaccin. Een dergelijke vaccinatiestrategie zou met name grote 
voordelen bieden tijdens een pandemie. In tegenstelling tot een epidemie moeten 
tijdens een pandemie grote delen van de bevolking worden gevaccineerd. Daarnaast 
bestaat het vaccinatieregime meestal uit twee doses, een “primer” en een “booster”. 
Hierdoor moet er binnen korte tijd zeer veel vaccin worden geproduceerd hetgeen 
gezien de beperkte productiefaciliteiten onmogelijk zou kunnen zijn. Met de 
hierboven beschreven  strategie zou de “primer” kunnen worden vervangen door 
een vaccin dat gemaakt is van een pandemische influenzastam die eerder heeft 
gecirculeerd. Dit zou de druk op de productiefaciliteiten om twee redenen enorm 
verlichten. Ten eerste hoeft er veel minder vaccin op basis van het virus dat dan 
circuleert te worden geproduceerd aangezien alleen de “booster” van dit vaccin hoeft 
te worden toegediend. Ten tweede is er meer tijd om het vaccin te produceren omdat 
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het vaccin pas gereed hoeft te zijn op het moment dat de “booster” toegediend 
moet worden. Ook is aangetoond dat het “primer” vaccin verwerkt kan worden tot 
een stabiele s.l. tablet. Een dergelijke tablet heeft grote voordelen boven vloeibare 
formuleringen omdat het buiten de koelkast bewaard kan worden, gemakkelijk 
te distribueren is en eenvoudig toegediend kan worden. Ook bij dit onderzoek 
werden alleen muizenstudies uitgevoerd en er zal dus ook bij deze vaccinatiestrategie 
onderzoek bij grotere proefdieren moeten worden uitgevoerd voordat het klinisch 
kan worden getest in de mens. Verder moet nog worden onderzocht in hoeverre deze 
vaccinatiestrategie leidt tot een adequate bescherming tegen het heterologe virus. 
Verschillende adjuvantia zouden kunnen worden geëvalueerd om de immuunreactie 
verder te verbeteren. Ten slotte zou onderzocht kunnen worden of de immuunreactie 
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